Edgar Filing: WELLPOINT, INC - Form 10-Q

WELLPOINT, INC Form 10-Q November 03, 2010 Table of Contents

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

FORM 10-Q

(Mark One)

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period ended September 30, 2010

OR

[] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______ to _____

Commission file number: 001-16751

WELLPOINT, INC.

 $(Exact\ name\ of\ registrant\ as\ specified\ in\ its\ charter)$

INDIANA

35-2145715

(State or other jurisdiction of

(I.R.S. Employer

incorporation or organization)

Identification Number)

120 MONUMENT CIRCLE;

INDIANAPOLIS, INDIANA

46204-4903

(Address of principal executive offices)

(Zip Code)

Registrant s telephone number, including area code: (317) 488-6000

Not Applicable

Edgar Filing: WELLPOINT, INC - Form 10-Q

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for at least the past 90 days. Yes [X] No []

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No []

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer , accelerated filer , and smaller reporting company in Rule 12b-2 of the Exchange Act (Check one):

Large accelerated filer [X] Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [X] No [X] Indicate the number of shares outstanding of each of the issuer is classes of common stock, as of the latest practicable date:

Title of Each ClassCommon Stock, \$0.01 par value

Outstanding at October 20, 2010 393,610,053 shares

WellPoint, Inc.

Quarterly Report on Form 10-Q

For the Period Ended September 30, 2010

Table of Contents

PART LFINANCIAL INFORMATION	Page
ITEM 1.FINANCIAL STATEMENTS	
Consolidated Balance Sheets as of September 30, 2010 (Unaudited)	
and December 31, 2009	2
Consolidated Statements of Income for the Three and Nine Months Ended	
September 30, 2010 and 2009 (Unaudited)	3
Consolidated Statements of Cash Flows for the Nine Months Ended	
September 30, 2010 and 2009 (Unaudited)	4
Consolidated Statements of Shareholders Equity for the Nine Months Ended September 20, 2010 and 2000 (Unavilited)	5
Ended September 30, 2010 and 2009 (Unaudited) Notes to Consolidated Financial Statements (Unaudited)	5 6
Total to Consolidated Financial Statements (Chaudited)	U
ITEM 2.MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	33
ITEM 3.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	73
ITEM 4.CONTROLS AND PROCEDURES	73
PART II.OTHER INFORMATION	
ITEM 1.LEGAL PROCEEDINGS	74
ITEM 1A.RISK FACTORS	74
ITEM 2.UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	75
ITEM 3.DEFAULTS UPON SENIOR SECURITIES	75
ITEM 4.(REMOVED AND RESERVED)	75
ITEM 5.OTHER INFORMATION	75
ITEM 6.EXHIBITS	75
<u>SIGNATURES</u>	76
INDEX TO EXHIBITS	77

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

WellPoint, Inc.

Consolidated Balance Sheets

(In millions, except share data)	September 30, 2010 (Unaudited)		Dec	ember 31, 2009
Assets				
Current assets:				
Cash and cash equivalents	\$	2,246.2	\$	4,816.1
Investments available-for-sale, at fair value:				
Fixed maturity securities (amortized cost of \$15,827.1 and \$15,203.1)		16,733.9		15,696.9
Equity securities (cost of \$821.9 and \$799.1)		1,072.9		1,010.7
Other invested assets, current		17.3		26.5
Accrued investment income		177.6		172.8
Premium and self-funded receivables		3,176.4		3,281.0
Other receivables		908.4		879.5
Securities lending collateral		893.6		394.8
Deferred tax assets, net		416.0		523.8
Other current assets		1,297.1		1,268.6
Total current assets		26,939.4		28,070.7
Long-term investments available-for-sale, at fair value:				
Fixed maturity securities (amortized cost of \$222.1 and \$223.0)		231.9		230.4
Equity securities (cost of \$32.4 and \$33.4)		32.3		32.5
Other invested assets, long-term		845.1		775.3
Property and equipment, net		1,206.7		1,099.6
Goodwill		13,265.4		13,264.6
Other intangible assets		8,056.5		8,259.3
Other noncurrent assets		455.1		393.0
Total assets	\$	51,032.4	\$	52,125.4
Liabilities and shareholders equity Liabilities				
Current liabilities:				
Policy liabilities:				
Medical claims payable	\$	4,956.3	\$	5,450.5
Reserves for future policy benefits		57.9		62.6
Other policyholder liabilities		1,705.1		1,617.6
Total policy liabilities		6,719.3		7,130.7
Unearned income		989.4		1,050.0
Accounts payable and accrued expenses		2,752.7		2,994.1
Income taxes payable		62.1		1,228.7
Security trades pending payable		264.0		37.6
Securities lending payable		894.9		396.6
Short-term borrowings		100.0		
Current portion of long-term debt		706.5		60.8
Other current liabilities		1,652.6		1,775.2
Total current liabilities		14,141.5		14,673.7
Long-term debt, less current portion		8,217.2		8,338.3

Edgar Filing: WELLPOINT, INC - Form 10-Q

Reserves for future policy benefits, noncurrent	653.8	664.6
Deferred tax liabilities, net	2,621.6	2,470.4
Other noncurrent liabilities	1,036.6	1,115.1
Total liabilities	26,670.7	27,262.1
Commitments and contingencies Note 10		
Shareholders equity		
Preferred stock, without par value, shares authorized 100,000,000;		
shares issued and outstanding none		
Common stock, par value \$0.01, shares authorized 900,000,000;		
shares issued and outstanding: 394,807,753 and 449,789,672	4.0	4.5
Additional paid-in capital	13,403.5	15,192.2
Retained earnings	10,581.8	9,598.5
Accumulated other comprehensive income	372.4	68.1
Total shareholders equity	24,361.7	24,863.3
Total liabilities and shareholders equity	\$ 51,032.4	\$ 52,125.4

See accompanying notes.

WellPoint, Inc.

Consolidated Statements of Income

(Unaudited)

(In millions, except per share data)		Three Months Ended September 30				Nine Mon Septen	30	
		2010		2009		2010		2009
Revenues								
Premiums	\$	13,366.7	\$	14,070.7	Φ	40,533.7	\$	42,397.2
Administrative fees	Ψ	963.1	Ψ	969.1	Ψ	2,865.1	Ψ	2,887.4
Other revenue		4.6		167.2		28.8		486.9
Total operating revenue		14,334.4		15,207.0		43,427.6		45,771.5
Net investment income		205.4		196.6		608.8		599.4
Net realized gains on investments		61.6		52.2		146.5		20.4
Other-than-temporary impairment losses on investments:								
Total other-than-temporary impairment losses on investments		(10.4)		(69.1)		(53.2)		(481.9)
Portion of other-than-temporary impairment losses recognized in other		, ,		Ì		, i		, í
comprehensive income		7.2		38.4		24.2		72.2
Other-than-temporary impairment losses recognized in income		(3.2)		(30.7)		(29.0)		(409.7)
Total revenues		14,598.2		15,425.1		44,153.9		45,981.6
Expenses								
Benefit expense		11,204.7		11,552.8		33,571.1		35,127.1
Selling, general and administrative expense:								
Selling expense		400.7		420.6		1,206.2		1,273.8
General and administrative expense		1,689.3		1,839.7		5,265.9		5,421.3
Total selling, general and administrative expense		2,090.0		2,260.3		6,472.1		6,695.1
Cost of drugs				112.7				346.4
Interest expense		106.3		110.6		305.9		343.7
Amortization of other intangible assets		60.4		66.0		182.0		200.5
Impairment of other intangible assets				205.5		21.1		205.5
Total expenses		13,461.4		14,307.9		40,552.2		42,918.3
Income before income tax expense		1,136.8		1,117.2		3,601.7		3,063.3
Income tax expense		397.7		387.0		1,263.4		1,059.2
Net income	\$	739.1	\$	730.2	\$	2,338.3	\$	2,004.1
Net income per share								
Basic	\$	1.86	\$	1.55	\$	5.59	\$	4.15
Diluted	\$	1.84	\$	1.53	\$	5.52	\$	4.12

See accompanying notes.

-3-

WellPoint, Inc.

Consolidated Statements of Cash Flows

(Unaudited)

(In millions)		ns Ended per 30
	2010	2009
Operating activities		
Net income	\$ 2,338.3	\$ 2,004.1
Adjustments to reconcile net income to net cash		
provided by operating activities:		
Net realized gains on investments	(146.5)	(20.4)
Other-than-temporary impairment losses recognized in income	29.0	409.7
Loss on disposal of assets	1.3	9.0
Deferred income taxes	111.0	(7.7)
Amortization, net of accretion	364.3	337.7
Impairment of other intangible assets	21.1	205.5
Depreciation expense	78.2	78.7
Share-based compensation	96.6	115.7
Excess tax benefits from share-based compensation	(25.1)	(5.3)
Changes in operating assets and liabilities, net of effect of business combinations:		
Receivables, net	(22.8)	(127.4)
Other invested assets	8.9	(39.0)
Other assets	(89.9)	9.4
Policy liabilities	(422.3)	(492.7)
Unearned income	(60.6)	10.3
Accounts payable and accrued expenses	(152.4)	243.6
Other liabilities	(116.6)	18.0
Income taxes	(1,143.9)	255.7
Other, net	(38.9)	4.3
Net cash provided by operating activities Investing activities	829.7	3,009.2
Purchases of fixed maturity securities	(8,212.6)	(5,331.1)
Proceeds from fixed maturity securities:	(-,,	(, , , , ,
Sales	5.454.4	2,967.2
Maturities, calls and redemptions	2,542.9	1,178.7
Purchases of equity securities	(191.9)	(195.0)
Proceeds from sales of equity securities	157.1	453.3
Purchases of other invested assets	(67.9)	(36.9)
Proceeds from sales of other invested assets	25.4	2.4
Changes in securities lending collateral	(498.3)	142.3
Purchases of subsidiaries, net of cash acquired	(0.2)	(66.3)
Purchases of property and equipment	(333.6)	(272.3)
Proceeds from sales of property and equipment	6.0	0.4
Other, net	(50.2)	(3.2)
Net cash used in investing activities	(1,168.9)	(1,160.5)
Financing activities		
Net repayments of commercial paper borrowings	(109.5)	(356.6)
Repayment of long-term borrowings	(480.0)	(602.9)
Proceeds from long-term borrowings	1,088.5	990.3
Net proceeds from short-term borrowings	100.0	2.0
Changes in securities lending payable	498.3	(142.3)

Edgar Filing: WELLPOINT, INC - Form 10-Q

Changes in bank overdrafts	(123.0)	(354.6)
Repurchase and retirement of common stock	(3,345.1)	(1,811.4)
Proceeds from exercise of employee stock options and employee stock purchase plan	116.2	77.6
Excess tax benefits from share-based compensation	25.1	5.3
Net cash used in financing activities	(2,229.5)	(2,192.6)
Effect of foreign exchange rates on cash and cash equivalents	(1.2)	2.2
Change in cash and cash equivalents	(2,569.9)	(341.7)
Cash and cash equivalents at beginning of period	4,816.1	2,183.9
Cash and cash equivalents at end of period	\$ 2,246.2	\$ 1,842.2

See accompanying notes.

WellPoint, Inc.

Consolidated Statements of Shareholders Equity

(Unaudited)

(In millions)	Commor	Stock						
			Additional		Other		Total	
	Number of	Par	Paid-in	Retained	-	prehensive	Sh	areholders
	Shares	Value	Capital	Earnings		ncome		Equity
January 1, 2010	449.8	\$ 4.5	\$ 15,192.2	\$ 9,598.5	\$	68.1	\$	24,863.3
Net income				2,338.3				2,338.3
Change in net unrealized gains/losses on								
investments						312.8		312.8
Non-credit component of other-than-temporary						(2.2)		(2.2)
impairment losses on investments, net of taxes						(3.2)		(3.2)
Change in net unrealized gains/losses on cash						(15.0)		(15.0)
flow hedges						(15.0)		(15.0)
Change in net periodic pension and						10.2		10.2
postretirement costs						10.2		10.2
Foreign currency translation adjustments						(0.5)		(0.5)
Comprehensive income								2,642.6
Repurchase and retirement of common stock	(58.9)	(0.5)	(1,989.6)	(1,355.0)				(3,345.1)
Issuance of common stock under employee stock								
plans, net of related tax benefits	3.9		200.9					200.9
September 30, 2010	394.8	\$ 4.0	\$ 13,403.5	\$ 10,581.8	\$	372.4	\$	24,361.7
January 1, 2009	503.2	\$ 5.0	\$ 16,843.0	\$ 5,479.4	\$	(895.7)	\$	21,431.7
Cumulative effect of adoption of								
FASB OTTI guidance, net of taxes				88.9		(88.9)		
Net income				2,004.1				2,004.1
Change in net unrealized gains/losses on								
investments						1,073.0		1,073.0
Non-credit component of other-than-temporary								
impairment losses on investments, net of taxes						(18.6)		(18.6)
Change in net unrealized gains/losses on cash								
flow hedges						(2.2)		(2.2)
Change in net periodic pension and								
postretirement costs						1.4		1.4
Foreign currency translation adjustments						3.5		3.5
Comprehensive income								3,061.2
Repurchase and retirement of common stock	(40.8)	(0.4)	(1,365.4)	(445.6)				(1,811.4)
Issuance of common stock under employee stock								
plans, net of related tax benefits	2.6		185.9					185.9
September 30, 2009	465.0	\$ 4.6	\$ 15,663.5	\$ 7,126.8	\$	72.5	\$	22,867.4
1			,	,		. =	-	,

See accompanying notes.

-5-

WellPoint, Inc.

Notes to Consolidated Financial Statements

(Unaudited)

September 30, 2010

(In Millions, Except Per Share Data or Otherwise Stated Herein)

1. Organization

References to the terms we, our, us, WellPoint or the Company used throughout these Notes to Consolidated Financial Statements refer to WellPoint, Inc., an Indiana corporation, and unless the context otherwise requires, its direct and indirect subsidiaries.

We are the largest health benefits company in terms of commercial membership in the United States, serving 33.5 medical members through our affiliated health plans and a total of 70.4 individuals through all subsidiaries as of September 30, 2010. We offer a broad spectrum of network-based managed care plans to large and small employer, individual, Medicaid and senior markets. Our managed care plans include: preferred provider organizations, or PPOs; health maintenance organizations, or HMOs; point-of-service, or POS, plans; traditional indemnity plans and other hybrid plans, including consumer-driven health plans, or CDHPs; and hospital only and limited benefit products. In addition, we provide a broad array of managed care services to self-funded customers, including claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs and other administrative services. We also provide an array of specialty and other products and services such as life and disability insurance benefits, dental, vision, behavioral health benefit services, radiology benefit management, analytics-driven personal health care guidance, long-term care insurance and flexible spending accounts. We are licensed to conduct insurance operations in all 50 states through our subsidiaries.

We are an independent licensee of the Blue Cross and Blue Shield Association, or BCBSA, an association of independent health benefit plans. We serve our members as the Blue Cross licensee for California; the Blue Cross and Blue Shield, or BCBS, licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding 30 counties in the Kansas City area), Nevada, New Hampshire, New York (as the BCBS licensee in 10 New York City metropolitan and surrounding counties and as the Blue Cross or BCBS licensee in selected upstate counties only), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a majority of these service areas we do business as Anthem Blue Cross, Anthem Blue Cross Blue Shield or Empire Blue Cross Blue Shield (in our New York service areas). We also serve customers throughout much of the country as UniCare.

During the first quarter of 2010, the U.S. Congress passed and the President signed into law the Patient Protection and Affordable Care Act as well as the Health Care and Education Reconciliation Act of 2010, which represent significant changes to the current U.S. health care system. The legislation is far-reaching and is intended to expand access to health insurance coverage over time by increasing the eligibility thresholds for most state Medicaid programs and providing certain other individuals and small businesses with tax credits to subsidize a portion of the cost of health insurance coverage. The legislation includes a requirement that most individuals obtain health insurance coverage beginning in 2014 and that most large employers offer coverage to their employees or they will be required to pay a financial penalty. In addition, the new laws encompass certain new taxes and fees, including an excise tax on high premium insurance policies, limitations on the amount of compensation that is tax deductible and new fees on companies in our industry which may not be deductible for income tax purposes.

The legislation also imposes new regulations on the health insurance sector, including, but not limited to, guaranteed coverage requirements, prohibitions on some annual and all lifetime limits on amounts paid on behalf of or to our members, increased restrictions on rescinding coverage, establishment of minimum medical loss ratio

-6-

requirements, a requirement to cover preventive services on a first dollar basis, the establishment of state insurance exchanges and essential benefit packages and greater limitations on how we price certain of our products. The legislation also reduces the reimbursement levels for health plans participating in the Medicare Advantage program over time.

Some provisions of the health care reform legislation became effective this year, including those that bar health insurance companies from placing lifetime limits on insurance coverage, those related to the increased restrictions on rescinding coverage and those that extend coverage of dependents to the age of 26. The establishment of minimum medical loss ratios, which could have a significant impact on our operations, will take effect for certain of our businesses beginning in 2011. Lastly, other significant changes, including the annual fees on health insurance companies, the excise tax on high premium insurance policies, the guaranteed coverage requirements and the requirement that individuals obtain coverage, do not become effective until 2014 or later.

Many of the details of the new law, including, but not limited to, the medical loss ratio requirements, require additional guidance and specificity to be provided by the Department of Health and Human Services, the Department of Labor, the Department of the Treasury and the National Association of Insurance Commissioners. While proposed regulations on some provisions have been released for review and comment, all of which we are carefully evaluating, it is too early to fully understand the impacts of the legislation on our overall business. For example, while the National Association of Insurance Commissioners has released their proposed regulations governing medical loss ratios, they are subject to finalization by the Department of Health and Human Services and could change significantly as a result. In addition, California recently passed legislation establishing an insurance exchange within that state to comply with the related provisions that become effective in 2014. As California is the first state to provide a structure for such state-based insurance exchanges pursuant to the new legislation, other states may adopt a similar format for their exchanges. Certain provisions of the new law, including the final minimum medical loss ratio regulations and the structure of future insurance exchanges, are likely to have significant impacts on our future operations, which, in turn, could impact the value of our business model and results of operations, including potential impairments of our goodwill and other intangible assets. We will continue to evaluate the impact of this legislation as additional guidance is made available.

In addition, federal and state regulatory agencies may further restrict our ability to obtain new product approvals, implement changes in premium rates or impose additional restrictions, under new or existing laws, such as minimum medical loss ratio requirements or restricted definitions of costs to be included when calculating medical loss ratios under such definitions. Our ability to secure sufficient premium rates, including regulatory approval for and implementation of such rates on a timely basis, may be restricted by additional changes in federal and state regulations or by the application of existing federal and state regulations. A limitation on our ability to increase or maintain our premium rates and more restrictive medical loss ratio requirements could adversely affect our business, cash flows, financial condition and results of operations.

2. Basis of Presentation

The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP, for interim financial reporting. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments, including normal recurring adjustments, necessary for a fair statement of the consolidated financial statements as of and for the three and nine months ended September 30, 2010 and 2009 have been recorded. The results of operations for the three and nine months ended September 30, 2010 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2010. These unaudited consolidated financial statements should be read in conjunction with our audited consolidated financial statements for the year ended December 31, 2009 included in our Annual Report on Form 10-K.

Certain of our subsidiaries operate outside of the United States and have functional currencies other than the U.S. dollar, or USD. We translate the assets and liabilities of those subsidiaries to USD using the exchange rate

-7-

in effect at the end of the period. We translate the revenues and expenses of those subsidiaries to USD using the average exchange rates in effect during the period. The net effect of these translation adjustments is included in Foreign currency translation adjustments in our consolidated statements of shareholders equity.

Our benefit expense includes costs of care for health services consumed by our members, such as outpatient care, inpatient hospital care, professional services (primarily physician care) and pharmacy benefit costs. Beginning January 1, 2010, we began classifying certain claims-related costs, which were historically classified as administrative expense, as benefit expense to better reflect costs incurred for our members traditional medical care as well as those expenses which improve our members health and medical outcomes. These reclassified costs are comprised of expenses incurred for: (i) medical management, including case and utilization management; (ii) health and wellness, including disease management services for such things as diabetes, high-risk pregnancies, congestive heart failure and asthma management and wellness initiatives like weight-loss programs and smoking cessation treatments; and (iii) clinical health policy. These types of claims-related costs ultimately lower our members cost of care. Prior year amounts have been reclassified to conform to the new presentation.

3. Investments

We evaluate our investment securities for other-than-temporary declines based on qualitative and quantitative factors. Other-than-temporary impairment losses recognized in income totaled \$3.2 and \$30.7 for the three months ended September 30, 2010 and 2009, respectively. Other-than-temporary impairment losses recognized in income totaled \$29.0 and \$409.7 for the nine months ended September 30, 2010 and 2009, respectively. There were no individually significant other-than-temporary impairment losses on investments by issuer during the three and nine months ended September 30, 2010 and 2009. We continue to review our investment portfolios under our impairment review policy. Given the current market conditions and the significant judgments involved, there is a continuing risk that further declines in fair value may occur and additional material other-than-temporary impairment losses on investments may be recorded in future periods.

The changes in the amount of the credit component of other-than-temporary impairment losses on fixed maturity securities recognized in income, for which a portion of the other-than-temporary impairment losses was recognized in other comprehensive income, was not material for the three months and nine months ended September 30, 2010 and 2009.

-8-

A summary of current and long-term investments, available-for-sale, at September 30, 2010 and December 31, 2009 is as follows:

	Cost or Amortized Cost	Gross Unrealized Gains	Gross Unro Less than 12 Months	Non-Credit Component of Other-Than- Temporary Impairments Recognized in AOCI		
September 30, 2010:						
Fixed maturity securities:						
United States Government securities	\$ 797.4	\$ 39.7	\$ (0.7)	\$	\$ 836.4	\$
Government sponsored securities	328.0	8.4			336.4	
States, municipalities and political						
subdivisions tax-exempt	4,516.8	278.5	(1.3)	(15.6)	4,778.4	
Corporate securities	6,999.6	505.9	(8.2)	(9.0)	7,488.3	(0.9)
Options embedded in convertible debt						
securities	83.5				83.5	
Residential mortgage-backed securities	2,762.4	132.1	(1.7)	(17.9)	2,874.9	(6.3)
Commercial mortgage-backed securities	279.8	12.4	(0.1)	(2.4)	289.7	
Other debt obligations	281.7	7.5	(0.1)	(10.9)	278.2	(1.2)
Total fixed maturity securities	16,049.2	984.5	(12.1)	(55.8)	16,965.8	\$ (8.4)
Equity securities	854.3	265.1	(14.2)	ф <i>(</i> 55.0)	1,105.2	
Total investments, available-for-sale	\$ 16,903.5	\$ 1,249.6	\$ (26.3)	\$ (55.8)	\$ 18,071.0	

	Cost or Amortized Cost	Gross Unrealized Gains	Gross Unro Less than 12 Months	ealized Losses Greater than 12 Months	Estimated Fair Value	Non-Credit Component of Other-Than- Temporary Impairments Recognized in AOCI
December 31, 2009:						
Fixed maturity securities:						
United States Government securities	\$ 715.4	\$ 14.8	\$ (2.4)	\$ (0.2)	\$ 727.6	\$
Government sponsored securities	632.8	8.3	(0.4)		640.7	
States, municipalities and political						
subdivisions tax-exempt	4,019.4	167.0	(5.7)	(34.4)	4,146.3	(0.5)
Corporate securities	6,219.3	352.2	(12.9)	(34.5)	6,524.1	(3.3)
Options embedded in convertible debt						
securities	88.3				88.3	
Residential mortgage-backed securities	3,295.0	120.0	(7.9)	(47.0)	3,360.1	(9.0)
Commercial mortgage-backed securities	137.6	3.6	(0.1)	(4.9)	136.2	
Other debt obligations	318.3	8.7	(1.1)	(21.9)	304.0	(5.7)
Total fixed maturity securities	15,426.1	674.6	(30.5)	(142.9)	15,927.3	\$ (18.5)
Equity securities	832.5	221.9	(11.2)		1,043.2	
Total investments, available-for-sale	\$ 16,258.6	\$ 896.5	\$ (41.7)	\$ (142.9)	\$ 16,970.5	

At September 30, 2010, we owned \$3,164.6 of mortgage-backed securities and \$278.2 of asset-backed securities out of a total available-for-sale investment portfolio of \$18,071.0. These securities included sub-prime and Alt-A securities with fair values of \$82.0 and \$257.9, respectively. These sub-prime and Alt-A securities had accumulated net unrealized losses of \$7.0 and \$7.3, respectively. The average credit rating of the sub-prime and Alt-A securities was BBB and BB , respectively.

The following tables summarize for fixed maturity securities and equity securities in an unrealized loss position at September 30, 2010 and December 31, 2009, the aggregate fair value and gross unrealized loss by length of time those securities have been continuously in an unrealized loss position.

		G	2 Months							
		Gross								
	Number of	Es	timated	Un	realized	Number of	Esti	mated	Unı	realized
(Securities are whole amounts)	Securities	Fai	r Value		Loss	Securities	Fair	Value]	Loss
September 30, 2010:										
Fixed maturity securities:										
United States Government securities	3	\$	29.9	\$	(0.7)		\$		\$	
States, municipalities and political subdivisions										
tax-exempt	75		231.1		(1.3)	110		189.1		(15.6)
Corporate securities	328		643.3		(8.2)	83		108.9		(9.0)
Residential mortgage-backed securities	117		261.3		(1.7)	90		176.4		(17.9)
Commercial mortgage-backed securities	6		20.1		(0.1)	3		8.2		(2.4)
Other debt obligations	10		21.6		(0.1)	41		51.3		(10.9)
Total fixed maturity securities	539		1,207.3		(12.1)	327		533.9		(55.8)
Equity securities	672		97.3		(14.2)					
					. ,					
Total fixed maturity and equity securities	1,211	\$	1,304.6	\$	(26.3)	327	\$	533.9	\$	(55.8)

		G	er than 12 N	Months						
		Gross						(Gross	
	Number of	Es	stimated	Uni	realized	Number of	Es	stimated	Un	realized
(Securities are whole amounts)	Securities	Fa	ir Value		Loss	Securities	Fa	ir Value		Loss
December 31, 2009:										
Fixed maturity securities:										
United States Government securities	18	\$	286.8	\$	(2.4)	3	\$	3.1	\$	(0.2)
Government sponsored securities	17		149.3		(0.4)					
States, municipalities and political subdivisions										
tax-exempt	162		417.6		(5.7)	185		314.8		(34.4)
Corporate securities	462		914.5		(12.9)	233		404.3		(34.5)
Residential mortgage-backed securities	219		439.0		(7.9)	128		256.1		(47.0)
Commercial mortgage-backed securities	7		9.8		(0.1)	14		39.9		(4.9)
Other debt obligations	24		112.5		(1.1)	49		61.0		(21.9)
Total fixed maturity securities	909		2,329.5		(30.5)	612		1,079.2		(142.9)
Equity securities	788		99.0		(11.2)					
Total fixed maturity and equity securities	1,697	\$	2,428.5	\$	(41.7)	612	\$	1,079.2	\$	(142.9)

The amortized cost and fair value of fixed maturity securities at September 30, 2010, by contractual maturity, are shown below. Expected maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties.

	Amortized	Estimated
	Cost	Fair Value
Due in one year or less	\$ 1,193.5	\$ 1,199.1
Due after one year through five years	5,189.9	5,513.5
Due after five years through ten years	4,155.2	4,475.1
Due after ten years	2,468.4	2,613.5
Mortgage-backed securities	3,042.2	3,164.6
Total available-for-sale fixed maturity securities	\$ 16,049.2	\$ 16,965.8

During the nine months ended September 30, 2010, we sold \$5,611.5 of fixed maturity and equity securities, which resulted in gross realized gains of \$218.9 and gross realized losses of \$72.4. In the ordinary course of business, we may sell securities at a loss for a number of reasons, including, but not limited to: (i) changes in the investment environment; (ii) expectation that the fair value could deteriorate further; (iii) desire to reduce exposure to an issuer or an industry; (iv) changes in credit quality; or (v) changes in expected cash flow.

All securities sold resulting in investment gains and losses are recorded on the trade date. Realized gains and losses are determined on the basis of the cost or amortized cost of the specific securities sold.

4. Derivative Instruments and Hedging Activities

In accordance with Financial Accounting Standards Board, or FASB, guidance, all investments in derivatives are recorded as assets or liabilities at fair value. A derivative is typically defined as an instrument whose value is derived from an underlying instrument, index or rate, has a notional amount, requires little or no initial investment and can be net settled. We typically invest in the following types of derivative financial instruments: interest rate swaps, forward contracts, put and call options, credit default swaps, embedded derivatives and warrants. Derivatives embedded within non-derivative instruments (such as options embedded in convertible fixed maturity securities) are bifurcated from the host instrument when the embedded derivative is not clearly and closely related to the host instrument.

Our use of derivatives is limited by statutes and regulations promulgated by the various regulatory bodies to which we are subject, and by our own derivative policy. Our derivative use is generally limited to hedging purposes and we generally do not use derivative instruments for speculative purposes.

We have exposure to economic losses due to interest rate risk arising from changes in the level or volatility of interest rates. We attempt to mitigate our exposure to interest rate risk through active portfolio management, which includes rebalancing our existing portfolios of assets and liabilities, as well as changing the characteristics of investments to be purchased or sold in the future. In addition, derivative financial instruments are used to modify the interest rate exposure of certain liabilities or forecasted transactions. These strategies include the use of interest rate swaps and forward contracts, which are used to lock interest rates or to hedge (on an economic basis) interest rate risks associated with variable rate debt. We have used these types of instruments as designated hedges against specific liabilities.

If certain correlation, hedge effectiveness and risk reduction criteria are met, a derivative may be specifically designated as a hedge of exposure to changes in fair value or cash flow. The accounting for changes in the fair value of a derivative depends on the intended use of the derivative and the nature of any hedge designation thereon. Amounts excluded from the assessment of hedge effectiveness, if any, as well as the ineffective portion of the gain or loss, are reported in results of operations immediately. We test for hedge effectiveness at hedge inception and

Table of Contents 18

-12-

re-assess at the end of each reporting period. No amounts were excluded from the assessment of hedge effectiveness. If the derivative is not designated as a hedge, the gain or loss resulting from the change in the fair value of the derivative is recognized in results of operations in the period of change.

We discontinue hedge accounting prospectively when it is determined that one of the following has occurred: (i) the derivative is no longer highly effective in offsetting changes in the fair value or cash flows of a hedged item; (ii) the derivative expires or is sold, terminated or exercised; (iii) the derivative is no longer designated as a hedge instrument because it is unlikely that a forecasted transaction will occur; (iv) a hedged firm commitment no longer meets the definition of a firm commitment; or (v) we otherwise determine that the designation of the derivative as a hedge instrument is no longer appropriate.

If hedge accounting is discontinued, the derivative will continue to be carried on our consolidated balance sheets at its fair value. When hedge accounting is discontinued because the derivative no longer qualifies as an effective fair value hedge, the related hedged asset or liability will no longer be adjusted for fair value changes. When hedge accounting is discontinued because it is probable that a forecasted transaction will not occur, the accumulated unrealized gains and losses included in accumulated other comprehensive income will be recognized immediately in results of operations. When hedge accounting is discontinued because the hedged item no longer meets the definition of a firm commitment, any asset or liability that was recorded pursuant to the firm commitment will be removed from the balance sheet and recognized as a gain or loss in current period results of operations. In all other situations in which hedge accounting is discontinued, changes in the fair value of the derivative are recognized in current period results of operations.

From time to time, we may also purchase derivatives to hedge, on an economic basis, our exposure to foreign currency exchange fluctuations associated with the operations of certain of our subsidiaries. We generally use futures or forward contracts for these transactions. We generally do not designate these contracts as hedges and, accordingly, the changes in fair value of these derivatives are recognized in income immediately. In addition, we purchase put and call options designed to reduce the volatility in the value of our equity securities portfolio due to changes in fair value. These options are not designated as hedges and, accordingly, the changes in fair value of these derivatives are recognized in income immediately.

Credit exposure associated with non-performance by the counterparties to derivative instruments is generally limited to the uncollateralized fair value of the asset related to instruments recognized in the consolidated balance sheets. We attempt to mitigate the risk of non-performance by selecting counterparties with high credit ratings and monitoring their creditworthiness and by diversifying derivatives among multiple counterparties. At September 30, 2010, we believe there were no material concentrations of credit risk with any individual counterparty.

Certain of our derivative agreements contain credit support provisions that require us to post collateral if our net exposure to the counterparty exceeds certain minimum thresholds, which is triggered based on declines in our credit rating. There was no collateral posted with counterparties as of September 30, 2010.

The contractual or notional amounts for derivatives are used to calculate the exchange of contractual payments under the agreements and are not representative of the potential for gain or loss on these instruments. Interest rates and equity prices may affect the fair value of derivatives. The fair values generally represent the estimated amounts that we would expect to receive or pay upon termination of the contracts at the reporting date. Fair values of options embedded in convertible debt securities are generally based on quoted market prices in active markets. Fair values of interest rate swaps are based on the quoted market prices by the financial institution that is the counterparty to the swap. We independently verify prices provided by the counterparties using valuation models that incorporate market observable inputs for similar interest rate swaps.

-13-

A summary of the aggregate contractual or notional amounts, balance sheet location and estimated fair values of derivative financial instruments at September 30, 2010 and December 31, 2009 is as follows:

		Contractual/ Balance Sheet Notional				ated Fair ⁄alue		
	A	Amount	Classification	A	Asset	(Li	iability)	
September 30, 2010:								
Hedging instruments								
Swaps			Other noncurrent assets/Other					
	\$	1,480.0	noncurrent liabilities	\$	109.7	\$		
Non-hedging instruments								
Derivatives embedded in convertible debt								
securities		381.5	Fixed maturity securities		83.5			
Credit default swaps		19.9	Equity securities				(0.3)	
Options		6,632.1	Equity securities		182.2		(204.5)	
•			• •					
Subtotal non-hedging instruments		7,033.5			265.7		(204.8)	
2		.,					(==)	
Total derivatives	\$	8,513.5		\$	375.4	\$	(204.8)	
		.,.					(
December 31, 2009:								
Hedging instruments								
Swaps			Other noncurrent assets/Other					
•								
	\$	1,775.0	noncurrent liabilities	\$	85.1	\$	(0.3)	
		,					()	
Non-hedging instruments								
Derivatives embedded in convertible debt		250.5			00.2			
securities		359.5	Fixed maturity securities		88.3		(0.2)	
Credit default swaps		19.3	Equity securities				(0.2)	
Subtotal non-hedging instruments		378.8			88.3		(0.2)	
Total derivatives	\$	2,153.8		\$	173.4	\$	(0.5)	

Fair Value Hedges

During the year ended December 31, 2009, we entered into a fair value hedge with a total notional value of \$600.0. The hedge is an interest rate swap agreement to receive a fixed 5.000% rate and pay a LIBOR-based floating rate and expires on January 15, 2011.

During the year ended December 31, 2006, we entered into two fair value hedges with a total notional value of \$440.0. The first hedge is a \$240.0 notional amount interest rate swap agreement to receive a fixed 6.800% rate and pay a LIBOR-based floating rate and expires on August 1, 2012. The second hedge is a \$200.0 notional amount interest rate swap agreement to receive a fixed 5.000% rate and pay a LIBOR-based floating rate and expires on December 15, 2014.

During the year ended December 31, 2005, we entered into two fair value hedges with a total notional value of \$660.0, which was subsequently reduced to \$440.0 during 2008. The first hedge is a \$240.0 notional amount interest rate swap agreement to exchange a fixed 6.800% rate for a LIBOR-based floating rate and expires on August 1, 2012. The second hedge is a \$200.0 notional amount interest rate swap agreement to exchange a fixed 5.000% rate for LIBOR-based floating rate and expires December 15, 2014.

-14-

A summary of the effect of fair value hedges on our income statement for the three and nine months ended September 30, 2010 and 2009 is as follows:

	Income Statement Classification of	н	edge		Hedş	ged Item	
Type of Fair	Derivative	Gain	(Loss)		Hedged Item	Gair	n (Loss)
Value Hedge	Gain (Loss)	Reco	gnized	Hedged Item	Gain (Loss)	Rec	ognized
Three Months Ended Septer	mber 30, 2010:						
Swaps	Interest expense	\$	11.5	Fixed rate debt	Interest expense	\$	(11.5)
Three Months Ended Septer	mber 30, 2009:						
Swaps	Interest expense	\$	9.9	Fixed rate debt	Interest expense	\$	(9.9)
Nine Months Ended Septem	ber 30, 2010:						
Swaps	Interest expense	\$	33.5	Fixed rate debt	Interest expense	\$	(33.5)
Nine Months Ended Septem	ber 30, 2009:						
Swaps	Interest expense	\$	27.1	Fixed rate debt	Interest expense	\$	(27.1)

Cash Flow Hedges

During the second and third quarters of 2010, we entered into forward starting pay fixed interest rate swaps with a notional amount of \$325.0 during each quarter. The objective of these hedges was to eliminate the variability of cash flows in the interest payments on the debt securities issued in August 2010. These swaps were terminated in August 2010, and we paid a net \$24.0, the net fair value at the time of termination. In addition, we recorded a loss of \$15.6, net of tax, in other comprehensive income.

Following the August 9, 2010 issuance of debt securities, the unamortized fair value of the forward starting pay fixed swaps included in accumulated other comprehensive income began amortizing into earnings, as an increase to interest expense. In addition, we have amounts recorded in accumulated other comprehensive income for certain forward starting pay fixed swaps that were terminated in prior years. The hedged debt securities have maturity dates ranging from 2011 to 2040.

Beginning in the fourth quarter of 2009 and continuing into the second quarter of 2010, we entered into a series of forward starting pay fixed interest rate swaps with a total combined notional amount of \$250.0. The objective of this series of hedges was to eliminate the variability of the cash flows associated with interest payments on our senior term loan. We agreed to receive a LIBOR-based floating rate and pay a fixed rate. The swaps began to expire on a monthly basis starting on April 30, 2010 and the final swap in the series expired at maturity on September 30, 2010.

In January 2009, we entered into forward starting pay fixed interest rate swaps with an aggregate notional amount of \$800.0. The objective of these hedges was to eliminate the variability of cash flows in the interest payments on the debt securities issued in February 2009. These swaps were terminated in February 2009, and we paid a net \$3.2, the net fair value at the time of termination. In addition, we recorded a loss of \$2.1, net of tax, in other comprehensive income. Following the February 5, 2009 issuance of debt securities, the unamortized fair value of the forward starting pay fixed interest rate swaps included in accumulated other comprehensive income began amortizing into earnings as an increase to interest expense. In addition, we have amounts recorded in accumulated other comprehensive income for certain forward starting pay fixed swaps that were terminated in prior years. The hedged debt securities have maturity dates ranging from 2014 to 2036.

Table of Contents

22

The unrecognized losses for all cash flow hedges included in accumulated other comprehensive income at September 30, 2010 and December 31, 2009 were \$25.8 and \$10.8, respectively. As of September 30, 2010, the total amount of amortization over the next twelve months for all cash flow hedges will increase interest expense by approximately \$2.2.

A summary of the effect of cash flow hedges on our financial statements for the three and nine months ended September 30, 2010 and 2009 is as follows:

	Effective Portion Income Statement Classification of	Н	Portion			
Type of Cash Flow Hedge	Hedge Gain (Loss) Recognized in Other Comprehensive Income	Gain (Loss) Reclassified from Accumulated Other Comprehensive Income	Gain (Loss) Reclassified from Accumulated Other Comprehensive Income		Income Statement Classification of Gain (Loss) Recognized	Hedge Gain (Loss) Recognized
Three Months Ended S	eptember 30, 2010:					
Forward starting pay fixed swaps	\$ (11.8)	Interest expense	\$	(0.4)	None	\$
Other fixed pay swaps	\$	Interest expense	\$	(0.2)	None	\$
Three Months Ended S	eptember 30, 2009:					
Forward starting pay fixed swaps	\$ (0.3)	Interest expense	\$	(0.1)	None	\$
Nine Months Ended Sep	ptember 30, 2010:					
Forward starting pay fixed swaps	\$ (24.0)	Interest expense	\$	(0.6)	None	\$
Other fixed pay swaps	\$	Interest expense	\$		None	\$
Nine Months Ended Sep	ptember 30, 2009:					
Forward starting pay fixed swaps	\$ (3.5)	Interest expense	\$	0.1	None	\$

Non-Hedging Derivatives

In June 2010, we entered into a series of put and call options on the Standard & Poor s 500, or S&P 500, index to hedge our exposure to fluctuations in the fair value of our equity securities portfolio.

Edgar Filing: WELLPOINT, INC - Form 10-Q

-16-

A summary of the effect of non-hedging derivatives on our income statement and included in net realized gains on investments for the three and nine months ended September 30, 2010 and 2009 is as follows:

Type of Non-hedging Derivatives			rivative n (Loss) ognized
Three Months Ended September 30, 2010:			
Derivatives embedded in convertible debt securities	Net realized gains (losses) on investments	\$	16.5
Credit default swaps	Net realized gains (losses) on investments		(2.9)
Options	Net realized gains (losses) on investments		(22.8)
Total		\$	(9.2)
Three Months Ended September 30, 2009:			
Derivatives embedded in convertible debt securities	Net realized gains (losses) on investments	\$	26.0
Credit default swaps	Net realized gains (losses) on investments		(0.8)
Options	Net realized gains (losses) on investments		(1.3)
Futures	Net realized gains (losses) on investments		2.2
Foreign currency derivatives	Net realized gains (losses) on investments		0.1
Total		\$	26.2
Nine Months Ended September 30, 2010:			
Derivatives embedded in convertible debt securities	Net realized gains (losses) on investments	\$	0.8
Credit default swaps	Net realized gains (losses) on investments		(4.1)
Options	Net realized gains (losses) on investments		(22.2)
Total		\$	(25.5)
Nine Months Ended September 30, 2009:			
Derivatives embedded in convertible debt securities	Net realized gains (losses) on investments	\$	30.9
Credit default swaps	Net realized gains (losses) on investments	Ψ	(0.7)
Options Options	Net realized gains (losses) on investments		(5.0)
Futures	Net realized gains (losses) on investments		3.0
Foreign currency derivatives	Net realized gains (losses) on investments		0.9
rotoign currency derivatives	rect realized gams (1055es) on investments		0.9
Total		\$	29.1

5. Fair Value

Assets and liabilities recorded at fair value in the consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Level inputs, as defined by FASB guidance for fair value measurements and disclosures, are as follows:

Level Input: Input Definition:

Level I Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date.

Edgar Filing: WELLPOINT, INC - Form 10-Q

Level II Inputs other than quoted prices included in Level I that are observable for the asset or liability through corroboration with market data at the measurement date.

Level III Unobservable inputs that reflect management s best estimate of what market participants would use in pricing the asset or liability at the measurement date.

Transfers between Levels, if any, are recorded as of the beginning of the reporting period.

The following methods and assumptions were used to determine the fair value of each class of the following assets and liabilities recorded at fair value in the consolidated balance sheets:

Cash equivalents: Cash equivalents primarily consist of highly rated money market funds with maturities of three months or less and are purchased daily at par value with specified yield rates. Due to the high ratings and short-term nature of the funds, we designate all cash equivalents as Level I.

Fixed maturity securities, available-for-sale: Fair values of available-for-sale fixed maturity securities are based on quoted market prices, where available. These fair values are obtained primarily from third party pricing services, which generally use Level I or Level II inputs, for the determination of fair value to facilitate fair value measurements and disclosures. United States Government securities represent Level I securities, while Level II securities primarily include corporate securities, securities from states, municipalities and political subdivisions and mortgage-backed securities. For securities not actively traded, the third party pricing services may use quoted market prices of comparable instruments or discounted cash flow analyses, incorporating inputs that are currently observable in the markets for similar securities. Inputs that are often used in the valuation methodologies include, but are not limited to, broker quotes, benchmark yields, credit spreads, default rates and prepayment speeds. We also have certain fixed maturity securities, primarily corporate debt and other fixed maturity securities, that are designated Level III securities. For these securities, the valuation methodologies may incorporate broker quotes or assumptions for benchmark yields, credit spreads, default rates and prepayment speeds that are not observable in the markets.

Equity securities, available-for-sale: Fair values of equity securities are generally designated as Level I and are based on quoted market prices. For certain equity securities, quoted market prices for the identical security are not always available and the fair value is estimated by reference to similar securities for which quoted prices are available. These securities are designated Level II. In addition, we invest in certain put and call options for which quoted market prices are not available and fair value is estimated based on inputs such as spot rates, interest rates, dividend rates and volatility assumptions, which are observable in the equity markets. These securities are also designated Level II. We also have certain equity securities, including private equity securities, for which the fair value is estimated based on each security s current condition and future cash flow projections. Such securities are designated Level III.

Other invested assets, current: Other invested assets, current include securities held in rabbi trusts that are classified as trading. Fair values are based on quoted market prices.

Securities lending collateral: Fair values of securities lending collateral are based on quoted market prices, where available. These fair values are obtained primarily from third party pricing services, which generally use Level I or Level II inputs, for the determination of fair value to facilitate fair value measurements and disclosures.

Derivatives interest rate swaps: Fair values are based on the quoted market prices by the financial institution that is the counterparty to the swap. We independently verify prices provided by the counterparties using valuation models that incorporate market observable inputs for similar interest rate swaps.

We obtain only one quoted price for each security from third party pricing services, which are derived through recently reported trades for identical or similar securities making adjustments through the reporting date based upon available market observable information. As we are responsible for the determination of fair value, we perform monthly analysis on the prices received from third parties to determine whether the prices are reasonable estimates of fair value. Our analysis includes a review of month-to-month price fluctuations. If unusual fluctuations are noted in this review, we may obtain additional information from other pricing services to validate the quoted price. There were no adjustments to quoted market prices obtained from third party pricing services during the three and nine months ended September 30, 2010 and 2009 that were material to the consolidated financial statements.

A summary of fair value measurements by level for assets measured at fair value on a recurring basis at September 30, 2010 and December 31, 2009 is as follows:

	Level I	Level II	Level III	Total
September 30, 2010:				
Assets:				
Cash equivalents	\$ 1,874.0	\$	\$	\$ 1,874.0
Investments available-for-sale:				
Fixed maturity securities:				
United States Government securities	836.4			836.4
Government sponsored securities		336.4		336.4
States, municipalities and political subdivisions tax-exempt		4,778.4		4,778.4
Corporate securities		7,264.2	224.2	7,488.4
Options embedded in convertible debt securities		83.5		83.5
Residential mortgage-backed securities		2,874.9		2,874.9
Commercial mortgage-backed securities		281.9	7.8	289.7
Other debt obligations		195.9	82.2	278.1
Total fixed maturity securities	836.4	15,815.2	314.2	16,965.8
Equity securities	1,055.1	46.8	3.3	1,105.2
Other invested assets, current	17.3			17.3
Securities lending collateral	396.6	497.0		893.6
Derivatives excluding embedded options (reported with other noncurrent assets)		109.7		109.7
Total	\$ 4,179.4	\$ 16,468.7	\$ 317.5	\$ 20,965.6
December 31, 2009: Assets:				
Cash equivalents	\$ 4,461.0	\$	\$	\$ 4,461.0
Investments available-for-sale:	\$ 4,401.0	Ψ	Φ	\$ 4,401.0
Fixed maturity securities:				
United States Government securities	727.6			727.6
Government sponsored securities	727.0	640.7		640.7
States, municipalities and political subdivisions tax-exempt		4,146.3		4,146.3
Corporate securities		6,292.4	231.7	6,524.1
Options embedded in convertible debt securities		88.3	231.7	88.3
Residential mortgage-backed securities		3,358.1	2.0	3,360.1
Commercial mortgage-backed securities		129.1	7.1	136.2
Other debt obligations		198.0	106.0	304.0
Total fixed maturity securities	727.6	14,852.9	346.8	15,927.3
Equity securities	980.4	58.3	4.5	1,043.2
Other invested assets, current	26.5	50.5	1.5	26.5
Securities lending collateral	305.3	89.5		394.8
Derivatives excluding embedded options (reported with other noncurrent assets)		85.1		85.1
Total	\$ 6,500.8	\$ 15,085.8	\$ 351.3	\$ 21,937.9
Liabilities:				
Derivatives (reported with other noncurrent liabilities)	\$	\$ (0.3)	\$	\$ (0.3)

Edgar Filing: WELLPOINT, INC - Form 10-Q

-19-

A reconciliation of the beginning and ending balances of assets measured at fair value on a recurring basis using Level III inputs for the three months ended September 30, 2010 and 2009 is as follows:

		rporate curities	Mor ba	dential tgage- cked ırities	Moi ba	mercial tgage- cked urities]	Other Debt igations		quity urities	,	Total
Three Months Ended September 30, 2010:												
Beginning balance at July 1, 2010	\$	227.3	\$		\$	7.2	\$	88.2	\$	3.9	¢	326.6
Total gains (losses):	Ф	221.3	Ф		Ф	1.2	Ф	00.2	Ф	3.9	Ф	320.0
Recognized in net income								(0.9)		(1.8)		(2.7)
Recognized in accumulated other								(0.2)		(1.0)		(2.7)
comprehensive income		11.8				0.9		4.0		1.2		17.9
Purchases, sales, issuances and		11.0				0.7		1.0		1.2		17.7
settlements, net		(14.9)				(0.3)		(9.1)				(24.3)
Transfers into Level III		(11.7)				(0.5)		().1)				(21.3)
Transfers out of Level III												
Transcers out of 20 vol 111												
Ending balance at September 30, 2010	\$	224.2	\$		\$	7.8	\$	82.2	\$	3.3	\$	317.5
Ending balance at September 30, 2010	Ψ	224.2	Ψ		Ψ	7.0	Ψ	02.2	Ψ	3.3	Ψ	317.3
Change in unrealized lesses included in not												
Change in unrealized losses included in net income related to assets still held for the												
three months ended September 30, 2010	\$		\$		\$		\$	(0.1)	\$	(1.8)	\$	(1.9)
tiffee months ended September 50, 2010	φ		φ		φ		φ	(0.1)	φ	(1.0)	φ	(1.9)
Three Months Ended September 30,												
2009:												
Beginning balance at July 1, 2009	\$	199.9	\$	5.8	\$	5.6	\$	105.7	\$	5.5	\$	322.5
Total gains (losses):												
Recognized in net income		0.1		(0.1)				(3.3)		0.1		(3.2)
Recognized in accumulated other												
comprehensive income		10.8		(0.5)		0.2		9.8		(0.4)		19.9
Purchases, sales, issuances and												
settlements, net		(2.9)				(0.3)		(2.4)		(0.3)		(5.9)
Transfers into Level III		0.1						6.9		0.1		7.1
Transfers out of Level III		(22.3)										(22.3)
Ending balance at September 30, 2009	\$	185.7	\$	5.2	\$	5.5	\$	116.7	\$	5.0	\$	318.1
Change in unrealized losses included in net												
income related to assets still held for the												
three months ended September 30, 2009	\$		\$	(0.1)	\$		\$	(1.7)	\$		\$	(1.8)

A reconciliation of the beginning and ending balances of assets measured at fair value on a recurring basis using Level III inputs for the nine months ended September 30, 2010 and 2009 is as follows:

	rporate curities	Mor ba	dential tgage- cked urities	Moi ba	mercial tgage- cked urities]	Other Debt igations	quity urities	ŗ	Γotal
Nine Months Ended September 30, 2010:										
Beginning balance at January 1, 2010	\$ 231.7	\$	2.0	\$	7.1	\$	106.0	\$ 4.5	\$	351.3
Total gains (losses):										
Recognized in net income	0.3						(3.3)	(2.6)		(5.6)
Recognized in accumulated other										
comprehensive income	19.3				1.5		11.9	0.9		33.6
Purchases, sales, issuances and										
settlements, net	(31.1)		(2.0)		(0.8)		(32.4)	0.5		(65.8)
Transfers into Level III	4.0									4.0
Transfers out of Level III										
Ending balance at September 30, 2010	\$ 224.2	\$		\$	7.8	\$	82.2	\$ 3.3	\$	317.5
Change in unrealized losses included in										
net income related to assets still held for										
the nine months ended September 30,										
2010	\$	\$		\$		\$	(0.3)	\$ (2.6)	\$	(2.9)
Nine Months Ended September 30,										
2009:										
Beginning balance at January 1, 2009	\$ 191.1	\$	7.0	\$	9.7	\$	138.7	\$ 11.2	\$	357.7
Total gains (losses):										
Recognized in net income			(0.1)				(49.2)	(0.4)		(49.7)
Recognized in accumulated other										
comprehensive income	12.0		(0.8)		(3.2)		42.8	(0.5)		50.3
Purchases, sales, issuances and										
settlements, net	(14.1)		(0.9)		(1.0)		(13.6)	(6.3)		(35.9)
Transfers into Level III	20.3						6.9	1.0		28.2
Transfers out of Level III	(23.6)						(8.9)			(32.5)
Ending balance at September 30, 2009	\$ 185.7	\$	5.2	\$	5.5	\$	116.7	\$ 5.0	\$	318.1
Change in unrealized losses included in net income related to assets still held for the nine months ended September 30,										
2009	\$	\$	(0.1)	\$		\$	(14.8)	\$	\$	(14.9)

There were no material transfers between Levels I and II during the three and nine months ended September 30, 2010 and 2009.

Certain assets and liabilities are measured at fair value on a nonrecurring basis; that is, the instruments are not measured at fair value on an ongoing basis but are subject to fair value adjustments only in certain circumstances. We completed our acquisition of DeCare Dental, LLC, or DeCare, on April 9, 2009. On that date, we acquired net assets with a fair value of \$82.8 and recorded goodwill with a fair value of \$15.0, which was subsequently reduced to \$14.4 resulting from purchase accounting adjustments. The net assets acquired and resulting goodwill were

Edgar Filing: WELLPOINT, INC - Form 10-Q

recorded at fair value using Level III inputs. The fair value of the net assets acquired was

-21-

internally estimated based on a blend of the income approach and market value approach. The income approach estimates fair value based on calculations of discounted future cash flows using internal estimates for inputs, including, but not limited to, revenue and expense projections and discount rates. The market value approach estimates fair value based on the market prices of actual sales of similar assets and on asking prices for similar assets available for sale. There were no other assets or liabilities measured at fair value on a nonrecurring basis during the three and nine months ended September 30, 2010 and 2009.

The carrying values and estimated fair values of financial instruments not recorded at fair value on our consolidated balance sheet at September 30, 2010 and December 31, 2009 are as follows:

	Septembe	er 30, 2010	December 31, 2009			
	Carrying Value	Estimated Fair Value	Carrying Value	Estimated Fair Value		
Assets:						
Other invested assets, long-term	\$ 845.1	\$ 845.1	\$ 775.3	\$ 775.3		
Liabilities:						
Debt:						
Short-term borrowings	100.0	100.0				
Commercial paper	391.1	391.1	500.6	500.6		
Notes, term loan and capital leases	8,532.6	9,261.7	7,898.5	8,128.8		

The following methods and assumptions were used to estimate the fair value of each class of the following financial instruments:

Other invested assets, long-term: Other invested assets, long-term include primarily our investments in limited partnerships, joint ventures and other non-controlled corporations, as well as the cash surrender value of corporate-owned life insurance policies. Investments in limited partnerships, joint ventures and other non-controlled corporations are carried at our share in the entities undistributed earnings, which approximates fair value. The carrying value of corporate-owned life insurance policies are the cash surrender value as reported by the respective insurer.

Short-term borrowings: The fair value of our short-term borrowings is based on quoted market prices for the same or similar debt, or, if no quoted market prices are available, the current rates estimated to be available to us for debt of similar terms and remaining maturities.

Long-term debt commercial paper: The carrying amount for commercial paper approximates fair value as the underlying instruments have variable interest rates at market value.

Long-term debt notes, term loan and capital leases: The fair value of notes and amounts due under our senior term loan is based on quoted market prices for the same or similar debt, or, if no quoted market prices were available, on the current rates estimated to be available to us for debt of similar terms and remaining maturities. Capital leases are carried at the unamortized present value of the minimum lease payments, which approximates fair value.

Non-financial instruments such as real estate, property and equipment, other current assets, deferred income taxes and intangible assets, and certain financial instruments such as policy liabilities are excluded from the fair value disclosures. Therefore, the fair value amounts cannot be aggregated to determine our underlying economic value.

The carrying amounts reported in the consolidated balance sheets for cash, accrued investment income, premium and self-funded receivables, other receivables, unearned income, accounts payable and accrued

expenses, income taxes payable, security trades pending payable, securities lending payable and certain other current liabilities approximate fair value because of the short-term nature of these items. These assets and liabilities are not listed in the table above.

6. Income Taxes

As of September 30, 2010, as further described below, certain of our tax years are being examined by the Internal Revenue Service, or IRS, and various state and local authorities. In addition, we continue to discuss certain industry issues with the IRS.

As of September 30, 2010, the examinations of our 2008, 2007, 2006, 2005 and 2004 tax years are nearing conclusion. In addition, there are several years with ongoing disputes related to our companies pre-acquisition years that are nearing conclusion. Many of the issues in open tax years have been resolved; however, several of the examinations still require approval from the United States Congress Joint Committee on Taxation before they can be finalized.

During the three months ended September 30, 2010 and 2009, we recognized income tax expense of \$397.7 and \$387.0, respectively, which represents effective tax rates of 35.0% and 34.6%, respectively. During the nine months ended September 30, 2010 and 2009, we recognized income tax expense of \$1,263.4 and \$1,059.2, respectively, which represents effective tax rates of 35.1% and 34.6%, respectively. The year to date increase in effective tax rates primarily resulted from the impact of compensation deduction limitations associated with health care reform legislation in 2010.

During the first quarter of 2010, we made tax payments of \$1,208.0 to the IRS, principally related to the gain we realized on the sale of our prescription benefits management, or PBM, business which occurred in the fourth quarter of 2009.

In March 2010, the Court of Appeals in the Seventh Circuit issued a decision ruling that various payments made to several states in prior years should be a deferred tax asset and not a current tax deduction for the year being litigated. The ruling did not have a material impact on our results of operations, financial position or cash flow.

7. Goodwill and Other Intangible Assets

In the first quarter of 2010, we recognized an impairment charge of \$21.1 for certain intangible assets associated with the UniCare provider networks, due to a decision we made to transfer certain membership to an alternative network.

8. Retirement Benefits

The components of net periodic benefit (credit) cost included in the consolidated statements of income for the three months ended September 30, 2010 and 2009 are as follows:

	2	Pension 2010		fits 2009	2	Other I	er Benefits 2009	
Service cost	\$	4.4	\$	5.8	\$	1.9	\$	1.8
Interest cost		22.2		23.0		8.7		8.0
Expected return on assets		(34.9)		(35.9)		(2.6)		(0.6)
Recognized actuarial loss		6.3		0.6		1.9		1.8
Amortization of prior service credit		(0.2)		(0.2)		(2.3)		(2.5)
N. C. P. L. C. C. C. Phys. C.	Ф	(2.2)	Ф	(C.7)	Ф	7.	ф	0.5
Net periodic benefit (credit) cost	\$	(2.2)	\$	(6.7)	\$	7.6	\$	8.5

The components of net periodic benefit (credit) cost included in the consolidated statements of income for the nine months ended September 30, 2010 and 2009 are as follows:

	2	Pension 2010	efits 2009	Other 2010		ts 009
Service cost	\$	13.0	\$ 17.2	\$	5.6	\$ 5.4
Interest cost		66.5	68.7		26.0	23.9
Expected return on assets		(104.7)	(107.3)		(7.7)	(1.9)
Recognized actuarial loss		19.1	1.7		5.8	5.3
Amortization of prior service credit		(0.6)	(0.6)		(7.1)	(7.4)
Net periodic benefit (credit) cost	\$	(6.7)	\$ (20.3)	\$	22.6	\$ 25.3

For the year ending December 31, 2010, no material contributions are expected to be necessary to meet the Employee Retirement Income Security Act, or ERISA, required funding levels; however, we may elect to make discretionary contributions up to the maximum amount deductible for income tax purposes. Contributions of \$15.0 and \$65.3 were made to our retirement benefit plans during the nine months ended September 30, 2010 and 2009, respectively.

9. Debt

On September 30, 2010, we entered into a senior credit facility, or the facility, with certain lenders for general corporate purposes. The facility provides credit up to \$2,000.0 and matures on September 30, 2013. The interest rate on the facility is based on either, (i) the LIBOR rate plus a predetermined percentage rate based on our credit rating at the date of utilization, or (ii) a base rate as defined in the facility agreement plus a predetermined percentage rate based on our credit rating at the date of utilization. Our ability to borrow under the facility is subject to compliance with certain covenants. Commitment and legal fees paid for the facility were \$7.5 and there are no conditions that are probable of occurring under which the facility may be withdrawn. There were no amounts outstanding under the facility as of September 30, 2010 or under a previous facility during the three or nine months then ended. At September 30, 2010, we had \$2,000.0 available under the facility. This facility replaced our previous senior credit facility, which provided credit up to \$2,392.0.

On August 12, 2010, we issued \$700.0 of 4.350% notes due 2020 and \$300.0 of 5.800% notes due 2040 under our shelf registration statement. We used a portion of the proceeds from this debt issuance to repay the remaining outstanding balance of our variable rate senior term loan. We intend to use the remainder of the proceeds from this debt issuance for general corporate purposes, including, but not limited to, repayment of short-term and long-term debt. The notes have a call feature that allows us to repurchase the notes at any time at our option and a put feature that allows a note holder to require us to repurchase the notes upon the occurrence of both a change of control event and a downgrade of the notes.

We have an authorized commercial paper program of up to \$2,500.0, the proceeds of which may be used for general corporate purposes. At September 30, 2010, we had \$391.1 outstanding under this program. Commercial paper borrowings have been classified as long-term debt at September 30, 2010 and December 31, 2009 in accordance with FASB guidance for short-term obligations expected to be refinanced, as our practice and intent is to replace short-term commercial paper outstanding at expiration with additional short-term commercial paper for an uninterrupted period extending for more than one year or our ability to redeem our commercial paper with borrowings under the senior credit facility described above.

We are a member of the Federal Home Loan Bank of Indianapolis and the Federal Home Loan Bank of Cincinnati, collectively, the FHLBs, and as a member we have the ability to obtain cash advances subject to certain requirements. In order to obtain cash advances, we are required to pledge securities as collateral to the FHLBs, initially equal to a certain percentage of the cash borrowings, depending on the type of securities pledged

as collateral. The market value of the collateral is monitored daily by the FHLBs, and if it falls below the required percentage of the cash borrowings, we are required to pledge additional securities as collateral or repay a portion of the outstanding cash advance balance. In addition, our borrowings may be limited based on the amount of our investment in the FHLBs common stock. Our investment in the FHLBs common stock at September 30, 2010 totaled \$11.4, which is reported in Investments available-for-sale Equity securities on the consolidated balance sheets. On May 11, 2010, we borrowed \$100.0 from the FHLBs with a six-month term at a fixed interest rate of 0.360%, which is reported in Short-term borrowings on the consolidated balance sheets. In addition, on April 12, 2010, we borrowed \$100.0 from the FHLBs with a two-year term at a fixed interest rate of 1.430%, which is reported with Long-term debt, less current portion on the consolidated balance sheets. Securities, primarily certain U.S. government sponsored mortgage-backed securities, with a fair value of \$236.9 at September 30, 2010, have been pledged as collateral. The securities pledged are reported in Investments available-for-sale Fixed maturity securities on the consolidated balance sheets.

During April 2010, we repaid the remaining \$42.0 outstanding balance of our 9.125% surplus notes.

10. Commitments and Contingencies

Litigation

In various California state courts, we are defending a number of individual lawsuits, including one filed by the Los Angeles City Attorney, and one purported class action alleging the wrongful rescission of individual insurance policies. The suits name WellPoint as well as Blue Cross of California, or BCC, and BC Life & Health Insurance Company, or BCL&H (which name changed to Anthem Blue Cross Life and Health Insurance Company in July 2007), both WellPoint subsidiaries. The lawsuits generally allege breach of contract, bad faith and unfair business practices in a purported practice of rescinding new individual members following the submission of large claims. The parties agreed to mediate most of these lawsuits and the mediation resulted in the resolution of some of these lawsuits. Final approval of the class action settlement was granted on July 13, 2010, and no appeals were filed. Payments pursuant to the terms of the settlement are expected to occur in the first or second quarter of 2011 and will not have a material impact on our consolidated financial position or results of operations.

We are currently defending several putative class actions filed as a result of the 2001 Anthem Insurance Companies, Inc., or AICI, demutualization. The suits name AICI as well as Anthem, Inc., or Anthem, n/k/a WellPoint, Inc. The suits are captioned as Ronald Gold, et al. v. Anthem, Inc. et al.; Mary E. Ormond, et al. v. Anthem, Inc., et al.; Ronald E. Mell, Sr., et al. v. Anthem, Inc., et al; and Jeffrey D. Jorling, et al., v. Anthem, Inc. (n/k/a WellPoint, Inc.) et al. AICI s 2001 Plan of Conversion, or the Plan, provided for the conversion of AICI from a mutual insurance company into a stock insurance company pursuant to Indiana law. Under the Plan, AICI distributed the fair value of the company at the time of conversion to its Eligible Statutory Members, or ESMs, in the form of cash or Anthem common stock in exchange for their membership interests in the mutual company. The lawsuits generally allege that AICI distributed value to the wrong ESMs or distributed insufficient value to the ESMs. In Gold, cross motions for summary judgment were granted in part and denied in part with regard to the issue of sovereign immunity asserted by co-defendant, the State of Connecticut (the State). The State appealed this denial to the Connecticut Supreme Court. We filed a cross-appeal. Oral argument was held in November 2008. On May 11, 2010, the Court reversed the judgment of the trial court denying the State s motion to dismiss the plaintiff s claims under sovereign immunity. Our cross-appeal was dismissed by the Court. The case was remanded to the trial court for further proceedings. In the *Ormond* suit, our Motion to Dismiss was granted in part and denied in part on March 31, 2008. The Court dismissed the claims for violation of federal and state securities laws, for violation of the Indiana Demutualization Law and for unjust enrichment. On September 29, 2009, a class was certified. The class consists of all ESMs residing in Ohio, Indiana, Kentucky or Connecticut who received cash compensation in connection with the demutualization. The class does not include employers located in Ohio and Connecticut that received compensation under the Plan. On November 4, 2009 a class was certified in the Mell suit. That class consists of persons who were employees or retirees who were continuously enrolled in the health benefit

-25-

plan sponsored by the City of Cincinnati between the dates of June 18, 2001 and November 2, 2001. On March 3, 2010, the Court issued an order granting our motion for summary judgment. As a result, the Mell suit has been dismissed. The plaintiffs have filed an appeal with the Sixth Circuit Court of Appeals, which is pending. We intend to vigorously defend these suits; however, their ultimate outcome cannot be presently determined.

We are currently a defendant in a putative class action relating to Out-of-Network, or OON, reimbursement of dental claims called *American Dental Association v. WellPoint Health Networks, Inc. and Blue Cross of California*. The lawsuit was filed in March 2002 by the American Dental Association, and three dentists who are suing on behalf of themselves and are seeking to sue on behalf of a nationwide class of all non-participating dental providers who were paid less than their actual charges for dental services provided to WellPoint dental members. The complaint alleges that WellPoint Health Networks Inc., Blue Cross of California and other WellPoint affiliates and subsidiaries (collectively, WellPoint) improperly set usual, customary and reasonable payment for OON dental services based on HIAA/Ingenix data. The plaintiffs claim, among other things, that the HIAA/Ingenix databases fail to account for differences in geography, provider specialty, outlier (high) charges, and complexity of procedure. The complaint further alleges that WellPoint was aware that this data was inappropriate to set usual, customary and reasonable rates. The dentists sue as assignees of their patients—rights to benefits under WellPoint s dental plans and assert that WellPoint breached its contractual obligations in violation of ERISA by routinely paying OON dentists less than their actual charges and representing that its OON payments were properly determined usual, customary and reasonable rates. The suit is currently pending in the United States District Court for the Southern District of Florida. We have refiled a motion for summary judgment, which is pending. We intend to vigorously defend this lawsuit; however, its ultimate outcome cannot be presently determined.

We are currently a defendant in eleven putative class actions relating to out-of-network reimbursement. The cases have been made part of a WellPoint-only multi-district litigation called In re WellPoint, Inc. Out-of-Network UCR Rates Litigation and are pending in the United States District Court for the Central District of California. The first lawsuit (Darryl and Valerie Samsell v. WellPoint, Inc., WellPoint Health Networks, Inc. and Anthem, Inc.) was filed in February 2009 by two former members on behalf of a putative class of members who received out-of-network services for which the defendants paid less than billed charges. The plaintiffs in that case allege that the defendants violated RICO, the Sherman Antitrust Act, ERISA, and federal regulations by relying on databases provided by Ingenix in determining out-of-network reimbursement. The second lawsuit (AMA et al. v. WellPoint, Inc.) was brought in March 2009 by the American Medical Association, or AMA, four state medical associations and two individual physicians on behalf of a putative class of out-of-network physicians. The third lawsuit (Roberts v. UnitedHealth Group, Inc. et al.) was brought in March 2009 by a WellPoint member as a putative class action on behalf of all persons or entities who have paid premiums for out-of-network health insurance coverage. The fourth lawsuit (JBW v. UnitedHealth Group, Inc. et al.) was brought in April 2009 by a WellPoint member as a putative class action on behalf of all persons who have paid premiums for out-of-network health insurance coverage. The fifth lawsuit (O Brien, et al. v. WellPoint, Inc., et al.) was brought in May 2009 by three WellPoint members as a putative class action on behalf of all persons who received out-of-network services. The sixth lawsuit (Higashi, D.C. d/b/a Mar Vista Institute of Health v. Blue Cross of California d/b/a WellPoint, Inc.) was brought in June 2009 by an out-of-network chiropractor as a putative class action on behalf of all out-of-network chiropractors. The seventh suit (North Peninsula Surgical Center v. WellPoint, Inc., et al.) was brought in June 2009 by an out-of-network surgical center as a putative class action on behalf of all out-of-network surgical centers. The eighth lawsuit (American Podiatric Medical Association, et al. v. WellPoint, Inc.) was brought in June 2009 by the American Podiatric Medical Association, California Chiropractic Association, California Psychological Association and an out-of-network clinical psychologist as a putative class action on behalf of out-of-network podiatrists, chiropractors and psychologists. The ninth lawsuit (Michael Pariser, et al. v. WellPoint, Inc.) was brought in July 2009 by an out-of-network psychologist as a putative class action on behalf of all out-of-network providers who are not medical doctors or doctors of osteopathy. The tenth lawsuit (Harold S. Bernard, Ph.D., et al. v. WellPoint, Inc.) was brought in July 2009 by an out-of-network psychologist as a putative class action on behalf of all non-medical doctor health care providers. The eleventh lawsuit (Ken Unmacht, Psy.D., et al. v. WellPoint,

-26-

Inc.) was brought in August 2009 by an out-of-network licensed psychotherapist as a putative class action on behalf of all non-medical doctor health care providers. A consolidated complaint was filed for the eleven cases, and then was amended to broaden the allegations in the lawsuit to out-of-network reimbursement methodologies beyond the use of Ingenix. We filed a revised motion to dismiss the amended consolidated complaint, which is pending. At the end of 2009, we filed a motion to enjoin the claims brought by the medical doctors and doctors of osteopathy based on prior litigation releases. The magistrate judge recommended that our motion to enjoin be granted. Plaintiffs recently filed a petition for declaratory judgment asking the Court to find that those claims are not barred by the prior litigation releases. We have filed a motion to dismiss the petition for declaratory judgment. We intend to vigorously defend these suits; however, their ultimate outcomes cannot be presently determined.

Other Contingencies

From time to time, we and certain of our subsidiaries are parties to various legal proceedings, many of which involve claims for coverage encountered in the ordinary course of business. We, like HMOs and health insurers generally, exclude certain health care and other services from coverage under our HMO, PPO and other plans. We are, in the ordinary course of business, subject to the claims of our enrollees arising out of decisions to restrict or deny reimbursement for uncovered services. The loss of even one such claim, if it results in a significant punitive damage award, could have a material adverse effect on us. In addition, the risk of potential liability under punitive damage theories may increase significantly the difficulty of obtaining reasonable settlements of coverage claims.

In addition to the lawsuits described above, we are also involved in other pending and threatened litigation of the character incidental to our business, arising out of our operations and our revision of earnings guidance in 2008, and are from time to time involved as a party in various governmental investigations, audits, reviews and administrative proceedings. These investigations, audits, reviews and administrative proceedings include routine and special inquiries by state insurance departments, state attorneys general, the U.S. Attorney General and subcommittees of the U.S. Congress. Such investigations, audits, reviews and administrative proceedings could result in the imposition of civil or criminal fines, penalties, other sanctions and additional rules, regulations or other restrictions on our business operations. Any liability that may result from any one of these actions, or in the aggregate, could have a material adverse effect on our consolidated financial position or results of operations.

The National Organization of Life & Health Insurance Guaranty Associations, or NOLHGA, is a voluntary association consisting of the state life and health insurance guaranty organizations located throughout the U.S. State life and health insurance guaranty organizations, working together with NOLHGA, provide a safety net for their state s policyholders, ensuring that they continue to receive coverage even if their insurer is declared insolvent. We are aware that the Pennsylvania Insurance Commissioner, or Insurance Commissioner, has placed Penn Treaty Network America Insurance Company and its subsidiary American Network Insurance Company, or collectively Penn Treaty, in rehabilitation, an intermediate action before insolvency. The Insurance Commissioner has petitioned the state court for liquidation, however, we do not know when a decision will be made, although we believe it is likely the state court will rule within the next twelve months. In the event that Penn Treaty is declared insolvent and placed in liquidation, we and other insurers may be required to pay a portion of their policyholder claims through NOLHGA guaranty association assessments in future periods. Given the uncertainty around whether Penn Treaty will ultimately be declared insolvent and, if so, the amount of the insolvency, the amount and timing of any associated future guaranty fund assessments and the availability and amount of any potential premium tax and other offsets, we currently cannot estimate our net exposure, if any, to this potential insolvency. We will continue to monitor the situation and may record a liability and expense in future reporting periods, which could be material to our operating results.

Contractual Obligations and Commitments

On December 1, 2009, we entered into a ten-year agreement with Express Scripts, Inc., or Express Scripts, to provide pharmacy benefit management services for our plans. Under this agreement, Express Scripts will be

-27-

the exclusive provider of certain specified pharmacy benefit management services, such as pharmacy network management, home delivery, pharmacy customer service, claims processing, rebate management, drug utilization and specialty pharmaceutical management services. Accordingly, the agreement contains certain financial and operational requirements obligating both Express Scripts and us. Express Scripts primary obligations relate to the performance of such services and meeting certain pricing guarantees and performance standards. Our primary obligations relate to oversight, provision of data, payment for services, transition services and certain minimum volume requirements. The failure by either party to meet the respective requirements could potentially serve as a basis for early termination of the contract. In addition, our failure to meet the minimum volume requirements may result in financial penalties that could have a material impact on our results of operations.

During 2009, we entered into an agreement with Affiliated Computer Services, Inc. to provide certain print and mailroom services that were previously performed in-house. Our remaining commitment under this agreement at September 30, 2010 was \$357.7 over a six year period. We have the ability to terminate this agreement upon the occurrence of certain events, subject to early termination fees.

During the first quarter of 2010, we entered into a new agreement with International Business Machines Corporation to provide information technology infrastructure services. This new agreement supersedes certain prior agreements and also includes provisions for additional services. Our commitment under this agreement at September 30, 2010 was \$1,100.4 over a five year period. We have the ability to terminate this agreement upon the occurrence of certain events, subject to early termination fees.

11. Capital Stock

Stock Repurchase Program

We regularly review the appropriate use of capital. Accordingly, under our Board of Directors authorization, we maintain a common stock repurchase program. Repurchases may be made from time to time at prevailing market prices, subject to certain restrictions on volume, pricing and timing. The repurchases are effected from time to time in the open market, in private transactions, including accelerated share repurchase agreements, and through plans designed to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

During the nine months ended September 30, 2010, we repurchased and retired approximately 58.9 shares at an average per share price of \$56.83, for an aggregate cost of \$3,345.1. During the nine months ended September 30, 2009, we repurchased and retired approximately 40.8 shares at an average per share price of \$44.38, for an aggregate cost of \$1,811.4. The excess of cost of the repurchased shares over par value is charged on a pro rata basis to additional paid-in capital and retained earnings.

On January 26, 2010, our Board of Directors increased the share repurchase authorization by \$3,500.0. As of September 30, 2010, \$538.6 remained authorized for future repurchases. Subsequent to September 30, 2010, we repurchased and retired approximately 1.4 shares for an aggregate cost of approximately \$76.7, leaving approximately \$461.9 for authorized future repurchases at October 20, 2010. On October 29, 2010, our Board of Directors increased the share repurchase authorization by \$500.0. Our stock repurchase program is discretionary as we are under no obligation to repurchase shares. We repurchase shares under the program when we believe it is a prudent use of capital.

-28-

Stock Incentive Plans

A summary of stock option activity for the nine months ended September 30, 2010 is as follows:

	Number of Shares	Weighted- Average Option Price per Share	Weighted- Average Remaining Contractual Life (Years)	Aggregate Intrinsic Value
Outstanding at January 1, 2010	26.5	\$ 56.98		
Granted	2.9	61.78		
Exercised	(2.2)	35.60		
Forfeited or expired	(1.3)	62.18		
Outstanding at September 30, 2010	25.9	59.06	4.7	\$ 200.3
Exercisable at September 30, 2010	19.7	62.74	4.4	\$ 120.0

A summary of the status of nonvested restricted stock activity, including restricted stock units, for the nine months ended September 30, 2010 is as follows:

	Restricted Stock Shares And Units	Weighted- Average Grant Date Fair Value per Share
Nonvested at January 1, 2010	4.2	\$ 36.02
Granted	1.7	61.65
Vested	(1.5)	40.19
Forfeited	(0.2)	40.12
Nonvested at September 30, 2010	4.2	44.57

12. Earnings per Share

The denominator for basic and diluted earnings per share for the three and nine months ended September 30, 2010 and 2009 is as follows:

	Three Months Ended September 30		Nine Months Ended September 30		
	2010	2009	2010	2009	
Denominator for basic earnings per share weighted average shares	397.6	471.5	418.5	483.2	
Effect of dilutive securities employee and director stock options and non-vested restricted stock awards	4.6	5.3	4.9	3.8	
Denominator for diluted earnings per share	402.2	476.8	423.4	487.0	

During the three months ended September 30, 2010 and 2009, weighted average shares related to certain stock options of 17.8 and 16.7, respectively, were excluded from the denominator for diluted earnings per share because the stock options were anti-dilutive. During the nine months ended September 30, 2010 and 2009, weighted average shares related to certain stock options of 17.3 and 18.4, respectively, were excluded from the denominator for diluted earnings per share because the stock options were anti-dilutive.

-29-

During the nine months ended September 30, 2010, we issued approximately 1.7 restricted stock units under our stock incentive plans, 0.3 of whose vesting is contingent upon us meeting specified annual operating gain targets for 2010. The 0.3 restricted stock units have been excluded from the denominator for diluted earnings per share and will be included only if and when the contingency is met.

13. Segment Information

Our organizational structure is comprised of three reportable segments: Commercial, Consumer and Other. Our Commercial and Consumer segments both offer a diversified mix of managed care products, including PPOs, HMOs, traditional indemnity benefits and POS plans, as well as a variety of hybrid benefit plans, including CDHPs, hospital only and limited benefit products.

Our Commercial segment includes Local Group (including UniCare), National Accounts and certain other ancillary business operations (dental, vision, life and disability and workers compensation). Business units in the Commercial segment offer fully-insured products and provide a broad array of managed care services to self-funded customers, including claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs and other administrative services.

Our Consumer segment includes Senior, State-Sponsored and Individual business. Senior business includes services such as Medicare Part D, Medicare Advantage, and Medicare Supplement, while State-Sponsored business includes our managed care alternatives for the Medicaid and State Children s Health Insurance Plan programs.

Our Other segment includes the Comprehensive Health Solutions Business unit, or CHS, that brings together our resources focused on optimizing the quality of health care and cost of care management. CHS included our prescription benefits management, or PBM, business until its sale to Express Scripts on December 1, 2009, and also includes provider relations, care and disease management, employee assistance programs, including behavioral health, radiology benefit management and analytics-driven personal health care guidance. Our Other segment also includes results from our Federal Government Solutions, or FGS, business. FGS business includes the Federal Employee Program and National Government Services, Inc., or NGS, which acts as a Medicare contractor in several regions across the nation. The Other segment also includes other businesses that do not meet the quantitative thresholds for an operating segment, as well as intersegment sales and expense eliminations and corporate expenses not allocated to the other reportable segments.

As a result of cost-reduction initiatives implemented in 2009, we recorded liabilities for employee termination costs and lease and other contract exit costs. Activity related to these liabilities for the nine months ended September 30, 2010 is as follows:

	Com	mercial	Cor	ısumer	Other	Tot	al
Employee termination costs:							
Beginning balance at January 1, 2010	\$	89.7	\$	19.6	\$ 9.9	\$ 11	19.2
Payments		(47.0)		(10.2)	(5.2)	(6	52.4)
Liability released		(14.7)		(3.3)	(1.6)	(1	19.6)
Employee termination costs ending balance at September 30, 2010		28.0		6.1	3.1	3	37.2
Lease and other contract exit costs:							
Beginning balance at January 1, 2010		31.8		3.2	9.1	4	14.1
Accrued expenses		0.2					0.2
Payments		(4.2)		(0.1)	(0.4)	((4.7)
Lease and other contract termination costs ending balance at September 30, 2010		27.8		3.1	8.7	3	39.6
Total 2009 cost-reduction initiatives ending balance at September 30, 2010	\$	55.8	\$	9.2	\$ 11.8	\$ 7	76.8

-30-

Financial data by reportable segment for the three and nine months ended September 30, 2010 and 2009 is as follows:

	Co	ommercial	C	Consumer	 ther and ninations	Total
Three Months Ended September 30, 2010:						
Operating revenue from external customers	\$	8,512.1	\$	4,039.1	\$ 1,783.2	\$ 14,334.4
Operating gain		760.9		261.7	17.1	1,039.7
Three Months Ended September 30, 2009:						
Operating revenue from external customers	\$	9,311.0	\$	4,089.8	\$ 1,806.2	\$ 15,207.0
Intersegment revenue					789.2	789.2
Elimination of intersegment revenue					(789.2)	(789.2)
Operating gain		628.0		520.0	133.2	1,281.2
Nine Months Ended September 30, 2010:						
Operating revenue from external customers	\$	26,104.8	\$	12,044.2	\$ 5,278.6	\$ 43,427.6
Operating gain		2,485.0		888.6	10.8	3,384.4
Nine Months Ended September 30, 2009:						
Operating revenue from external customers	\$	28,018.3	\$	12,215.7	\$ 5,537.5	\$ 45,771.5
Intersegment revenue					2,274.4	2,274.4
Elimination of intersegment revenue					(2,274.4)	(2,274.4)
Operating gain		2,113.5		1,120.8	368.6	3,602.9

A reconciliation of reportable segments operating revenues to total revenues reported in the consolidated statements of income for the three and nine months ended September 30, 2010 and 2009 is as follows:

	Three Months Ended September 30		Nine Months Ended September 30				
		2010	2009		2010		2009
Reportable segments operating revenues	\$	14,334.4	\$ 15,207.0	\$	43,427.6	\$	45,771.5
Net investment income		205.4	196.6		608.8		599.4
Net realized gains on investments		61.6	52.2		146.5		20.4
Other-than-temporary impairment losses recognized in income		(3.2)	(30.7)		(29.0)		(409.7)
Total revenues	\$	14,598.2	\$ 15,425.1	\$	44,153.9	\$	45,981.6

A reconciliation of reportable segments operating gain to income before income tax expense included in the consolidated statements of income for the three and nine months ended September 30, 2010 and 2009 is as follows:

	Three Mon Septem		Nine Months Ended September 30		
	2010	2009	2010	2009	
Reportable segments operating gain	\$ 1,039.7	\$ 1,281.2	\$ 3,384.4	\$ 3,602.9	
Net investment income	205.4	196.6	608.8	599.4	
Net realized gains on investments	61.6	52.2	146.5	20.4	
Other-than-temporary impairment losses recognized in income	(3.2)	(30.7)	(29.0)	(409.7)	
Interest expense	(106.3)	(110.6)	(305.9)	(343.7)	
Amortization of other intangible assets	(60.4)	(66.0)	(182.0)	(200.5)	
Impairment of other intangible assets		(205.5)	(21.1)	(205.5)	

Income before income tax expense

\$ 1,136.8

\$ 1,117.2 \$ 3,601.7 \$ 3,063.3

-31-

14. Comprehensive Income

The components of comprehensive income for the three and nine months ended September 30, 2010 and 2009 are as follows:

		nths Ended nber 30	Nine Months Ended September 30		
	2010	2009	2010	2009	
Net income	\$ 739.1	\$ 730.2	\$ 2,338.3	\$ 2,004.1	
Change in net unrealized gains/losses on investments	233.7	489.9	312.8	1,073.0	
Change in non-credit component of other-than-temporary impairment losses on					
investments	0.1	2.7	(3.2)	(18.6)	
Change in net unrealized gains/losses on cash flow hedges	(7.3)	(0.1)	(15.0)	(2.2)	
Change in net periodic pension and postretirement costs	3.4	1.8	10.2	1.4	
Foreign currency translation adjustments	1.8	1.5	(0.5)	3.5	
Comprehensive income	\$ 970.8	\$ 1,226.0	\$ 2,642.6	\$ 3,061.2	

15. Subsequent Events

We have evaluated subsequent events for recognition or disclosure in our consolidated financial statements filed on Form 10-Q with the SEC and no events have occurred that require disclosure.

ITEM 2. MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
References to the terms we, our or us used throughout this Management s Discussion and Analysis of Financial Condition and Results of Operations, or MD&A, refer to WellPoint, Inc., an Indiana corporation, and unless the context otherwise requires, its direct and indirect

Operations, or MD&A, refer to WellPoint, Inc., an Indiana corporation, and unless the context otherwise requires, its direct and indirect subsidiaries.

Certain prior year amounts have been reclassified to conform to current year presentation.

The structure of our MD&A is as follows:

- I. Executive Summary
- II. Overview
- III. Significant Transactions
- IV. Membership September 30, 2010 Compared to September 30, 2009
- V. Cost of Care
- VI. Results of Operations Three Months Ended September 30, 2010 Compared to the Three Months Ended September 30, 2009
- VII. Results of Operations Nine Months Ended September 30, 2010 Compared to the Nine Months Ended September 30, 2009
- VIII. Critical Accounting Policies and Estimates
- IX. Liquidity and Capital Resources
- X. Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995

This MD&A should be read in conjunction with our audited consolidated financial statements as of and for the year ended December 31, 2009 and the MD&A included in our 2009 Form 10-K, and in conjunction with our unaudited consolidated financial statements and accompanying notes as of and for the three and nine months ended September 30, 2010 included in this Form 10-Q. Results of operations, cost of care trends, investment yields and other measures for the three and nine month periods ended September 30, 2010 are not necessarily indicative of the results and trends that may be expected for the full year ending December 31, 2010. Also see Item 1A. Risk Factors in Part I of our 2009 Form 10-K and Part II of this Form 10-Q.

I. Executive Summary

We are the largest health benefits company in terms of medical membership in the United States, serving 33.5 million medical members through our affiliated health plans and a total of 70.4 million individuals through all subsidiaries as of September 30, 2010. We are an independent licensee of the Blue Cross and Blue Shield Association, or BCBSA, an association of independent health benefit plans. We serve our members as the Blue Cross licensee in California and as the Blue Cross and Blue Shield, or BCBS, licensee for: Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding 30 counties in the Kansas City area), Nevada, New Hampshire, New York (as BCBS in 10 New York City metropolitan and surrounding counties, and as Blue Cross or BCBS in selected upstate counties only), Ohio, Virginia (excluding Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a majority of these service areas we do business as Anthem Blue Cross, Anthem Blue Cross Blue Shield or Empire Blue Cross Blue Shield (in our New York service areas). We also serve customers throughout much of the country as UniCare. We are licensed to conduct insurance operations in all 50 states through our subsidiaries.

Operating revenue for the three months ended September 30, 2010 was \$14.3 billion, a decrease of \$0.9 billion, or 6%, from the three months ended September 30, 2009, primarily due to fully-insured membership

-33-

declines in our Local Group and National Accounts businesses, the conversion from fully-insured to self-funded status of both a large municipal account in April 2010 and a large state employer account in July 2010, certain UniCare members transitioning to Health Care Service Corporation, or HCSC, beginning January 1, 2010 and the sale of our prescription benefit management, or PBM, business. In addition, the loss of certain 2010 Medicare Part D auto-assigned Low-Income Subsidy, or Part D LIS, membership within our Senior business contributed to the decline in premiums. These decreases were partially offset by higher premiums in our Local Group and National Accounts businesses that were necessary to cover cost trends. In addition, operating revenue in 2010 increased due to higher Federal Employee Program, or FEP, reimbursements and increased revenue due to membership gains in our Senior Medicare Advantage business.

Operating revenue for the nine months ended September 30, 2010 was \$43.4 billion, a decrease of \$2.3 billion, or 5%, from the nine months ended September 30, 2009, primarily due to fully-insured membership declines in our Local Group and National Accounts businesses resulting from the unfavorable economic conditions, certain UniCare members transitioning to HCSC beginning January 1, 2010 and the conversion of a large municipal account from fully-insured to self-funded status in April 2010. In addition, the sale of our PBM business and the loss of certain 2010 Part D LIS membership within our Senior business contributed to the operating revenue decline. These decreases were partially offset by higher premiums in our Local Group and National Accounts businesses that were necessary to cover cost trends, increased reimbursement in the FEP program and increased membership in our Senior Medicare Advantage business and certain State-Sponsored programs.

Net income for the three months ended September 30, 2010 was \$739.1 million, an increase of \$8.9 million, or 1%, from the three months ended September 30, 2009. This increase in net income resulted primarily from a charge for impairment of other intangible assets in 2009 that was not repeated in the third quarter of 2010, improved operating results in our Commercial segment, a decline in other-than-temporary impairment losses on investments and increased realized gains on investments. These increases were partially offset by lower operating results in our Consumer and Other segments. For additional details, see Results of Operations Three Months Ended September 30, 2010 Compared to the Three Months Ended September 30, 2009 included in this MD&A. Our fully-diluted earnings per share, or EPS, was \$1.84 for the three months ended September 30, 2010, which represents a 20% increase over the EPS of \$1.53 for the three months ended September 30, 2009. The increase in EPS resulted primarily from the lower number of shares outstanding in 2010 due to share buy back activity under our share repurchase program.

Net income for the nine months ended September 30, 2010 was \$2.3 billion, an increase of \$334.2 million, or 17%, from the nine months ended September 30, 2009. This increase in net income resulted primarily from a decline in other-than-temporary impairment losses on investments, increased realized gains on investments, improved operating results in our Commercial segment, reduced impairment of other intangible assets, lower interest expense and lower amortization of other intangible assets. These increases were partially offset by lower operating results in our Other and Consumer segments and increased income taxes resulting primarily from increased net income. For additional details, see Results of Operations Nine Months Ended September 30, 2010 Compared to the Nine Months Ended September 30, 2009 included in this MD&A. Our fully-diluted EPS was \$5.52 for the nine months ended September 30, 2010, which represents a 34% increase over the EPS of \$4.12 for the nine months ended September 30, 2009. The increase in EPS resulted primarily from both the lower number of shares outstanding in 2010 due to share buy back activity under our share repurchase program and increased net income.

Our results of operations discussed throughout this MD&A are determined in accordance with U.S. generally accepted accounting principles, or GAAP. We also calculate adjusted net income, adjusted EPS and operating gain, which are non-GAAP measures, to further aid investors in understanding and analyzing our core operating results and comparing them period-over-period. Adjusted net income and adjusted EPS exclude realized gains and losses on investments, other-than-temporary losses on investments recognized in income, impairment of other intangible assets and certain other items, if applicable, that we do not consider a part of our core operating results. Operating gain is calculated as total operating revenue less benefit expense, selling, general and administrative expense and cost of drugs. We use these measures as a basis for evaluating segment

-34-

performance, allocating resources, setting incentive compensation targets and for forecasting future operating periods. This information is not intended to be considered in isolation or as a substitute for net income or diluted EPS prepared in accordance with GAAP, and may not be comparable to similarly titled measures reported by other companies. For additional details on operating gain, see our Results of Operations discussion within this MD&A. The table below reconciles net income and EPS calculated in accordance with GAAP to adjusted net income and adjusted EPS for the three months ended September 30, 2010 and 2009.

		onths Ended		
(In millions)	2010	mber 30 2009	Change	% Change
Net income	\$ 739.1	\$ 730.2	\$ 8.9	1%
Less (net of tax):				
Net realized gains on investments, net of tax expense of \$21.6				
million and \$18.0 million, respectively	40.0	34.2	5.8	
Other-than-temporary impairment losses on investments, net of tax				
benefit of \$1.1 million and \$10.6 million, respectively	(2.1)	(20.1)	18.0	
Impairment of other intangible assets, net of tax benefit of \$0.0				
million and \$71.1 million, respectively		(134.4)	134.4	
Adjusted net income	\$ 701.2	\$ 850.5	\$ (149.3)	(18)%
EPS	\$ 1.84	\$ 1.53	\$ 0.31	20%
Less (net of tax):				
Net realized gains on investments	0.10	0.07	0.03	
Other-than-temporary impairment losses on investments		(0.04)	0.04	
Impairment of other intangible assets		(0.28)	0.28	
Adjusted EPS	\$ 1.74	\$ 1.78	\$ (0.04)	(2)%

The table below reconciles net income and EPS calculated in accordance with GAAP to adjusted net income and adjusted EPS for the nine months ended September 30, 2010 and 2009.

	Nine Mon Septem			
(In millions)	2010	2009	Change	% Change
Net income	\$ 2,338.3	\$ 2,004.1	\$ 334.2	17%
Less (net of tax):				
Net realized gains on investments, net of tax expense of \$51.6 million				
and \$6.7 million, respectively	94.9	13.7	81.2	
Other-than-temporary impairment losses on investments, net of tax				
benefit of \$10.2 million and \$143.7 million, respectively	(18.8)	(266.0)	247.2	
Impairment of other intangible assets, net of tax benefit of \$7.4 million				
and \$71.1 million, respectively	(13.7)	(134.4)	120.7	
Adjusted net income	\$ 2,275.9	\$ 2,390.8	\$ (114.9)	(5)%
EPS	\$ 5.52	\$ 4.12	\$ 1.40	34%
Less (net of tax):				
Net realized gains on investments	0.21	0.03	0.18	
Other-than-temporary impairment losses on investments	(0.04)	(0.54)	0.50	
Impairment of other intangible assets	(0.03)	(0.28)	0.25	

Adjusted EPS \$ 5.38 \$ 4.91 \$ 0.47 10%

-35-

Operating cash flow for the nine months ended September 30, 2010 was \$829.7 million, and included a \$1.2 billion tax payment in March 2010 to the Internal Revenue Service, or IRS, related to the gain we realized on our PBM sale on December 1, 2009. Operating cash flow for the nine months ended September 30, 2009 was \$3.0 billion, or 1.5 times net income. The decrease in operating cash flow from 2009 was driven primarily by the \$1.2 billion tax payment, increased incentive compensation payments in 2010, claims run out from the membership transfers in Texas and Illinois and a reduction in Medicare Part D LIS enrollment, in 2010.

II. Overview

We manage our operations through three reportable segments: Commercial; Consumer; and Other.

Our Commercial and Consumer segments both offer a diversified mix of managed care products, including preferred provider organizations, or PPOs; health maintenance organizations, or HMOs; traditional indemnity benefits and point-of-service plans, or POS plans; as well as a variety of hybrid benefit plans, including consumer-driven health plans, or CDHPs, hospital only and limited benefit products.

Our Commercial segment includes Local Group (including UniCare), National Accounts and certain other ancillary business operations (dental, vision, life and disability and workers compensation). Business units in the Commercial segment offer fully-insured products and provide a broad array of managed care services to self-funded customers, including claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs and other administrative services.

Our Consumer segment includes Senior, State-Sponsored and Individual businesses. Senior business includes services such as Medicare Part D, Medicare Advantage and Medicare Supplement, while State-Sponsored business includes our managed care alternatives for the Medicaid and State Children s Health Insurance Plan programs. Individual business includes individual customers under age 65 and their covered dependents.

The Other segment includes our Comprehensive Health Solutions Business unit, or CHS, that brings together our resources focused on optimizing the quality of health care and cost of care management. CHS included our PBM business until its sale to Express Scripts, Inc., or Express Scripts, on December 1, 2009, and also encompasses provider relations, care and disease management, employee assistance programs, including behavioral health, radiology benefit management and analytics-driven personal health care guidance. Our Other segment also contains results from our Federal Government Solutions, or FGS, business. FGS business is comprised of the FEP and National Government Services, Inc., or NGS, which acts as a Medicare contractor in several regions across the nation. Finally, the Other segment also includes other businesses that do not meet the quantitative thresholds for an operating segment as defined in Financial Accounting Standards Board, or FASB, guidance for disclosures about segments of an enterprise and related information, as well as intersegment sales and expense eliminations and corporate expenses not allocated to the other reportable segments.

Our operating revenue consists of premiums, administrative fees and other revenue. Premium revenue comes from fully-insured contracts where we indemnify our policyholders against costs for covered health and life benefits. Administrative fees come from contracts where our customers are self-insured, or where the fee is based on either processing of transactions or a percent of network discount savings realized. Additionally, we earn administrative fee revenues from our Medicare processing business and from other health-related businesses, including disease management programs. Other revenue was principally generated from member co-payments and deductibles associated with the mail-order sale of drugs by our PBM business prior to its sale on December 1, 2009.

Our benefit expense primarily includes costs of care for health services consumed by our members, such as outpatient care, inpatient hospital care, professional services (primarily physician care) and pharmacy benefit costs. All four components are affected both by unit costs and utilization rates. Unit costs include the cost of

outpatient medical procedures per visit, inpatient hospital care per admission, physician fees per office visit and prescription drug prices. Utilization rates represent the volume of consumption of health services and typically vary with the age and health status of our members and their social and lifestyle choices, along with clinical protocols and medical practice patterns in each of our markets. A portion of benefit expense recognized in each reporting period consists of actuarial estimates of claims incurred but not yet paid by us. Any changes in these estimates are recorded in the period the need for such an adjustment arises. While we offer a diversified mix of managed care products, including PPO, HMO, POS and CDHP products, our aggregate cost of care can fluctuate based on a change in the overall mix of these products. We have seen an increase in COBRA coverage within these product offerings that can further impact our cost of care. COBRA is named for the Consolidated Omnibus Budget Reconciliation Act of 1986, which provides unemployed group members with coverage for up to 18 months after losing their job. On February 17, 2009, the American Recovery and Reinvestment Act of 2009, or ARRA, was signed into law. ARRA originally provided for a temporary subsidy of COBRA premiums for individuals that were involuntarily terminated from employment (for reasons other than gross misconduct) between September 1, 2008 and February 28, 2010. The eligibility period was extended twice and ran through May 31, 2010. The COBRA subsidy under ARRA has caused more individuals to elect COBRA coverage.

Beginning January 1, 2010, we began classifying certain claims-related costs, which were historically classified as administrative expenses, as benefit expense to better reflect costs incurred for our members traditional medical care as well as those expenses which improve our members health and medical outcomes. These reclassified costs are comprised of expenses incurred for: (i) medical management, including case and utilization management; (ii) health and wellness, including disease management services for such things as diabetes, high-risk pregnancies, congestive heart failure and asthma management and wellness initiatives like weight-loss programs and smoking cessation treatments; and (iii) clinical health policy. These types of claims-related costs ultimately lower our members cost of care. Prior year amounts have been reclassified to conform to the new presentation.

Our selling expense consists of external broker commission expenses and generally varies with premium volume. Our general and administrative expense consists of fixed and variable costs. Examples of fixed costs are depreciation, amortization and certain facilities expenses. Other costs are variable or discretionary in nature. Certain variable costs, such as premium taxes, vary directly with premium volume. Other variable costs, such as salaries and benefits, do not vary directly with changes in premium, but are more aligned with changes in membership. The acquisition or loss of a significant block of business would likely impact staffing levels, and thus associate compensation expense. Examples of discretionary costs include professional and consulting expenses and advertising. Other factors can impact our administrative cost structure, including systems efficiencies, inflation and changes in productivity.

Our cost of drugs historically consisted of the amounts we paid to pharmaceutical companies for the drugs we sold via mail order through our PBM and specialty pharmacy companies until the sale of our PBM operations on December 1, 2009. This amount excluded the cost of drugs related to our members recorded in benefit expense. Our cost of drugs was influenced by the volume of prescriptions in our PBM business, as well as cost changes, driven by prices set by pharmaceutical companies and the mix of drugs sold. Following the sale of our PBM business to Express Scripts, we no longer record any cost of drugs on our income statement.

Our results of operations depend in large part on our ability to accurately predict and effectively manage health care costs through effective contracting with providers of care to our members and our medical management and health and wellness programs. Several economic factors related to health care costs, such as regulatory mandates of coverage as well as direct-to-consumer advertising by providers and pharmaceutical companies, have a direct impact on the volume of care consumed by our members. While we price our business so that expected premium yield exceeds total costs, where total costs includes health care costs and selling, general and administrative expenses, the potential effect of escalating health care costs, any changes in our ability to negotiate competitive rates with our providers and any regulatory or market driven restrictions on our ability to obtain adequate premium rates to offset overall inflation in health care costs, including increases in unit costs and

-37-

utilization resulting from the aging of the population and other demographics, as well as advances in medical technology, may impose further risks to our ability to profitably underwrite our business, and may have a material impact on our results of operations.

Our future results of operations may also be impacted by certain external forces and resulting changes in our business model and strategy. During the first quarter of 2010, the U.S. Congress passed and the President signed into law the Patient Protection and Affordable Care Act as well as the Health Care and Education Reconciliation Act of 2010, which represent significant changes to the current U.S. health care system. The legislation is far-reaching and is intended to expand access to health insurance coverage over time by increasing the eligibility thresholds for most state Medicaid programs and providing certain other individuals and small businesses with tax credits to subsidize a portion of the cost of health insurance coverage. The legislation includes a requirement that most individuals obtain health insurance coverage beginning in 2014 and that most large employers offer coverage to their employees or they will be required to pay a financial penalty. In addition, the new laws encompass certain new taxes and fees, including an excise tax on high premium insurance policies, limitations on the amount of compensation that is tax deductible and new fees on companies in our industry which may not be deductible for income tax purposes. The legislation also imposes new regulations on the health insurance sector, including, but not limited to, guaranteed coverage requirements, prohibitions on some annual and all lifetime limits on amounts paid on behalf of or to our members, increased restrictions on rescinding coverage, establishment of minimum medical loss ratio requirements, a requirement to cover preventative services on a first dollar basis, the establishment of state insurance exchanges and essential benefit packages, and greater limitations on how we price certain of our products. The legislation also reduces the reimbursement levels for health plans participating in the Medicare Advantage program over time.

Some provisions of the health care reform legislation became effective this year, including those that bar health insurance companies from placing lifetime limits on insurance coverage, those related to the increased restrictions on rescinding coverage and those that extend coverage of dependents to age 26. The establishment of minimum medical loss ratios, which could have a significant impact on our operations, will take effect for certain of our businesses beginning in 2011. Lastly, other significant changes, including the annual fees on health insurance companies, the excise tax on high premium insurance policies, the guaranteed coverage requirements and the requirement that individuals obtain coverage, do not become effective until 2014 or later.

Many of the details of the new law, including, but not limited to, the medical loss ratio requirements, require additional guidance and specificity to be provided by the Department of Health and Human Services, the Department of Labor, the Department of the Treasury and the National Association of Insurance Commissioners, or NAIC. While proposed regulations on some provisions have been released for review and comment, all of which we are carefully evaluating, it is too early to fully understand the impacts of the legislation on our overall business. For example, while the National Association of Insurance Commissioners has released their proposed regulations governing medical loss ratios, they are subject to finalization by the Department of Health and Human Services and could change significantly as a result. In addition, California recently passed legislation establishing an insurance exchange within that state to comply with the related provisions that become effective in 2014. As California is the first state to provide a structure for such state-based insurance exchanges pursuant to the new legislation, other states may adopt a similar format for their exchanges. Certain provisions of the new law, including the final minimum medical loss ratio regulations and the structure of future insurance exchanges, are likely to have significant impacts on our future operations, which, in turn, could impact the value of our business model and results of operations, including potential impairments of our goodwill and other intangible assets. We will continue to evaluate the impact of this legislation as additional guidance is made available.

In addition, federal and state regulatory agencies may further restrict our ability to obtain new product approvals, implement changes in premium rates or impose additional restrictions, under new or existing laws, such as minimum medical loss ratio requirements or restricted definitions of costs to be included when calculating medical loss ratios under such definitions. Our ability to secure sufficient premium rates, including regulatory approval for and implementation of such rates on a timely basis, may be restricted by additional

-38-

changes in federal and state regulations or by the application of existing federal and state regulations. A limitation on our ability to increase or maintain our premium rates and more restrictive medical loss ratio requirements could adversely affect our business, cash flows, financial condition and results of operations.

During June 2010, we resubmitted our March 2010 Individual market rate filings with the California Department of Insurance, or CDI, and the California Department of Managed Health Care, or CDMHC. We began implementing these rate increases on October 1, 2010. Current estimates indicate that the revised rates will not cover our costs, as we made the strategic business decision not to increase premium rates further than what is proposed in the revised rate filings in an effort to avoid further destabilization of this portion of our business. As a result, based on our current estimates, we expect to incur approximately \$150 million of losses on our business in the California Individual market during 2010. The results of this business in 2011 and beyond are not currently estimable due to the inability to appropriately determine underlying assumptions including, but not limited to, membership renewals, pricing expectations and cost trends.

In addition to external forces discussed in the preceding paragraphs, our results of operations are impacted by levels and mix of membership. During 2009 and early 2010, we experienced both fully-insured and self-funded membership declines. Given the current economic conditions in the U.S., it is expected that unemployment levels will remain high throughout the remainder of 2010, which may impact our ability to increase or even maintain current membership levels. These membership trends could have a material adverse effect on our future results of operations.

The National Organization of Life & Health Insurance Guaranty Associations, or NOLHGA, is a voluntary association consisting of the state life and health insurance guaranty organizations located throughout the U.S. State life and health insurance guaranty organizations, working together with NOLHGA, provide a safety net for their state s policyholders, ensuring that they continue to receive coverage even if their insurer is declared insolvent. We are aware that the Pennsylvania Insurance Commissioner, or Insurance Commissioner, has placed Penn Treaty Network America Insurance Company and its subsidiary American Network Insurance Company, or collectively Penn Treaty, in rehabilitation, an intermediate action before insolvency. The Insurance Commissioner has petitioned the state court for liquidation; however, we do not know when a decision will be made, although we believe it is likely the state court will rule within the next twelve months. In the event that Penn Treaty is declared insolvent and placed in liquidation, we and other insurers may be required to pay a portion of their policyholder claims through NOLHGA guaranty association assessments in future periods. Given the uncertainty around whether Penn Treaty will ultimately be declared insolvent and, if so, the amount of the insolvency, the amount and timing of any associated future guaranty fund assessments and the availability and amount of any potential premium tax and other offsets, we currently cannot estimate our net exposure, if any, to this potential insolvency. We will continue to monitor the situation and may record a liability and expense in future reporting periods, which could be material to our cash flows and results of operations.

III. Significant Transactions Senior Credit Facility

On September 30, 2010, we entered into a senior credit facility, or the facility, with certain lenders. The borrowings from the facility, if any, will be used for general corporate purposes. The facility provides credit up to \$2.0 billion and matures on September 30, 2013. The interest rate on the facility is based on either, (i) the LIBOR rate plus a predetermined percentage rate based on our credit rating at the date of utilization, or (ii) a base rate as defined in the facility agreement plus a predetermined percentage rate based on our credit rating at the date of utilization. Our ability to borrow under the facility is subject to compliance with certain covenants. This facility replaced our previous senior credit facility, which provided credit up to \$2.4 billion.

Bond Issue

On August 12, 2010, we issued \$700.0 million of 4.350% notes due 2020 and \$300.0 million of 5.800% notes due 2040 under our shelf registration statement. We used a portion of the proceeds from this debt issuance

-39-

to repay the remaining outstanding balance of our variable rate senior term loan. We intend to use the remainder of the proceeds from this debt issuance for general corporate purposes, including, but not limited to, repayment of short-term and long-term debt. The notes have a call feature that allows us to repurchase the notes at any time at our option and a put feature that allows a note holder to require us to repurchase the notes upon the occurrence of both a change of control event and a downgrade of the notes.

Stock Repurchase Program

We regularly review the appropriate use of capital. Accordingly, under our Board of Directors authorization, we maintain a common stock repurchase program. Repurchases may be made from time to time at prevailing market prices, subject to certain restrictions on volume, pricing and timing. The repurchases are effected from time to time in the open market, in private transactions, including accelerated share repurchase agreements, and through plans designed to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

During the nine months ended September 30, 2010, we repurchased and retired approximately 58.9 million shares at an average per share price of \$56.83, for an aggregate cost of \$3.3 billion. During the nine months ended September 30, 2009, we repurchased and retired approximately 40.8 million shares at an average per share price of \$44.38, for an aggregate cost of \$1.8 billion. The excess of cost of the repurchased shares over par value is charged on a pro rata basis to additional paid-in capital and retained earnings.

On January 26, 2010, our Board of Directors increased the share repurchase authorization by \$3.5 billion. As of September 30, 2010, \$538.6 million remained authorized for future repurchases. Subsequent to September 30, 2010, we repurchased and retired approximately 1.4 million shares for an aggregate cost of approximately \$76.7 million, leaving approximately \$461.9 million for authorized future repurchases at October 20, 2010. On October 29, 2010, our Board of Directors increased the share repurchase authorization by \$500.0 million. Our stock repurchase program is discretionary as we are under no obligation to repurchase shares. We repurchase shares under the program when we believe it is a prudent use of capital.

IV. Membership September 30, 2010 Compared to September 30, 2009

Our medical membership includes seven different customer types: Local Group, Individual, National Accounts, BlueCard, Senior, State-Sponsored and FEP. BCBSA-branded business generally refers to members in our service areas licensed by the BCBSA. Non-BCBSA-branded business refers to UniCare members predominately outside of our BCBSA service areas.

Local Group (including UniCare) consists of those employer customers with less than 5% of eligible employees located outside of the employer s headquarter state, as well as customers with more than 5% of eligible employees located outside of the headquarter state with up to 5,000 eligible employees.

Individual consists of individual customers under age 65 (including UniCare) and their covered dependents.

National Accounts generally consist of multi-state employer groups primarily headquartered in a WellPoint service area with at least 5% of the eligible employees located outside of the headquarter state and with more than 5,000 eligible employees. Some exceptions are allowed based on broker relationships.

BlueCard host members represent enrollees of Blue Cross and/or Blue Shield plans not owned by WellPoint who receive health care services in our BCBSA licensed markets. BlueCard membership consists of estimated host members using the national BlueCard program. Host members are generally members who reside in or travel to a state in which a WellPoint subsidiary is the Blue Cross and/or Blue Shield licensee and who are covered under an employer-sponsored health plan issued by a non-WellPoint controlled BCBSA licensee (i.e., the home plan). We perform certain administrative

Table of Contents 56

-40-

functions for BlueCard members, for which we receive administrative fees from the BlueCard members home plans. Other administrative functions, including maintenance of enrollment information and customer service, are performed by the home plan. Host members are computed using, among other things, the average number of BlueCard claims received per month.

Senior members are Medicare-eligible individual members age 65 and over who have enrolled in Medicare Advantage, a managed care alternative for the Medicare program, or who have purchased Medicare Supplement benefit coverage.

State-Sponsored membership represents eligible members with State-Sponsored managed care alternatives in Medicaid and State Children s Health Insurance Plan programs.

FEP members consist of United States government employees and their dependents within our geographic markets through our participation in the national contract between the BCBSA and the U.S. Office of Personnel Management.

In addition to reporting our medical membership by customer type, we report by funding arrangement according to the level of risk that we assume in the product contract. Our two funding arrangement categories are fully-insured and self-funded. Fully-insured products are products in which we indemnify our policyholders against costs for health benefits. Self-funded products are offered to customers, generally larger employers, who elect to retain most or all of the financial risk associated with their employees health care costs. Some self-funded customers choose to purchase stop-loss coverage to limit their retained risk.

-41-

The following table presents our medical membership by customer type, funding arrangement and reportable segment as of September 30, 2010 and 2009. Also included below is other membership by product. The medical membership and other membership presented are unaudited and in certain instances include estimates of the number of members represented by each contract at the end of the period.

September 3	())
-------------	---	---	---

(In	tho	usand	ls)
-----	-----	-------	-----

Medical Membership	2010	2009	Change	% Change
Customer Type			g-	,, c g c
Local Group	15,171	15,717	(546)	(3)%
Individual	1,967	2,173	(206)	(9)
National:	,	,	(11)	(-)
National Accounts	7,091	6,857	234	3
BlueCard	4,783	4,779	4	
Total National	11,874	11,636	238	2
Senior	1,256	1,225	31	3
State-Sponsored	1,752	1,717	35	2
FEP	1,453	1,387	66	5
Total Medical Membership by Customer Type	33,473	33,855	(382)	(1)
J. J	,	,	(= -)	()
Funding Arrangement				
Self-Funded	19,650	18,316	1,334	7
Fully-Insured	13,823	15,539	(1,716)	(11)
•	·	,		, ,
Total Medical Membership by Funding Arrangement	33,473	33,855	(382)	(1)
Town Medical Medical population granding Management	22,	22,022	(802)	(1)
Reportable Segment				
Commercial	27,050	27,530	(480)	(2)
Consumer	4,970	4,938	32	1
Other	1,453	1,387	66	5
	1,100	1,507		
Total Medical Membership by Reportable Segment	33,473	33,855	(382)	(1)
Total Wedical Wellociship by Reportable Segment	33,473	33,633	(362)	(1)
Other Membership				
Behavioral Health	23,776	22,883	893	4
Life and Disability	5,152	5,425	(273)	(5)
Dental	4,028	4,322	(294)	(7)
Managed dental ¹	4,280	3,953	327	8
Vision	3,475	3,037	438	14
Medicare Part D	1,234	1,633	(399)	(24)

Managed dental membership includes members for which we provide administrative services only.

Medical Membership

During the twelve months ended September 30, 2010, total medical membership decreased 382,000, or 1%, primarily due to decreases in Local Group and Individual businesses (including UniCare), partially offset by increases in our National Accounts, FEP, State-Sponsored and Senior membership. The majority of the decline in our Local Group and Individual businesses primarily reflects the loss of non-BCBSA-branded membership resulting from the transition of certain UniCare members to HCSC beginning January 1, 2010 as well as lapses and net unfavorable

in-group change exceeding new sales, caused by higher unemployment resulting from the unfavorable economic conditions. In-group enrollment change represents membership changes within a group that still remains our customer.

-42-

Self-funded medical membership increased 1,334,000, or 7%, primarily due to the conversion from fully-insured to self-funded status of both a large municipal account in April 2010 and a large state employer account in July 2010, an increase in self-funded National Accounts membership driven by additional sales, partially offset by declines in self-funded non-BCBSA branded Local Group membership.

Fully-insured membership decreased 1,716,000 members, or 11%, primarily due to the conversions from fully-insured to self-funded status of both a large municipal account in April 2010 and a large state employer account in July 2010, declines in fully-insured Local Group membership driven by lapses and the transition of certain UniCare members to HCSC (both Local Group and Individual membership).

Local Group membership decreased 546,000, or 3%, primarily due to membership declines in our non-BCBSA-branded membership, including the impact of the transition of certain UniCare members to HCSC, and a decline in BCBSA-branded business associated with the unfavorable economic conditions.

Individual membership decreased 206,000, or 9%, primarily due to the transition of certain UniCare members to HCSC.

National Accounts membership increased 234,000, or 3%, primarily driven by additional sales, reflective of our extensive and cost-effective provider networks and a broad and innovative product portfolio, and favorable in-group enrollment changes in several large accounts. These increases were partially offset by lapses due to the unfavorable economic conditions.

BlueCard membership increased 4,000, or less than 1%, primarily due to increased utilization by other BCBSA licensee members who reside in or travel to our licensed areas.

Senior membership increased 31,000, or 3%, primarily due to increases in our Medicare Advantage plans, partially offset by lower membership in our Medicare Supplement plans.

State-Sponsored membership increased 35,000, or 2%, primarily due to growth in Virginia and Indiana, partially offset by lower membership in California resulting from product changes and competition.

FEP membership increased 66,000, or 5%, following the 2010 open enrollment period.

Other Membership

Our Other products are often ancillary to our health business, and can therefore be impacted by corresponding changes in our medical membership.

Behavioral health membership increased 893,000, or 4%, primarily due to new sales to several major accounts, partially offset by higher unemployment resulting from the current economic downturn.

Life and disability membership decreased 273,000, or 5%, primarily due to the transition of certain UniCare members to HCSC beginning January 1, 2010. Life and disability products are generally offered as a part of Commercial medical fully-insured membership sales.

Dental membership decreased 294,000, or 7%, primarily due to the transition of certain UniCare members to HCSC, lapses and net unfavorable in-group enrollment changes due to the current economic conditions.

Managed dental membership increased 327,000, or 8%, primarily due to new sales to two large accounts.

Vision membership increased 438,000, or 14%, primarily due to strong sales and market penetration of our Blue View vision product and embedding of vision benefits in certain of our Consumer products.

Medicare Part D membership decreased 399,000, or 24%, primarily reflecting the loss of certain 2010 Part D LIS membership.

V. Cost of Care

The following discussion summarizes our aggregate underlying cost of care trends for the rolling 12 months ended September 30, 2010 for our Local Group fully-insured business only.

Our cost of care trends are calculated by comparing the year-over-year change in average per member per month claim costs, including member co-payments and deductibles. While our cost of care trend varies by geographic location, based on underlying medical cost trends, we have lowered our 2010 cost of care trend estimate to 7.0% plus or minus 50 basis points. This change from our prior guidance estimate of 8.0% plus or minus 50 basis points is driven by lower than expected flu season impacts, favorable trend restatement in prior periods, and continued focused efforts on re-contracting.

Overall, our medical cost trend was driven more by unit cost than utilization. Inpatient hospital trend was in the low double digit range and was primarily related to increases in cost per admission. Primary contributors to unit cost trends include elevated average case acuity (intensity) as well as negotiated rate increases with hospitals. As we are successful in moving lower intensity procedures to lower cost outpatient services, the remaining inpatient procedures are generally of higher average intensity. Inpatient admission counts per thousand members were lower than prior year, however, inpatient day counts per thousand members were slightly higher. As a result, the average length of inpatient stays increased slightly compared to prior year levels. Continued clinical management and re-contracting efforts are in place to help mitigate the inpatient trend. Focused review efforts continue in key areas, including inpatient behavioral health stays and spinal surgery cases, among others. Additionally, we have introduced new programs related to readmission management, focused utilization management at high costs facilities, and post-discharge follow-up care. Programs such as the enterprise-wide enhanced 360° Health care management programs, the industry s first program to integrate all care management programs and tools into a centralized, consumer-friendly resource, continue to aid our members in accessing the most comprehensive and appropriate care available.

Outpatient trend was in the high single digit range and was 85% cost driven and 15% utilization driven. Outpatient costs are a collection of different types of expenses, such as outpatient facilities, labs, x-rays, emergency room, and occupational and physical therapy. Per visit costs are still the largest contributor to overall outpatient trend, influenced largely by price increases within certain provider contracts. Outpatient utilization (visits per thousand members) was higher than the prior year. We continue to work with vendors and providers to help optimize site of service decisions including key areas such as ER v. urgent care, laboratory service location (hospital v. free-standing lab), and surgery settings (hospital v. ambulatory surgical center). Continued expansion and optimization of our utilization management programs is also serving to moderate trend. Additionally, we continued to see the positive impact of incorporating the technology of our American Imaging Management, Inc., or AIM, subsidiary. This is allowing us to achieve greater efficiencies in the high trend area of radiology, ensuring that consumers receive the quality tests they need. Leveraging AIM s platform and expertise in areas such as nuclear cardiology management, specialty pharmacy reviews and myocardial perfusion imaging is aiding our efforts to mitigate trend increases.

Physician services trend was in the mid single digit range and was 55% cost driven and 45% utilization driven. Increases in the physician care category were partially driven by contracting changes as well as increased utilization in late 2009 related to H1N1. We continue to collaborate with physicians to improve quality of care through pay-for-performance programs.

Pharmacy trend was in the mid single digit range and was 75% unit cost (cost per prescription) related and 25% utilization (prescriptions per member per year) driven. Recent inflation in the average wholesale price of drugs is applying upward pressure to the overall cost per prescription as is the increased use of specialty

-44-

drugs. Specialty drugs, also known as biotech drugs, are generally higher cost and are being utilized more frequently. The increase in cost per prescription measures were mitigated by increases in our generic usage rates and benefit plan design changes. We are continuously evaluating our drug formulary to ensure the most effective pharmaceutical therapies are available to our members.

In response to cost trends, we continue to pursue contracting and plan design changes, promote and implement performance-based contracts that reward clinical outcomes and quality, and expand our radiology management, disease management and advanced care management programs. Expansion continues on 360° Health, which assists patients in navigating the health care system, using their health benefits and accessing the most comprehensive and appropriate care available. Additionally, our Resolution Health, Inc. subsidiary is allowing us to fully integrate their suite of products aimed to improve health care quality and reduce health care costs. As an example, My Health Advantage is a Resolution Health product that uses market-leading technology to analyze medical claims, pharmacy claims, lab results, benefit plan information and personal health information to identify opportunities to help close gaps between recommended care and the care that members actually receive. Furthermore, the sale of our PBM business and the resulting strategic alliance with Express Scripts is bringing with it greater capabilities and resources, allowing members to leverage more cost-effective solutions and state-of-the-art PBM services.

VI. Results of Operations Three Months Ended September 30, 2010 Compared to the Three Months Ended September 30, 2009 Our consolidated results of operations for the three months ended September 30, 2010 and 2009 are discussed in the following section.

In millions, except per share data 2010 2009 \$ Change % Change Premiums \$ 13,365, \$ 14,070,7 \$ (704.0) (5)% Administrative fees 963.1 969.1 (6.0) (1) (0.0) (1) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0)			Three Months Ended September 30					
Premiums \$13,366.7 \$14,070.7 \$704.0 (5)% Administrative fees 963.1 969.1 (6.0) (1) Other revenue 4.6 167.2 (162.6) (97) Total operating revenue 14,334.4 15,207.0 (872.6) (6) Net investment income 205.4 196.6 8.8 4 Net realized gains on investments 61.6 52.2 9.4 NMI Other-than-temporary impairment losses on investments: 10.0 (69.1) 58.7 85 Portion of other-than-temporary impairment losses recognized in other comprehensive income 7.2 38.4 (31.2) (81) Other-than-temporary impairment losses recognized in income (3.2) (30.7) 27.5 90 Other-than-temporary impairment losses recognized in income (3.2) (30.7) 27.5 90 Total revenues 14,598.2 15,425.1 (826.9) (5) Benefit expense 11,204.7 11,552.8 (348.1) (3) Selling expense 400.7 420.6	(In millions, except per share data)		2010		2009	\$	Change	% Change
Total operating revenue		\$	13,366.7	\$	14,070.7	\$	(704.0)	(5)%
Total operating revenue 14,334.4 15,207.0 (872.6) (6) Net investment income 205.4 196.6 8.8 4 Net realized gains on investments 61.6 52.2 9.4 NM¹ Other-than-temporary impairment losses on investments:	Administrative fees		963.1		969.1		(6.0)	(1)
Net investment income 205.4 196.6 8.8 4 Net realized gains on investments 61.6 52.2 9.4 NM¹ Other-than-temporary impairment losses on investments:	Other revenue		4.6		167.2		(162.6)	(97)
Net investment income 205.4 196.6 8.8 4 Net realized gains on investments 61.6 52.2 9.4 NM¹ Other-than-temporary impairment losses on investments: Total other-than-temporary impairment losses on investments Portion of other-than-temporary impairment losses recognized in other comprehensive income 7.2 38.4 (31.2) (81) Other-than-temporary impairment losses recognized in income (3.2) (30.7) 27.5 90 Other-than-temporary impairment losses recognized in income (3.2) (30.7) 27.5 90 Total revenues 14,598.2 15,425.1 (826.9) (5) Benefit expense 11,204.7 11,552.8 (348.1) (3) Selling, general and administrative expense: Selling expense 400.7 420.6 (19.9) (5) General and administrative expense 1,689.3 1,839.7 (150.4) (8) Total selling, general and administrative expense 2,090.0 2,260.3 (170.3) (8) Cost of drugs 112.7 (112.7) (100) Interest expense 106.3 110.6 (4.3) (4) Amortization of other intangible assets 60.4 66.0 (5.6) (8) Impairment of intangible assets 13,461.4 14,307.9 (846.5) (6) Income before income tax expense 1,136.8 1,117.2 19.6 2 Income before income tax expense 1,136.8 1,117.2 19.6 2 Income before income tax expense 1,136.8 1,117.2 19.6 2 Income before income tax expense 1,136.8 1,117.2 19.6 2 Income tax expense 397.7 387.0 10.7 3 Net income \$7.39.1 \$7.30.2 \$8.9 1 Average diluted shares outstanding 402.2 476.8 (74.6) (16)% Benefit expense ratio² 83.8% 82.1% 170bp³ Selling, general and administrative expense ratio³ 14.6% 14.9% (30)bp³								
Net realized gains on investments Cher-than-temporary impairment losses on investments Total other-than-temporary impairment losses on investments Cher-than-temporary impairment losses on investments Cher-than-temporary impairment losses Cher-than-temporary impairment losses Cher-than-temporary impairment losses Cher-than-temporary impairment losses Cher-than-temporary impairment losses recognized in income Cher-than-temporary impairment losses Cher-than-temporary impairment loses Cher-than-temporary impairment losses Cher-than-temporary impairment losses Cher-than-temporary impairment losses Cher-than-temporary impairment losses Cher-than-temporary impairm	Total operating revenue		14,334.4		15,207.0		(872.6)	(6)
Detail chan-temporary impairment losses on investments: Total other-than-temporary impairment losses or investments (10.4) (69.1) 58.7 85 Portion of other-than-temporary impairment losses recognized in other comprehensive income 7.2 38.4 (31.2) (81) Other-than-temporary impairment losses recognized in income (3.2) (30.7) 27.5 90 Other-than-temporary impairment losses recognized in income 14.598.2 15.425.1 (826.9) (5) Benefit evenues 14.598.2 15.425.1 (826.9) (5) Benefit evenues 11.204.7 11.552.8 (348.1) (3) (3) Selling, general and administrative expense: (3.2) (30.7) 420.6 (19.9) (5) General and administrative expense 400.7 420.6 (19.9) (5) General and administrative expense 1.689.3 1.839.7 (150.4) (8) Total selling, general and administrative expense 2.090.0 2.260.3 (170.3) (8) Cost of drugs 112.7 (112.7) (100) Interest expense 106.3 110.6 (4.3) (4) Amortization of other intangible assets 60.4 66.0 (5.6) (8) Impairment of intangible assets 60.4 66.0 (5.6) (8) Impairment of intangible assets 1.3461.4 14,307.9 (846.5) (6) Income before income tax expense 1,136.8 1,117.2 19.6 (2) Income before income tax expense 1,136.8 1,117.2 19.6 (2) Income tax expense 397.7 387.0 10.7 (3) Net income 739.1 730.2 8.9 1 Average diluted shares outstanding 402.2 476.8 (74.6) (16)% Diluted net income per share 1.84 5.153 0.31 20% Benefit expense ratio 83.8% 82.1% 1700p3 Selling, general and administrative expense ratio 14.6% 14.9% (30)bp3 Income teore income tax ex as a percentage of total revenue 7.8% (7.2% (50)bp3	Net investment income		205.4		196.6		8.8	4
Total other-than-temporary impairment losses on investments (10.4) (69.1) 58.7 85 Portion of other-than-temporary impairment losses recognized in other comprehensive income 7.2 38.4 (31.2) (81) Other-than-temporary impairment losses recognized in income (3.2) (30.7) 27.5 90 Total revenues 14.598.2 15.425.1 (826.9) (5) Benefit expense 11.204.7 11.552.8 (348.1) (3) Selling, general and administrative expense: 8 (1.58) (348.1) (3) Selling expense 400.7 420.6 (19.9) (5) General and administrative expense 1,689.3 1,839.7 (150.4) (8) Total selling, general and administrative expense 2,090.0 2,260.3 (170.3) (8) Cost of drugs 112.7 (112.7) (100) Interest expense 106.3 110.6 (4.3) (4) Amortization of other intangible assets 60.4 66.0 (5.6) (8) Impairment of intangible assets <t< td=""><td>Net realized gains on investments</td><td></td><td>61.6</td><td></td><td>52.2</td><td></td><td>9.4</td><td>NM^1</td></t<>	Net realized gains on investments		61.6		52.2		9.4	NM^1
Investments	Other-than-temporary impairment losses on investments:							
Portion of other-than-temporary impairment losses recognized in other comprehensive income 7.2 38.4 (31.2) (81)	Total other-than-temporary impairment losses on							
recognized in other comprehensive income 7.2 38.4 (31.2) (81) Other-than-temporary impairment losses recognized in income (3.2) (30.7) 27.5 90 Total revenues 14,598.2 15,425.1 (826.9) (5) Benefit expense 11,204.7 11,552.8 (348.1) (3) Selling, general and administrative expense: 28.0 (19.9) (5) General and administrative expense 1,689.3 1,839.7 (150.4) (8) Total selling, general and administrative expense 2,090.0 2,260.3 (170.3) (8) Cost of drugs 112.7 (112.7) (100) Interest expense 106.3 110.6 (4.3) (4) Amortization of other intangible assets 60.4 66.0 (5.6) (8) Impairment of intangible assets 13,461.4 14,307.9 (846.5) (6) Total expenses 1,136.8 1,117.2 19.6 2 Income before income tax expense 1,136.8 1,117.2 19.6 2	investments		(10.4)		(69.1)		58.7	85
Other-than-temporary impairment losses recognized in income (3.2) (30.7) 27.5 90 Total revenues 14,598.2 15,425.1 (826.9) (5) Benefit expense 11,204.7 11,552.8 (348.1) (3) Selling, general and administrative expense: Selling expense 400.7 420.6 (19.9) (5) General and administrative expense 1,689.3 1,839.7 (150.4) (8) Total selling, general and administrative expense 2,090.0 2,260.3 (170.3) (8) Cost of drugs 112.7 (112.7) (100) Interest expense 106.3 110.6 (4.3) (4) Amortization of other intangible assets 60.4 66.0 (5.6) (8) Impairment of intangible assets 13,461.4 14,307.9 (846.5) (6) Total expenses 1,136.8 1,117.2 19.6 2 Income before income tax expense 1,136.8 1,117.2 19.6 2 Income tax expense 397.7 387.0 10.7 <td>Portion of other-than-temporary impairment losses</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	Portion of other-than-temporary impairment losses							
income (3.2) (30.7) 27.5 90 Total revenues 14,598.2 15,425.1 (826.9) (5) Benefit expense 11,204.7 11,552.8 (348.1) (3) Selling, general and administrative expense: Selling expense 400.7 420.6 (19.9) (5) General and administrative expense 1,689.3 1,839.7 (150.4) (8) Total selling, general and administrative expense 2,090.0 2,260.3 (170.3) (8) Cost of drugs 112.7 (112.7) (100) Interest expense 106.3 110.6 (4.3) (4) Amortization of other intangible assets 60.4 66.0 (5.6) (8) Impairment of intangible assets 205.5 (205.5) (100) Total expenses 13,461.4 14,307.9 (846.5) (6) Income before income tax expense 1,136.8 1,117.2 19.6 2 Income tax expense 397.7 387.0 10.7 3 Net income	recognized in other comprehensive income		7.2		38.4		(31.2)	(81)
income (3.2) (30.7) 27.5 90 Total revenues 14,598.2 15,425.1 (826.9) (5) Benefit expense 11,204.7 11,552.8 (348.1) (3) Selling, general and administrative expense: Selling expense 400.7 420.6 (19.9) (5) General and administrative expense 1,689.3 1,839.7 (150.4) (8) Total selling, general and administrative expense 2,090.0 2,260.3 (170.3) (8) Cost of drugs 112.7 (112.7) (1000) Interest expense 106.3 110.6 (4.3) (4) Amortization of other intangible assets 60.4 66.0 (5.6) (8) Impairment of intangible assets 205.5 (205.5) (100) Total expenses 13,461.4 14,307.9 (846.5) (6) Income before income tax expense 1,136.8 1,117.2 19.6 2 Income tax expense 397.7 387.0 10.7 3 Net income								
Total revenues 14,598.2 15,425.1 (826.9) (5)	Other-than-temporary impairment losses recognized in							
Benefit expense	income		(3.2)		(30.7)		27.5	90
Benefit expense								
Selling, general and administrative expense 400.7 420.6 (19.9) (5) General and administrative expense 1,689.3 1,839.7 (150.4) (8) Total selling, general and administrative expense 2,090.0 2,260.3 (170.3) (8) Cost of drugs 112.7 (112.7) (100) Interest expense 106.3 110.6 (4.3) (4) Amortization of other intangible assets 60.4 66.0 (5.6) (8) Impairment of intangible assets 205.5 (205.5) (100) Total expenses 13,461.4 14,307.9 (846.5) (6) Income before income tax expense 1,136.8 1,117.2 19.6 2 Income tax expense 397.7 387.0 10.7 3 Net income \$ 739.1 \$ 730.2 \$ 8.9 1 Average diluted shares outstanding 402.2 476.8 (74.6) (16)% Diluted net income per share \$ 1.84 \$ 1.53 \$ 0.31 20% Benefit expense ratio² </td <td>Total revenues</td> <td></td> <td>14,598.2</td> <td></td> <td>15,425.1</td> <td></td> <td>(826.9)</td> <td>(5)</td>	Total revenues		14,598.2		15,425.1		(826.9)	(5)
Selling, general and administrative expense 400.7 420.6 (19.9) (5) General and administrative expense 1,689.3 1,839.7 (150.4) (8) Total selling, general and administrative expense 2,090.0 2,260.3 (170.3) (8) Cost of drugs 112.7 (112.7) (100) Interest expense 106.3 110.6 (4.3) (4) Amortization of other intangible assets 60.4 66.0 (5.6) (8) Impairment of intangible assets 205.5 (205.5) (100) Total expenses 13,461.4 14,307.9 (846.5) (6) Income before income tax expense 1,136.8 1,117.2 19.6 2 Income tax expense 397.7 387.0 10.7 3 Net income \$ 739.1 \$ 730.2 \$ 8.9 1 Average diluted shares outstanding 402.2 476.8 (74.6) (16)% Diluted net income per share \$ 1.84 \$ 1.53 \$ 0.31 20% Benefit expense ratio² </td <td>Benefit expense</td> <td></td> <td>11,204.7</td> <td></td> <td></td> <td></td> <td>` ′</td> <td></td>	Benefit expense		11,204.7				` ′	
Selling expense 400.7 420.6 (19.9) (5) General and administrative expense 1,689.3 1,839.7 (150.4) (8) Total selling, general and administrative expense 2,090.0 2,260.3 (170.3) (8) Cost of drugs 112.7 (112.7) (100) Interest expense 106.3 110.6 (4.3) (4) Amortization of other intangible assets 60.4 66.0 (5.6) (8) Impairment of intangible assets 205.5 (205.5) (100) Total expenses 13,461.4 14,307.9 (846.5) (6) Income before income tax expense 1,136.8 1,117.2 19.6 2 Income tax expense 397.7 387.0 10.7 3 Net income \$ 739.1 \$ 730.2 \$ 8.9 1 Average diluted shares outstanding 402.2 476.8 (74.6) (16)% Diluted net income per share \$ 1.84 \$ 1.53 \$ 0.31 20% Benefit expense ratio ² 83.8%	Selling, general and administrative expense:						· · ·	, ,
General and administrative expense 1,689.3 1,839.7 (150.4) (8) Total selling, general and administrative expense 2,090.0 2,260.3 (170.3) (8) Cost of drugs 112.7 (112.7) (100) Interest expense 106.3 110.6 (4.3) (4) Amortization of other intangible assets 60.4 66.0 (5.6) (8) Impairment of intangible assets 205.5 (205.5) (100) Total expenses 1,136.8 1,117.2 19.6 2 Income before income tax expense 1,136.8 1,117.2 19.6 2 Income tax expense 397.7 387.0 10.7 3 Net income \$739.1 \$730.2 \$8.9 1 Average diluted shares outstanding 402.2 476.8 (74.6) (16)% Diluted net income per share \$1.84 \$1.53 \$0.31 20% Benefit expense ratio ² 83.8% 82.1% 170bp³ Selling, general and administrative expense ratio ⁴ 14.6% </td <td></td> <td></td> <td>400.7</td> <td></td> <td>420.6</td> <td></td> <td>(19.9)</td> <td>(5)</td>			400.7		420.6		(19.9)	(5)
Total selling, general and administrative expense 2,090.0 2,260.3 (170.3) (8) Cost of drugs 112.7 (112.7) (100) Interest expense 106.3 110.6 (4.3) (4) Amortization of other intangible assets 60.4 66.0 (5.6) (8) Impairment of intangible assets 205.5 (205.5) (100) Total expenses 13,461.4 14,307.9 (846.5) (6) Income before income tax expense 1,136.8 1,117.2 19.6 2 Income tax expense 397.7 387.0 10.7 3 Net income \$ 739.1 \$ 730.2 \$ 8.9 1 Average diluted shares outstanding 402.2 476.8 (74.6) (16)% Diluted net income per share \$ 1.84 \$ 1.53 \$ 0.31 20% Benefit expense ratio ² 83.8% 82.1% 170bp³ Selling, general and administrative expense ratio ⁴ 14.6% 14.9% (30)bp³ Income before income taxes as a percentage of total revenue			1,689.3		1,839.7			
Cost of drugs 112.7 (112.7) (100) Interest expense 106.3 110.6 (4.3) (4) Amortization of other intangible assets 60.4 66.0 (5.6) (8) Impairment of intangible assets 205.5 (205.5) (100) Total expenses 13,461.4 14,307.9 (846.5) (6) Income before income tax expense 1,136.8 1,117.2 19.6 2 Income tax expense 397.7 387.0 10.7 3 Net income \$ 739.1 \$ 730.2 \$ 8.9 1 Average diluted shares outstanding 402.2 476.8 (74.6) (16)% Diluted net income per share \$ 1.84 \$ 1.53 \$ 0.31 20% Benefit expense ratio ² 83.8% 82.1% 170bp³ Selling, general and administrative expense ratio ⁴ 14.6% 14.9% (30)bp³ Income before income taxes as a percentage of total revenue 7.8% 7.2% 60bp³	•		Í		·		· ·	ì
Cost of drugs 112.7 (112.7) (100) Interest expense 106.3 110.6 (4.3) (4) Amortization of other intangible assets 60.4 66.0 (5.6) (8) Impairment of intangible assets 205.5 (205.5) (100) Total expenses 13,461.4 14,307.9 (846.5) (6) Income before income tax expense 1,136.8 1,117.2 19.6 2 Income tax expense 397.7 387.0 10.7 3 Net income \$ 739.1 \$ 730.2 \$ 8.9 1 Average diluted shares outstanding 402.2 476.8 (74.6) (16)% Diluted net income per share \$ 1.84 \$ 1.53 \$ 0.31 20% Benefit expense ratio ² 83.8% 82.1% 170bp³ Selling, general and administrative expense ratio ⁴ 14.6% 14.9% (30)bp³ Income before income taxes as a percentage of total revenue 7.8% 7.2% 60bp³	Total selling general and administrative expense		2.090.0		2.260.3		(170.3)	(8)
Interest expense 106.3 110.6 (4.3) (4) Amortization of other intangible assets 60.4 66.0 (5.6) (8) Impairment of intangible assets 205.5 (205.5) (100) Total expenses 13,461.4 14,307.9 (846.5) (6) Income before income tax expense 1,136.8 1,117.2 19.6 2 Income tax expense 397.7 387.0 10.7 3 Net income \$739.1 \$730.2 \$8.9 1 Average diluted shares outstanding 402.2 476.8 (74.6) (16)% Diluted net income per share \$1.84 \$1.53 \$0.31 20% Benefit expense ratio² 83.8% 82.1% 170bp³ Selling, general and administrative expense ratio⁴ 14.6% 14.9% (30)bp³ Income before income taxes as a percentage of total revenue 7.8% 7.2% 60bp³			2,070.0					. ,
Amortization of other intangible assets 60.4 66.0 (5.6) (8) Impairment of intangible assets 205.5 (205.5) (100) Total expenses 13,461.4 14,307.9 (846.5) (6) Income before income tax expense 1,136.8 1,117.2 19.6 2 Income tax expense 397.7 387.0 10.7 3 Net income \$739.1 \$730.2 \$8.9 1 Average diluted shares outstanding 402.2 476.8 (74.6) (16)% Diluted net income per share \$1.84 \$1.53 \$0.31 20% Benefit expense ratio² 83.8% 82.1% 170bp³ Selling, general and administrative expense ratio⁴ 14.6% 14.9% (30)bp³ Income before income taxes as a percentage of total revenue 7.8% 7.2% 60bp³	•		106.3				` ′	
Impairment of intangible assets 205.5 (205.5) (100) Total expenses 13,461.4 14,307.9 (846.5) (6) Income before income tax expense 1,136.8 1,117.2 19.6 2 Income tax expense 397.7 387.0 10.7 3 Net income \$739.1 \$730.2 \$8.9 1 Average diluted shares outstanding 402.2 476.8 (74.6) (16)% Diluted net income per share \$1.84 \$1.53 \$0.31 20% Benefit expense ratio ² 83.8% 82.1% 170bp³ Selling, general and administrative expense ratio ⁴ 14.6% 14.9% (30)bp³ Income before income taxes as a percentage of total revenue 7.8% 7.2% 60bp³	*							. ,
Total expenses 13,461.4 14,307.9 (846.5) (6) Income before income tax expense 1,136.8 1,117.2 19.6 2 Income tax expense 397.7 387.0 10.7 3 Net income \$ 739.1 \$ 730.2 \$ 8.9 1 Average diluted shares outstanding 402.2 476.8 (74.6) (16)% Diluted net income per share \$ 1.84 \$ 1.53 \$ 0.31 20% Benefit expense ratio ² 83.8% 82.1% 170bp³ Selling, general and administrative expense ratio ⁴ 14.6% 14.9% (30)bp³ Income before income taxes as a percentage of total revenue 7.8% 7.2% 60bp³							` ′	
Income before income tax expense 1,136.8 1,117.2 19.6 2 Income tax expense 397.7 387.0 10.7 3 Net income \$ 739.1 \$ 730.2 \$ 8.9 1 Average diluted shares outstanding 402.2 476.8 (74.6) (16)% Diluted net income per share \$ 1.84 \$ 1.53 \$ 0.31 20% Benefit expense ratio ² 83.8% 82.1% 170bp³ Selling, general and administrative expense ratio ⁴ 14.6% 14.9% (30)bp³ Income before income taxes as a percentage of total revenue 7.8% 7.2% 60bp³							(====)	()
Income before income tax expense 1,136.8 1,117.2 19.6 2 Income tax expense 397.7 387.0 10.7 3 Net income \$ 739.1 \$ 730.2 \$ 8.9 1 Average diluted shares outstanding 402.2 476.8 (74.6) (16)% Diluted net income per share \$ 1.84 \$ 1.53 \$ 0.31 20% Benefit expense ratio ² 83.8% 82.1% 170bp³ Selling, general and administrative expense ratio ⁴ 14.6% 14.9% (30)bp³ Income before income taxes as a percentage of total revenue 7.8% 7.2% 60bp³	Total expenses		13.461.4		14 307 0		(846.5)	(6)
Income tax expense 397.7 387.0 10.7 3 Net income \$ 739.1 \$ 730.2 \$ 8.9 1 Average diluted shares outstanding 402.2 476.8 (74.6) (16)% Diluted net income per share \$ 1.84 \$ 1.53 \$ 0.31 20% Benefit expense ratio² 83.8% 82.1% 170bp³ Selling, general and administrative expense ratio⁴ 14.6% 14.9% (30)bp³ Income before income taxes as a percentage of total revenue 7.8% 7.2% 60bp³	Total expenses		13,401.4		14,507.9		(040.5)	(0)
Income tax expense 397.7 387.0 10.7 3 Net income \$ 739.1 \$ 730.2 \$ 8.9 1 Average diluted shares outstanding 402.2 476.8 (74.6) (16)% Diluted net income per share \$ 1.84 \$ 1.53 \$ 0.31 20% Benefit expense ratio² 83.8% 82.1% 170bp³ Selling, general and administrative expense ratio⁴ 14.6% 14.9% (30)bp³ Income before income taxes as a percentage of total revenue 7.8% 7.2% 60bp³			1 126 0		1 117 0		10.6	2
Net income \$ 739.1 \$ 730.2 \$ 8.9 1 Average diluted shares outstanding 402.2 476.8 (74.6) (16)% Diluted net income per share \$ 1.84 \$ 1.53 \$ 0.31 20% Benefit expense ratio² 83.8% 82.1% 170bp³ Selling, general and administrative expense ratio⁴ 14.6% 14.9% (30)bp³ Income before income taxes as a percentage of total revenue 7.8% 7.2% 60bp³	*							
Average diluted shares outstanding 402.2 476.8 (74.6) $(16)\%$ Diluted net income per share $$1.84$ $$1.53$ $$0.31$ 20% Benefit expense ratio ² 83.8% 82.1% $170bp^3$ Selling, general and administrative expense ratio ⁴ 14.6% 14.9% $(30)bp^3$ Income before income taxes as a percentage of total revenue 7.8% 7.2% $60bp^3$	income tax expense		391.1		387.0		10.7	3
Average diluted shares outstanding 402.2 476.8 (74.6) $(16)\%$ Diluted net income per share $$1.84$ $$1.53$ $$0.31$ 20% Benefit expense ratio ² 83.8% 82.1% $170bp^3$ Selling, general and administrative expense ratio ⁴ 14.6% 14.9% $(30)bp^3$ Income before income taxes as a percentage of total revenue 7.8% 7.2% $60bp^3$	Not income	¢	720.1	¢	720.2	¢	9.0	1
Diluted net income per share \$ 1.84 \$ 1.53 \$ 0.31 20% Benefit expense ratio ² 83.8% 82.1% $170bp^3$ Selling, general and administrative expense ratio ⁴ 14.6% 14.9% (30)bp ³ Income before income taxes as a percentage of total revenue 7.8% 7.2% $60bp^3$	Net income	Ф	/39.1	Ф	730.2	Ф	8.9	1
Diluted net income per share \$ 1.84 \$ 1.53 \$ 0.31 20% Benefit expense ratio ² 83.8% 82.1% $170bp^3$ Selling, general and administrative expense ratio ⁴ 14.6% 14.9% $(30)bp^3$ Income before income taxes as a percentage of total revenue 7.8% 7.2% $60bp^3$	Average diluted shares outstanding		402.2		476.8		(74.6)	(16)%
Benefit expense ratio ² 83.8% 82.1% 170 bp ³ Selling, general and administrative expense ratio ⁴ 14.6% 14.9% (30) bp ³ Income before income taxes as a percentage of total revenue 7.8% 7.2% 60 bp ³		\$		\$		\$		
Selling, general and administrative expense ratio ⁴ 14.6% 14.9% $(30)bp^3$ Income before income taxes as a percentage of total revenue 7.8% 7.2% $60bp^3$				_		Ψ	2.2.2	
Income before income taxes as a percentage of total revenue 7.8% 7.2% $60bp^3$								

Certain of the following definitions are also applicable to all other results of operations tables in this discussion:

- NM = Not meaningful
- Benefit expense ratio = Benefit expense ÷ Premiums.
- bp = basis point; one hundred basis points = 1%.
- Selling, general and administrative expense ratio = Total selling, general and administrative expense ÷ Total operating revenue.

-46-

Premiums decreased \$704.0 million, or 5%, to \$13.4 billion in 2010, primarily due to fully-insured membership declines in our Local Group and National Accounts businesses, the conversion from fully-insured to self-funded status of both a large municipal account in April 2010 and a large state employer account in July 2010 and certain UniCare members transitioning to HCSC beginning January 1, 2010. In addition, the loss of certain 2010 Part D LIS membership within our Senior business contributed to the decline in premiums. These decreases were partially offset by higher premiums in our Local Group and National Accounts businesses that were necessary to cover cost trends, increased reimbursement in the FEP program and increased revenue due to membership gains in our Senior Medicare Advantage business. The decrease in premiums related to the conversion of the large municipal account was largely offset by a comparable reduction of benefit expense, as further described below.

Administrative fees decreased \$6.0 million, or 1%, to \$963.1 million in 2010, primarily due to reductions of certain PBM related revenues earned in 2009 which are not reflected in 2010 due to the sale of our PBM business to Express Scripts in December 2009, partially offset by increased revenue in our self-funded National Accounts business resulting from both membership increases and improved pricing.

The majority of other revenue was historically comprised of co-payments and deductibles associated with the sale of mail-order prescription drugs by our PBM companies. The decline in other revenue in 2009 is primarily due to the sale of our PBM business in December 2009. Accordingly, our operating results do not reflect other revenue for this business in 2010, and other revenue of \$4.6 million recorded in 2010 was primarily associated with miscellaneous activities.

Net investment income increased \$8.8 million, or 4%, to \$205.4 million in 2010, primarily resulting from dividends of \$24.8 million associated with one of our cost method investments, partially offset by lower yields earned on short-term and fixed maturity investments.

A summary of our net realized gains (losses) on investments for the three months ended September 30, 2010 and 2009 is as follows:

	Th	ree Months En September 30	
(In millions)	2010	2009	\$ Change
Net realized gains (losses) on investments			
Net realized gains from fixed maturity securities	\$ 64.2	\$ 11.4	\$ 52.8
Net realized (losses) gains from equity securities	(2.5)	40.5	(43.0)
Other net realized (losses) gains on investments	(0.1)	0.3	(0.4)
Net realized gains on investments	61.6	52.2	9.4
Other-than-temporary impairment losses recognized in income			
Other-than-temporary impairment losses equity securities	(2.4)	(18.3)	15.9
Other-than-temporary impairment losses fixed maturity securities	(0.8)	(12.4)	11.6
Other-than-temporary impairment losses recognized in income	(3.2)	(30.7)	27.5
Net realized gains on investments and other-than-temporary impairment losses recognized in			
income	\$ 58.4	\$ 21.5	\$ 36.9

Net realized gains on investments increased in 2010 primarily due to increased gains from the sale of fixed maturity securities, partially offset by increased net realized losses from equity securities.

Other-than-temporary impairment losses recognized in income decreased in 2010. Other-than-temporary impairment losses recognized in income during the three months ended September 30, 2009 were related to both impairment of equity securities due to declines in stock prices and impairment of fixed maturity securities, primarily from credit related events. There was no individually significant other-than-temporary impairment of investments by issuer during the three months ended September 30, 2010 or 2009.

-47-

Benefit expense decreased \$348.1 million, or 3%, to \$11.2 billion in 2010, primarily due to fully-insured membership declines in our Local Group and National Accounts businesses, the conversion of a large municipal account from fully-insured to self-funded status in April 2010 and certain UniCare members transitioning to HCSC beginning January 1, 2010. These decreases were partially offset by increases in benefit costs in our Local Group BCBSA-branded, Senior Medicare Advantage and FEP businesses. Medicare Advantage related increases in benefit expense were primarily due to higher membership. We receive reimbursement for FEP costs plus a fee.

Our benefit expense ratio increased 170 basis points to 83.8% in 2010, due to increases in our Consumer segment, partially offset by improvements in our Local Group BCBSA-branded business. The Consumer segment increases included our Senior business and were driven primarily by increases in Medicare Advantage due to the reduction in federal reimbursement rates for 2010. Increases in the Individual business were driven primarily by reduced and delayed premium increases in certain of our markets. Improvements in the Local Group BCBSA-branded business reflected disciplined pricing, and the conversion of a large municipal account from fully-insured to self funded status in April 2010.

Selling, general and administrative expense decreased \$170.3 million, or 8%, to \$2.1 billion in 2010. Our selling, general and administrative expense decreased due to lower base compensation costs, incentive compensation, selling expenses and other operating expenses, partially offset by increases in outside services costs. The selling expense decline included reduced amounts related to a portion of our UniCare business in Texas and Illinois that transitioned to HCSC. Our 2010 general and administrative expenses also no longer include the administrative expenses formerly incurred by our PBM business, as these operations were sold to Express Scripts in December 2009. The expenses associated with administering PBM products to our medical members are now reflected in the drug prices charged to us by Express Scripts as part of our ten year contract and are included in benefit expense described above. Our selling, general and administrative expense ratio decreased 30 basis points to 14.6% in 2010, primarily due to lower base compensation costs, incentive compensation, selling expenses and other operating expenses, partially offset by a decline in operating revenue and increased outside services costs.

Cost of drugs sold decreased \$112.7 million, or 100%, due to no PBM activity in 2010 as compared to 2009. These cost of drugs sold were associated with other revenue generated from mail order sales of drugs. Following the sale of our PBM business, we do not record any cost of drugs on our income statement as we no longer market and sell prescription drugs.

Interest expense decreased \$4.3 million, or 4%, to \$106.3 million in 2010, primarily due to lower average debt balances and lower short-term rates on floating rate debt.

Amortization of other intangible assets decreased \$5.6 million, or 8%, to \$60.4 million in 2010, primarily due to reduced balances of certain amortizable intangible assets acquired in prior years.

During the third quarter of 2009, we identified and recorded a pre-tax impairment charge relating to our UniCare tradenames of \$205.5 million, the majority of which was driven by the loss of certain 2010 Part D LIS membership.

Income tax expense increased \$10.7 million, or 3%, to \$397.7 million in 2010. This increase was primarily due to higher income before income taxes. The effective tax rates in 2010 and 2009 were 35.0% and 34.6%, respectively.

The factors noted above led to net income as a percentage of total revenue increasing 40 basis points to 5.1% in 2010 as compared to 2009.

Reportable Segments

We use operating gain to evaluate the performance of our reportable segments, as described in FASB guidance, which are Commercial, Consumer and Other. Operating gain is calculated as total operating revenue

-48-

less benefit expense, selling, general and administrative expense and cost of drugs. It does not include net investment income, net realized gains or losses on investments, interest expense, amortization or impairment of other intangible assets or income taxes, as these items are managed in a corporate shared service environment and are not the responsibility of operating segment management. For additional information, see Note 13 to our unaudited consolidated financial statements for the three and nine months ended September 30, 2010 included in this Form 10-Q. The discussions of segment results for the three months ended September 30, 2010 and 2009 presented below are based on operating gain, as described above, and operating margin, which is calculated as operating gain divided by operating revenue. Our definitions of operating gain and operating margin may not be comparable to similarly titled measures reported by other companies.

Commercial

Our Commercial segment s summarized results of operations for the three months ended September 30, 2010 and 2009 are as follows:

	Three Mont	Three Months Ended					
	Septeml	ber 30					
(In millions)	2010	2009	\$ Change	% Change			
Operating revenue	\$ 8,512.1	\$ 9,311.0	\$ (798.9)	(9)%			
Operating gain	\$ 760.9	\$ 628.0	\$ 132.9	21%			
Operating margin	8.9%	6.7%		220bp			

Operating revenue decreased \$798.9 million, or 9%, to \$8.5 billion in 2010, primarily due to fully-insured membership declines in our Local Group BCBSA-branded business and National Accounts business due to unfavorable economic conditions. In addition, operating revenue decreased due to the conversion from fully-insured to self-funded status of both a large municipal account and a large state employer account. Also, certain UniCare members transitioning to HCSC beginning January 1, 2010 reduced operating revenue. These decreases were partially offset by higher premiums that were necessary to cover cost trend and increased revenue in our self-funded National Accounts business from both membership increases and improved pricing.

Operating gain increased \$132.9 million, or 21%, to \$760.9 million in 2010 primarily due to improvements in our Local Group BCBSA-branded business and lower selling, general and administrative expenses. The improvement in our Local Group BCBSA-branded business reflects higher premium revenue necessary to cover cost trend, partially off set by fully insured membership declines.

The factors above led to an operating margin in 2010 of 8.9%, a 220 basis point increase over 2009.

Consumer

Our Consumer segment summarized results of operations for the three months ended September 30, 2010 and 2009 are as follows:

	Three Mont	ths Ended		
	Septeml	per 30		
(In millions)	2010	2009	\$ Change	% Change
Operating revenue	\$ 4,039.1	\$ 4,089.8	\$ (50.7)	(1)%
Operating gain	\$ 261.7	\$ 520.0	\$ (258.3)	(50)%
Operating margin	6.5%	12.7%		(620)bp

Operating revenue decreased \$50.7 million, or 1%, to \$4.0 billion in 2010, primarily due to our loss of certain 2010 Part D LIS membership, lower risk score revenues in our Medicare Advantage business, membership declines and lower premium revenue in our Individual business caused by unfavorable economic

conditions and a change during 2010 in the provider of pharmacy benefits for the Indiana Medicaid program included in our State-Sponsored programs. These decreases were partially offset by increases in our Medicare Advantage business due to higher membership.

Operating gain decreased \$258.3 million, or 50%, to \$261.7 million in 2010, primarily due to lower operating results in our Medicare Advantage and Individual businesses. The lower operating gain in our Medicare Advantage business is due to lower risk score revenues and the reduction in federal reimbursement rates for 2010. The lower operating results in our Individual business reflect the impact of delayed and reduced premium rate increases necessary to cover cost trends in certain markets, and the recognition of a premium credit to be issued to certain policyholders in Colorado during the third quarter of 2010.

The factors above led to an operating margin in 2010 of 6.5%, a 620 basis point decrease from 2009.

Other

Our Other segment s summarized results of operations for the three months ended September 30, 2010 and 2009 are as follows:

<i>a</i>	I nree Mon	uns Enaea		
	Septem	iber 30		
(In millions)	2010	2009	\$ Change	% Change
Operating revenue	\$ 1,783.2	\$ 1,806.2	\$ (23.0)	(1)%
Operating gain	\$ 17.1	\$ 133.2	\$ (116.1)	(87)%

Operating revenue decreased \$23.0 million, or 1%, to \$1.8 billion in 2010, primarily due to the sale of the PBM business on December 1, 2009, partially offset by growth in our FEP business.

Operating gain decreased \$116.1 million, or 87%, to \$17.1 million in 2010, primarily due to the sale of the PBM business on December 1, 2009.

VII. Results of Operations Nine Months Ended September 30, 2010 Compared to the Nine Months Ended September 30, 2009 Our consolidated results of operations for the nine months ended September 30, 2010 and 2009 are discussed in the following section.

	Nine Months Ended September 30					
(In millions, except per share data)	2010		2009		Change	% Change
Premiums	\$ 40,533		42,397.2	\$	(1,863.5)	(4)%
Administrative fees	2,865	.1	2,887.4		(22.3)	(1)
Other revenue	28	3.8	486.9		(458.1)	(94)
Total angusting gavenus	43,427	1.6	15 771 5		(2.242.0)	(5)
Total operating revenue Net investment income	43,427		45,771.5 599.4		(2,343.9)	(5) 2.
			20.4			NM^1
Net realized gains on investments Other-than-temporary impairment losses on investments:	146		20.4		126.1	INIVI
	(50	(2)	(481.9)		1207	89
Total other-than-temporary impairment losses on investments Portion of other-than-temporary impairment losses	(33	3.2)	(481.9)		428.7	89
	2		72.2		(49.0)	(66)
recognized in other comprehensive income	22	1.2	72.2		(48.0)	(66)
Other-than-temporary impairment losses recognized in income	(29	0.0)	(409.7)		380.7	93
Total revenues	44,153	.9	45,981.6		(1,827.7)	(4)
Benefit expense	33,571	.1	35,127.1		(1,556.0)	(4)
Selling, general and administrative expense:						
Selling expense	1,206	.2	1,273.8		(67.6)	(5)
General and administrative expense	5,265	.9	5,421.3		(155.4)	(3)
Total selling, general and administrative expense	6,472	0 1	6,695.1		(223.0)	(3)
Cost of drugs	0,472	1	346.4		(346.4)	(100)
Interest expense	305	0	343.7		(37.8)	(100)
Amortization of other intangible assets	182		200.5		(37.8) (18.5)	(9)
Impairment of other intangible assets	21		205.5		(184.4)	(90)
impairment of other intaligible assets	21	.1	203.3		(104.4)	(90)
Total expenses	40,552	2	42,918.3		(2,366.1)	(6)
Income before income tax expense	3,601		3,063.3		538.4	18
Income tax expense	1,263	.4	1,059.2		204.2	19
Net income	\$ 2,338	3.3 \$	2,004.1	\$	334.2	17
Average diluted shares outstanding	423		487.0		(63.6)	(13)%
Diluted net income per share		52 \$	4.12	\$	1.40	34%
Benefit expense ratio ²	82	2.8%	82.9%			$(10)bp^3$
Selling, general and administrative expense ratio ⁴		1.9%	14.6%			$30bp^3$
Income before income taxes as a percentage of total revenue	8	3.2%	6.7%			$150bp^3$
Net income as a percentage of total revenue	5	5.3%	4.4%			$90bp^3$

Certain of the following definitions are also applicable to all other results of operations tables in this discussion:

- NM = Not meaningful
- Benefit expense ratio = Benefit expense ÷ Premiums.
- bp = basis point; one hundred basis points = 1%.
- Selling, general and administrative expense ratio = Total selling, general and administrative expense ÷ Total operating revenue.

-51-

Premiums decreased \$1.9 billion, or 4%, to \$40.5 billion in 2010, primarily due to fully-insured membership declines in our Local Group and National Accounts businesses resulting from the unfavorable economic conditions, certain UniCare members transitioning to HCSC beginning January 1, 2010, the conversion of a large municipal account from fully-insured to self-funded status in April 2010 and the loss of certain 2010 Part D LIS membership within our Senior business. The decrease in premiums related to the conversion of the large municipal account was largely offset by a comparable reduction of benefit expense, as further described below. These decreases were partially offset by higher premiums that were necessary to cover cost trends, as discussed above, increased reimbursement in the FEP program and increased membership in our Senior Medicare Advantage business and certain State-Sponsored programs.

Administrative fees decreased \$22.3 million, or 1%, to \$2.9 billion in 2010, primarily due to reductions of certain PBM related revenues earned in 2009 which are not reflected in 2010 due to the sale of our PBM in December 2009 and lower revenues in our NGS Medicare business, partially offset by increased revenue in our self-funded National Accounts business resulting from both membership increases and improved pricing, as well as increased managed dental revenue.

The majority of other revenue was historically comprised of co-payments and deductibles associated with the sale of mail-order prescription drugs by our PBM companies. The decline in other revenue is due to the sale of our PBM business to in December 2009. Accordingly, our operating results do not reflect other revenue for this business in 2010, and other revenue of \$28.8 million recorded in 2010 is primarily associated with miscellaneous activities.

Net investment income increased \$9.4 million, or 2%, to \$608.8 million in 2010, primarily resulting from dividends of \$30.0 million associated with one of our cost method investments partially offset by lower yields earned on short-term and fixed maturity investments.

A summary of our net realized gains (losses) on investments for the nine months ended September 30, 2010 and 2009 is as follows:

	Nine Months Ended September 30			
(In millions)	2010	2009	\$ Change	
Net realized gains (losses) on investments				
Net realized gains from fixed maturity securities	\$ 161.9	\$ 15.7	\$ 146.2	
Net realized (losses) gains from equity securities	(15.3)	4.8	(20.1)	
Other net realized losses on investments	(0.1)	(0.1)		
Net realized gains on investments	146.5	20.4	126.1	
Other-than-temporary impairment losses recognized in income				
Other-than-temporary impairment losses equity securities	(12.4)	(201.8)	189.4	
Other-than-temporary impairment losses fixed maturity securities	(16.6)	(207.9)	191.3	
Other-than-temporary impairment losses recognized in income	(29.0)	(409.7)	380.7	
Net realized gains (losses) on investments and other-than-temporary impairment losses				
recognized in income	\$ 117.5	\$ (389.3)	\$ 506.8	

Net realized gains on investments increased in 2010 primarily due to increased gains from the sale of fixed maturity securities, partially offset by increased net realized losses from equity securities.

Other-than-temporary impairment losses recognized in income decreased in 2010. Other-than-temporary impairment losses recognized in income in 2009 were related to both impairment of fixed maturity securities, primarily from credit related events, and impairment of equity securities due to declines in stock prices. There was no individually significant other-than-temporary impairment of investments by issuer during the nine months ended September 30, 2010 or 2009.

Edgar Filing: WELLPOINT, INC - Form 10-Q

-52-

Benefit expense decreased \$1.6 billion, or 4%, to \$33.6 billion in 2010, primarily due to fully-insured membership declines in our Local Group and National Accounts businesses, the conversion of a large municipal account from fully-insured to self-funded status in April 2010, certain UniCare members transitioning to HCSC beginning January 1, 2010 and the loss of certain 2010 Part D LIS membership within our Senior business. These decreases were partially offset by increases in benefit costs in our Local Group BCBSA-branded, Senior Medicare Advantage and FEP businesses. We receive reimbursement for FEP costs plus a fee. The increase in Local Group BCBSA-branded benefit expense was driven by higher unit costs and the impact of the recession on business mix changes, including higher COBRA membership year over year. The Medicare Advantage related increases in benefit expense were primarily due to higher membership.

Our benefit expense ratio decreased 10 basis points to 82.8% in 2010, due to improvements in our Commercial segment, partially offset by increases in our Consumer segment. Improvements in the Commercial segment were primarily related to our Local Group BCBSA-branded business, which reflected disciplined pricing and lower flu-related costs. Our Consumer segment increases included increases in Medicare Advantage due to the reduction in federal reimbursement rates for 2010 and increases in the Individual business driven primarily by reduced and delayed premium increases in certain of our markets.

Selling, general and administrative expense decreased \$223.0 million, or 3%, to \$6.5 billion in 2010. Our selling, general and administrative expense decreased due to lower base compensation costs, selling expenses and other operating expenses, partially offset by increases in outside services costs. The selling expense decline included reduced amounts related to a portion of our UniCare business in Texas and Illinois that transitioned to HCSC during 2010. Our 2010 general and administrative expenses also no longer include the administrative expenses formerly incurred by our PBM business, as these operations were sold to Express Scripts in December 2009. The expenses associated with administering PBM products to our medical members are now reflected in the drug prices charged to us by Express Scripts as part of our ten year contract and are included in benefit expense described above. While overall selling, general and administrative expense decreased, our selling, general and administrative expense ratio increased 30 basis points to 14.9% in 2010, primarily due to a decline in operating revenue and increased outside services costs, partially offset by lower base compensation costs, selling expenses and other operating expenses.

Cost of drugs sold decreased \$346.4 million, or 100%, due to no PBM activity in 2010 as compared to 2009. These cost of drugs sold were associated with other revenue generated from mail order sales of drugs. Following the sale of our PBM business, we do not record any cost of drugs on our income statement as we no longer market and sell prescription drugs.

Interest expense decreased \$37.8 million, or 11%, to \$305.9 million in 2010, primarily due to lower average debt balances and lower short-term rates on floating rate debt.

Amortization of other intangible assets decreased \$18.5 million, or 9%, to \$182.0 million in 2010, primarily due to reduced balances of certain amortizable intangible assets acquired in prior years.

In the first quarter of 2010, we recognized an impairment charge of \$21.1 million for certain intangible assets associated with the UniCare provider networks, due to a decision we made to transfer certain membership to an alternative network. During the third quarter of 2009, we identified and recorded a pre-tax impairment charge relating to our UniCare tradenames of \$205.5 million, the majority of which was driven by the loss of certain 2010 Part D LIS membership.

Income tax expense increased \$204.2 million, or 19%, to \$1.3 billion in 2010. This increase was primarily due to higher income before taxes, and to a lesser extent, an increased effective tax rate. The effective tax rates in 2010 and 2009 were 35.1% and 34.6%, respectively. The increase in effective tax rates resulted primarily from the impact of compensation deduction limitations associated with health care reform in 2010.

The factors noted above led to net income as a percentage of total revenue increasing 90 basis points to 5.3% in 2010 as compared to 2009.

Reportable Segments

We use operating gain to evaluate the performance of our reportable segments, as described in FASB guidance, which are Commercial, Consumer and Other. Operating gain is calculated as total operating revenue less benefit expense, selling, general and administrative expense and cost of drugs. It does not include net investment income, net realized gains or losses on investments, interest expense, amortization or impairment of other intangible assets or income taxes, as these items are managed in a corporate shared service environment and are not the responsibility of operating segment management. For additional information, see Note 13 to our unaudited consolidated financial statements for the three and nine months ended September 30, 2010 included in this Form 10-Q. The discussions of segment results for the nine months ended September 30, 2010 and 2009 presented below are based on operating gain, as described above, and operating margin, which is calculated as operating gain divided by operating revenue. Our definitions of operating gain and operating margin may not be comparable to similarly titled measures reported by other companies.

Commercial

Our Commercial segment s summarized results of operations for the nine months ended September 30, 2010 and 2009 are as follows:

	Nine Mo	nths Ended		
	Septe			
(In millions)	2010	2009	\$ Change	% Change
Operating revenue	\$ 26,104.8	\$ 28,018.3	\$ (1,913.5)	(7)%
Operating gain	\$ 2,485.0	\$ 2,113.5	\$ 371.5	18%
Operating margin	9.5%	7.5%		200bp

Operating revenue decreased \$1.9 billion, or 7%, to \$26.1 billion in 2010, primarily due to fully-insured membership declines in our Local Group BCBSA-branded business and National Accounts business due to unfavorable economic conditions. In addition, operating revenue decreased due to certain UniCare members transitioning to HCSC beginning January 1, 2010, and the conversion of a large municipal account from fully-insured to self-funded status. These decreases were partially offset by higher premiums that were necessary to cover cost trend, increased revenue in our self-funded National Accounts business and managed dental administrative revenues.

Operating gain increased \$371.5 million, or 18%, to \$2.5 billion in 2010 primarily due to improvements in our Local Group BCBSA-branded business, partially off set by fully insured membership declines. The improvement in our Local Group BCBSA-branded business reflected higher premiums necessary to cover cost trend and lower flu-related costs. The operating gain also improved due to additional favorable reserve releases in 2010 as compared to 2009.

The factors above led to an operating margin in 2010 of 9.5%, a 200 basis point increase over 2009.

Consumer

Our Consumer segment summarized results of operations for the nine months ended September 30, 2010 and 2009 are as follows:

	Nine Month	is Ended		
	Septemb	oer 30		
(In millions)	2010	2009	\$ Change	% Change
Operating revenue	\$ 12,044.2	\$ 12,215.7	\$ (171.5)	(1)%
Operating gain	\$ 888.6	\$ 1,120.8	\$ (232.2)	(21)%
Operating margin	7.4%	9.2%		(180)bp

Operating revenue decreased \$171.5 million, or 1%, to \$12.0 billion in 2010, primarily due to our loss of certain 2010 Part D LIS membership and, to a lesser degree, lower membership in our Individual business and a change during 2010 in the provider of pharmacy benefits for the Indiana Medicaid program included in our State-Sponsored programs. These decreases were partially offset by increases in our Medicare Advantage business due to higher membership.

Operating gain decreased \$232.2 million, or 21%, to \$888.6 million in 2010, primarily due to lower operating gain in our Medicare Advantage business due to the reduction in federal reimbursement rates for 2010 and lower operating gain in our Individual business reflecting the impact of delayed and reduced premium rate increases necessary to cover cost trends in certain markets. In addition, the lower operating gain resulted from lower favorable reserve releases in 2010 compared to 2009. These operating gain declines were partially offset by improved results in our Medicare Part D business, reflecting the impact of the reduced Part D LIS membership.

The factors above led to an operating margin in 2010 of 7.4%, a 180 basis point decrease from 2009.

Other

Our Other segment s summarized results of operations for the nine months ended September 30, 2010 and 2009 are as follows:

	Nine Mon	ths Ended			
	September 30				
(In millions)	2010	2009	\$ Change	% Change	
Operating revenue	\$ 5,278.6	\$ 5,537.5	\$ (258.9)	(5)%	
Operating gain	\$ 10.8	\$ 368.6	\$ (357.8)	(97)%	

Operating revenue decreased \$258.9 million, or 5%, to \$5.3 billion in 2010, primarily due to the sale of the PBM business on December 1, 2009 and lower administrative fees in our NGS Medicare business, partially offset by growth in our FEP business.

Operating gain decreased \$357.8 million, or 97%, to \$10.8 million in 2010, primarily due to the sale of the PBM business on December 1, 2009.

VIII. Critical Accounting Policies and Estimates

We prepare our consolidated financial statements in conformity with U.S. generally accepted accounting principles, or GAAP. Application of GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes and within this MD&A. We consider some of our most important accounting policies that require estimates and management judgment to be those policies with respect to liabilities for medical claims payable, income taxes, goodwill and other intangible assets, investments and retirement benefits, which are discussed below. Our significant accounting policies are summarized in Note 2 to our audited consolidated financial statements as of and for the year ended December 31, 2009 included in our 2009 Annual Report on Form 10-K.

We continually evaluate the accounting policies and estimates used to prepare the consolidated financial statements. In general, our estimates are based on historical experience, evaluation of current trends, information from third party professionals and various other assumptions that we believe to be reasonable under the known facts and circumstances.

Medical Claims Payable

The most judgmental accounting estimate in our consolidated financial statements is our liability for medical claims payable. At September 30, 2010, this liability was \$5.0 billion and represented 19% of our total

consolidated liabilities. We record this liability and the corresponding benefit expense for incurred but not paid claims, including the estimated costs of processing such claims. Incurred but not paid claims include (1) an estimate for claims that are incurred but not reported, as well as claims reported to us but not yet processed through our systems, which approximated 97%, or \$4.8 billion, of our total medical claims liability as of September 30, 2010; and (2) claims reported to us and processed through our systems but not yet paid, which approximated 3%, or \$145.3 million, of the total medical claims liability as of September 30, 2010. The level of claims payable processed through our systems but not yet paid may fluctuate from one period end to the next, from 1% to 5% of our total medical claims liability, due to timing of when claim payments are made.

Liabilities for both claims incurred but not reported and reported but not yet processed through our systems are determined in aggregate, employing actuarial methods that are commonly used by health insurance actuaries and meet Actuarial Standards of Practice. Actuarial Standards of Practice require that the claim liabilities be adequate under moderately adverse circumstances. We determine the amount of the liability for incurred but not paid claims by following a detailed actuarial process that entails using both historical claim payment patterns as well as emerging medical cost trends to project our best estimate of claim liabilities. Under this process, historical paid claims data is formatted into claim triangles, which compare claim incurred dates to the dates of claim payments. This information is analyzed to create completion factors that represent the average percentage of total incurred claims that have been paid through a given date after being incurred. Completion factors are applied to claims paid through the period end date to estimate the ultimate claim expense incurred for the period. Actuarial estimates of incurred but not paid claim liabilities are then determined by subtracting the actual paid claims from the estimate of the ultimate incurred claims.

For the most recent incurred months (typically the most recent two months), the percentage of claims paid for claims incurred in those months is generally low. This makes the completion factor methodology less reliable for such months. Therefore, incurred claims for recent months are not projected from historical completion and payment patterns; rather they are projected by estimating the claims expense for those months based on recent claims expense levels and health care trend levels, or trend factors.

Because the reserve methodology is based upon historical information, it must be adjusted for known or suspected operational and environmental changes. These adjustments are made by our actuaries based on their knowledge and their estimate of emerging impacts to benefit costs and payment speed. Circumstances to be considered in developing our best estimate of reserves include changes in utilization levels, unit costs, mix of business, benefit plan designs, provider reimbursement levels, processing system conversions and changes, claim inventory levels, claim processing patterns, claim submission patterns and operational changes resulting from business combinations. A comparison of prior period liabilities to re-estimated claim liabilities based on subsequent claims development is also considered in making the liability determination. In our comparison of prior year, the methods and assumptions are not changed as reserves are recalculated; rather the availability of additional paid claims information drives our changes in the re-estimate of the unpaid claim liability. To the extent appropriate, changes in such development are recorded as a change to current period benefit expense.

In addition to incurred but not paid claims, the liability for medical claims payable includes reserves for premium deficiencies, if appropriate. Premium deficiencies are recognized when it is probable that expected claims and administrative expenses will exceed future premiums on existing medical insurance contracts without consideration of investment income. Determination of premium deficiencies for longer duration life and disability contracts includes consideration of investment income. For purposes of premium deficiencies, contracts are grouped in a manner consistent with our method of acquiring, servicing and measuring the profitability of such contracts. No premium deficiencies were established at September 30, 2010.

We regularly review and set assumptions regarding cost trends and utilization when initially establishing claim liabilities. We continually monitor and adjust the claims liability and benefit expense based on subsequent paid claims activity. If it is determined that our assumptions regarding cost trends and utilization are significantly different than actual results, our income statement and financial position could be impacted in future periods.

Adjustments of prior year estimates may result in additional benefit expense or a reduction of benefit expense in the period an adjustment is made. Further, due to the considerable variability of health care costs, adjustments to claim liabilities occur each quarter and are sometimes significant as compared to the net income recorded in that quarter. Prior period development is recognized immediately upon the actuary s judgment that a portion of the prior period liability is no longer needed or that an additional liability should have been accrued. That determination is made when sufficient information is available to ascertain that the re-estimate of the liability is reasonable. During the nine months ended September 30, 2010, higher than anticipated favorable reserve releases of approximately \$210.0 million were recognized and not reestablished at September 30, 2010. The majority of these releases resulted from year end claim seasonality developing to be less severe than originally anticipated, as well as continued recognition of improvements in our processing environment.

While there are many factors that are used as a part of the estimation of our medical claims payable liability, the two key assumptions having the most significant impact on our incurred but not paid liability as of September 30, 2010 were the completion and trend factors. As discussed above, these two key assumptions can be influenced by other operational variables including system changes, provider submission patterns and business combinations.

There is variation in the reasonable choice of completion factors by duration for durations of three months through 12 months where the completion factors have the most significant impact. As previously discussed, completion factors tend to be less reliable for the most recent months and therefore are not specifically utilized for months one and two. In our analysis for the claim liabilities at September 30, 2010, the variability in months three to five was estimated to be between 30 and 90 basis points, while months six through twelve have much lower variability ranging from 10 to 20 basis points.

The difference in completion factor assumptions, assuming moderately adverse experience, results in variability of 4%, or approximately \$181.0 million, in the September 30, 2010 incurred but not paid claim liability, depending on the completion factors chosen. It is important to note that the completion factor methodology inherently assumes that historical completion rates will be reflective of the current period. However, it is possible that the actual completion rates for the current period will develop differently from historical patterns and therefore could fall outside the possible variations described herein.

The other major assumption used in the establishment of the September 30, 2010 incurred but not paid claim liability was the trend factors. In our analysis for the period ended September 30, 2010, there was a 440 basis point differential in the high and low trend factors assuming moderately adverse experience. This range of trend factors would imply variability of 7%, or approximately \$328.0 million, in the incurred but not paid claims liability, depending upon the trend factors used. Because historical trend factors are often not representative of current claim trends, the trend experience for the most recent six to nine months, plus knowledge of recent events likely affecting current trends, have been taken into consideration in establishing the incurred but not paid claim liability at September 30, 2010.

Note 11 to our audited consolidated financial statements as of and for the year ended December 31, 2009 included in our 2009 Annual Report on Form 10-K provides historical information regarding the accrual and payment of our medical claims liability. Components of the total incurred claims for each year include amounts accrued for current year estimated claims expense as well as adjustments to prior year estimated accruals. In Note 11 to our audited consolidated financial statements, the line labeled Net incurred medical claims: Prior years redundancies accounts for those adjustments made to prior year estimates. The impact of any reduction of Net incurred medical claims: Prior years redundancies claims may be offset as we establish the estimate of Net incurred medical claims: Current year . Our reserving practice is to consistently recognize the actuarial best estimate of our ultimate liability for our claims. When we recognize a release of the redundancy, we disclose the amount that is not in the ordinary course of business, if material. We believe we have consistently applied our methodology in determining our best estimate for unpaid claims liability at each reporting date.

-57-

A reconciliation of the beginning and ending balance for medical claims payable for the nine months ended September 30, 2010 and 2009 and the years ended December 31, 2009, 2008 and 2007 is as follows:

	Nine Months Ended September 30		Years Ended December 31		r 31
(In millions)	2010	2009	2009	2008	2007
Gross medical claims payable, beginning of period	\$ 5,450.5	\$ 6,184.7	\$ 6,184.7	\$ 5,788.0	\$ 5,290.3
Ceded medical claims payable, beginning of period	(29.9)	(60.3)	(60.3)	(60.7)	(51.0)
Net medical claims payable, beginning of period	5,420.6	6,124.4	6,124.4	5,727.3	5,239.3
Business combinations and purchase adjustments Net incurred medical claims:		2.8	2.8		15.2
Current year	33,834.5	35,422.9	47,315.1	47,940.9	43,366.2
Prior years redundancies	(704.8)	(751.9)	(807.2)	(263.2)	(332.7)
Filor years redundancies	(704.6)	(731.9)	(007.2)	(203.2)	(332.1)
Total net incurred medical claims	33,129.7	34,671.0	46,507.9	47,677.7	46,033.5
Net payments attributable to:					
Current year medical claims	29,137.6	30,093.0	42,056.9	42,020.7	40,765.7
Prior years medical claims	4,486.9	5,007.3	5,157.6	5,259.9	4,795.0
Total net payments	33,624.5	35,100.3	47,214.5	47,280.6	45,560.7
Net medical claims payable, end of period	4,925.8	5,697.9	5,420.6	6,124.4	5,727.3
Ceded medical claims payable, end of period	30.5	65.3	29.9	60.3	60.7
Gross medical claims payable, end of period	\$ 4,956.3	\$ 5,763.2	\$ 5,450.5	\$ 6,184.7	\$ 5,788.0
Current year medical claims paid as a percentage of current year net incurred medical claims	86.1%	85.0%	88.9%	87.7%	87.9%
Prior year redundancies in the current period as a percentage of prior year net medical claims payable less prior year redundancies in the current period	14.9%	14.0%	15.2%	4.8%	6.8%
Prior year redundancies in the current period as a percentage of prior year net incurred medical claims	1.5%	1.6%	1.7%	0.6%	0.8%

Amounts incurred related to prior years vary from previously estimated liabilities as the claims are ultimately settled. Liabilities at any period end are continually reviewed and re-estimated as information regarding actual claims payments, or runout, becomes known. This information is compared to the originally established year end liability. Negative amounts reported for incurred related to prior years result from claims being settled for amounts less than originally estimated. The prior year redundancy of \$704.8 million shown above for the nine months ended September 30, 2010 represents an estimate based on paid claim activity from January 1, 2010 to September 30, 2010. Medical claim liabilities

Edgar Filing: WELLPOINT, INC - Form 10-Q

are usually described as having a short tail , which means that they are generally paid within several months of the member receiving service from the provider. Accordingly, the majority of the \$704.8 million redundancy relates to claims incurred in calendar year 2009.

-58-

The following table provides a summary of the completion and trend factor assumptions, which had the most significant impact on the actual development of our incurred but not paid claims liability estimates for the nine months ended September 30, 2010 and 2009. As discussed above, these two key assumptions can be influenced by other operational variables, including system changes, provider submission patterns and business combinations.

	•	Favorable Developments by Changes in Key Assumptions		
	2010		2009	
Assumed trend factors	\$ 523.6	\$	439.7	
Assumed completion factors	181.2		312.2	
Total	\$ 704.8	\$	751.9	

The favorable development in 2010 resulted primarily from claims trends restating to a more favorable level than originally estimated.

The favorable development in 2009 resulted from incurred-to-paid cycle times shortening significantly in 2008 causing claims to be more complete than estimated at December 31, 2008 and claims trends restating to a more favorable level than originally estimated.

The ratio of current year medical claims paid as a percent of current year net medical claims incurred was 88.9% for 2009, 87.7% for 2008, and 87.9% for 2007. Comparison of these ratios reflects acceleration in processing that has occurred. Review of the nine month periods presented above shows that as of September 30, 2010, 86.1% of current year net incurred medical claims had been paid in the period incurred, as compared to 85.0% for the same period in 2009. These ratios reflect incurred and paid claim amounts for the first nine months of 2010 and 2009 only and, therefore, are not indicative of the ratios that can be expected for the full year.

We calculate the percentage of prior year redundancies in the current period as a percent of prior year net incurred claims payable less prior year redundancies in the current period in order to demonstrate the development of the prior year reserves. This metric was 14.9% for the nine months ended September 30, 2010 and 14.0% for the nine months ended September 30, 2009. The 90 basis point increase over the two periods resulted primarily from restated claims trends differing more significantly from the original assumptions used in the most recent year compared to the prior year. The percentage of prior year redundancies in the current period as a percent of prior year net incurred claims payable less prior year redundancies in the current period was 15.2% for 2009, 4.8% for 2008, and 6.8% for 2007.

We calculate the percentage of prior year redundancies in the current period as a percent of prior year net incurred medical claims to indicate the percentage of redundancy included in the preceding year calculation of current year net incurred medical claims. We believe this calculation indicates the reasonableness of our prior year estimate of incurred medical claims and the consistency of our methodology. For the nine months ended September 30, 2010, this metric was 1.5%, which was calculated using the redundancy of \$704.8 million shown above. For the nine months ended September 30, 2009, the comparable metric was 1.6%, which was calculated using the redundancy of \$751.9 shown above and represents an estimate based on paid medical claims activity from January 1, 2009 to September 30, 2009. This metric was 1.7% for full year 2009, 0.6% for 2008, and 0.8% for 2007.

Income Taxes

We account for income taxes in accordance with FASB guidance, which requires, among other things, the separate recognition of deferred tax assets and deferred tax liabilities. Such deferred tax assets and deferred tax liabilities represent the tax effect of temporary differences between financial reporting and tax reporting

measured at tax rates enacted at the time the deferred tax asset or liability is recorded. A valuation allowance must be established for deferred tax assets if it is more likely than not that all or a portion may be unrealized. Our judgment is required in determining an appropriate valuation allowance.

At each financial reporting date, we assess the adequacy of the valuation allowance by evaluating each of our deferred tax assets based on the following:

the types of temporary differences that created the deferred tax asset;

the amount of taxes paid in prior periods and available for a carry-back claim;

the forecasted future taxable income, and therefore, likely future deduction of the deferred tax item; and

any significant other issues impacting the likely realization of the benefit of the temporary differences.

We, like other companies, frequently face challenges from tax authorities regarding the amount of taxes due. These challenges include questions regarding the timing and amount of deductions that we have taken on our tax returns. In evaluating any additional tax liability associated with various positions taken in our tax return filings, we record additional liabilities for potential adverse tax outcomes. Based on our evaluation of our tax positions, we believe we have appropriately accrued for uncertain tax benefits, as required by the guidance. To the extent we prevail in matters we have accrued for, our future effective tax rate would be reduced and net income would increase. If we are required to pay more than accrued, our future effective tax rate would increase and net income would decrease. Our effective tax rate and net income in any given future period could be materially impacted.

In the ordinary course of business, we are regularly audited by federal and other tax authorities, and from time to time, these audits result in proposed assessments. We believe our tax positions comply with applicable tax law and intend to defend our positions vigorously through the federal, state and local appeals processes. We believe we have adequately provided for any reasonable foreseeable outcome related to these matters. Accordingly, although their ultimate resolution may require additional tax payments, we do not anticipate any material impact on our results of operations from these matters. As of September 30, 2010, the examinations of our 2008, 2007, 2006, 2005 and 2004 tax years are being concluded by the IRS. In addition, we have several tax years for which there are ongoing disputes related to companies pre-acquisition years that are being concluded by the IRS. We joined the IRS Compliance Assurance Process, or CAP, in 2007 and continue to remain a participant. The objective of CAP is to reduce taxpayer burden and uncertainty while assuring the IRS of the accuracy of tax returns prior to filing, thereby reducing or eliminating the need for post-filing examinations. Administrative tax appeals and proceedings also continue for certain subsidiaries for tax years prior to being included in our consolidated tax return.

In March 2010, the Court of Appeals in the Seventh Circuit issued a decision ruling that various payments made to several states in prior years should be a deferred tax asset and not a current tax deduction for the year being litigated. The ruling did not have a material impact on our results of operations, financial position or cash flow.

For additional information, see Note 7 to our audited consolidated financial statements as of and for the year ended December 31, 2009 included in our Annual Report on Form 10-K.

Goodwill and Other Intangible Assets

Our consolidated goodwill at September 30, 2010 was \$13.3 billion and other intangible assets were \$8.1 billion. The sum of goodwill and intangible assets represented 42% of our total consolidated assets and 88% of our consolidated shareholders equity at September 30, 2010.

We follow FASB guidance for business combinations and goodwill and other intangible assets, which specifies the types of acquired intangible assets that are required to be recognized and reported separately from

Edgar Filing: WELLPOINT, INC - Form 10-Q

-60-

Edgar Filing: WELLPOINT, INC - Form 10-Q

Table of Contents

goodwill. Under the guidance, goodwill and other intangible assets (with indefinite lives) are not amortized but are tested for impairment at least annually. Furthermore, goodwill and other intangible assets are allocated to reporting units for purposes of the annual impairment test. Our impairment tests require us to make assumptions and judgments regarding the estimated fair value of our reporting units, which include goodwill and other intangible assets. In addition, certain other intangible assets with indefinite lives, such as trademarks, are also tested separately.

In the first quarter of 2010, we recognized an impairment charge of \$21.1 million for certain intangible assets associated with the UniCare provider networks, due to a decision we made to transfer certain membership to an alternative network.

Fair value is estimated using the income and market approaches for our goodwill reporting units and the income approach for our indefinite lived intangible assets. The income and market approaches for our goodwill impairment test reflects our view that both valuation methodologies provide a reasonable estimate of fair value.

The income approach is developed using assumptions about future revenue, expenses and net income derived from our internal planning process. These estimated future cash flows are then discounted. Our assumed discount rate is based on our industry s weighted average cost of capital. The discount rate used in the 2009 valuation had increased from the discount rate used in 2008, which reflects an increase in stock volatility and higher risk and uncertainty related to health care reform.

Market valuations are based on observed multiples of certain measures including membership, revenue, EBITDA (earnings before interest, taxes, depreciation and amortization) and book value as well as market capitalization analysis of WellPoint and other comparable companies.

As a result of our annual and interim impairment tests during 2009, 2008 and 2007, we recorded impairment of goodwill and other intangible assets of \$262.5 million, \$141.4 million and \$0.0 million, respectively.

While we believe we have appropriately allocated the purchase price of our acquisitions, this allocation requires many assumptions to be made regarding the fair value of assets and liabilities acquired. In addition, estimated fair values developed based on our assumptions and judgments might be significantly different if other reasonable assumptions and estimates were to be used. If estimated fair values are less than the carrying values of goodwill and other intangible assets with indefinite lives in future annual impairment tests, or if significant impairment indicators are noted relative to other intangible assets subject to amortization, we may be required to record impairment losses against future income.

For additional information, see Note 9 to our audited consolidated financial statements as of and for the year ended December 31, 2009 included in our 2009 Annual Report on Form 10-K.

Investments

Current and long-term available-for-sale investment securities were \$18.1 billion at September 30, 2010 and represented 35% of our total consolidated assets at September 30, 2010. We classify the fixed maturity and equity securities in our investment portfolio as available-for-sale or trading and report those securities at fair value. Certain fixed maturity securities are available to support current operations and, accordingly, we classify such investments as current assets without regard to their contractual maturity. Investments used to satisfy contractual, regulatory or other requirements are classified as long-term, without regard to contractual maturity.

Investment income is recorded when earned, and realized gains or losses, determined by specific identification of investments sold, are included in income when securities are sold.

We review investment securities to determine if declines in fair value below cost are other-than-temporary. This review is subjective and requires a high degree of judgment. We conduct this review on a quarterly basis,

using both qualitative and quantitative factors, to determine whether a decline in value is other-than-temporary. Such factors considered include the length of time and the extent to which a security s market value has been less than its cost, the reasons for the decline in value (i.e., credit event compared to liquidity, general credit spread widening, currency exchange rate or interest rate factors), financial condition and near term prospects of the issuer, including the credit ratings and changes in the credit ratings of the issuer, recommendations of investment advisors, and forecasts of economic, market or industry trends. In addition, for equity securities, we determine whether we have the intent and ability to hold the security for a period of time to allow for a recovery of its fair value above its carrying amount. If any declines of equity securities are determined to be other-than-temporary, we charge the losses to income when that determination is made.

Certain FASB other-than-temporary impairment, or FASB OTTI, guidance applies to fixed maturity securities and provides guidance on the recognition and presentation of other-than-temporary impairments. In addition, this FASB OTTI guidance requires additional disclosures related to other-than-temporary impairments. If a fixed maturity security is in an unrealized loss position and we have the intent to sell the fixed maturity security, or it is more likely than not that we will have to sell the fixed maturity security before recovery of its amortized cost basis, the decline in value is deemed to be other-than-temporary and is recorded to other-than-temporary impairment losses recognized in income in our consolidated income statements. For impaired fixed maturity securities that we do not intend to sell or it is more likely than not that we will not have to sell such securities, but we expect that we will not fully recover the amortized cost basis, the credit component of the other-than-temporary impairment losses recognized in income in our consolidated income statements and the non-credit component of the other-than-temporary impairment is recognized in other comprehensive income. Furthermore, unrealized losses entirely caused by non-credit related factors related to fixed maturity securities for which we expect to fully recover the amortized cost basis continue to be recognized in accumulated other comprehensive income.

The credit component of an other-than temporary impairment is determined by comparing the net present value of projected future cash flows with the amortized cost basis of the fixed maturity security. The net present value is calculated by discounting our best estimate of projected future cash flows at the effective interest rate implicit in the fixed maturity security at the date of acquisition. For mortgage-backed and asset-backed securities, cash flow estimates are based on assumptions regarding the underlying collateral including prepayment speeds, vintage, type of underlying asset, geographic concentrations, default rates, recoveries and changes in value. For all other debt securities, cash flow estimates are driven by assumptions regarding probability of default, including changes in credit ratings, and estimates regarding timing and amount of recoveries associated with a default. We have a committee of certain accounting and investment associates and management that is responsible for managing the impairment review process. The current economic environment and volatility of securities markets increase the difficulty of assessing investment impairment and the same influences tend to increase the risk of potential impairment of these assets. Other-than-temporary impairment losses recognized in income totaled \$29.0 million and \$409.7 million, for the nine months ended September 30, 2010 and 2009, respectively. There were no individually significant other-than-temporary impairment losses on investments by issuer during the nine months ended September 30, 2010 or 2009. As of September 30, 2010, we had approximately \$82.1 million of gross unrealized losses on investments recognized in accumulated other comprehensive income, \$67.9 million of which related to fixed maturity securities and \$14.2 million of which related to equity securities.

We believe we have adequately reviewed our investment securities for impairment and that our investment securities are carried at fair value. However, over time, the economic and market environment may provide additional insight regarding the fair value of certain securities, which could change our judgment regarding impairment. This could result in other-than-temporary impairment losses on investments being charged against future income. Given the current market conditions and the significant judgments involved, there is continuing risk that further declines in fair value may occur and additional, material other-than-temporary impairment losses on investments may be recorded in future periods.

-62-

A primary objective in the management of fixed maturity and equity portfolios is to maximize total return relative to underlying liabilities and respective liquidity needs. In achieving this goal, assets may be sold to take advantage of market conditions or other investment opportunities as well as tax considerations. Sales will generally produce realized gains and losses. In the ordinary course of business, we may sell securities at a loss for a number of reasons, including, but not limited to: (i) changes in the investment environment; (ii) expectations that the fair value could deteriorate further; (iii) desire to reduce exposure to an issuer or an industry; (iv) changes in credit quality; or (v) changes in expected cash flow.

We maintain various rabbi trusts to account for the assets and liabilities under certain deferred compensation plans. Under these deferred compensation plans, the participants can defer certain types of compensation and elect to receive a return on the deferred amounts based on the changes in fair value of various investment options, primarily a variety of mutual funds. We also generally purchase corporate-owned life insurance policies on participants in the deferred compensation plans. The cash surrender value of the corporate-owned life insurance policies is reported in Other invested assets, long-term in the consolidated balance sheets. The change in cash surrender value is reported as an offset to the premium expense of the policies, classified as general and administrative expenses.

In addition to available-for-sale investment securities, we held additional long-term investments of \$845.1 million, or 2% of total consolidated assets, at September 30, 2010. These long-term investments consist primarily of real estate, cash surrender value of corporate-owned life insurance policies and certain other investments. Due to their less liquid nature, these investments are classified as long-term.

We participate in securities lending programs whereby marketable securities in our investment portfolio are transferred to independent brokers or dealers based on, among other things, their creditworthiness in exchange for cash collateral initially equal to at least 102% of the value of the securities on loan and is thereafter maintained at a minimum of 100% of the market value of the securities loaned (calculated as the ratio of initial cash collateral to current market value of the securities on loan). Accordingly, the market value of the securities on loan to each borrower is monitored daily and the borrower is required to deliver additional cash collateral if the market value of the securities on loan exceeds the initial cash collateral delivered. We recognize the collateral as an asset, which is reported as securities lending collateral on our consolidated balance sheets and we record a corresponding liability for the obligation to return the collateral to the borrower, which is reported as securities lending payable. The securities on loan are reported in the applicable investment category on the consolidated balance sheets.

Through our investing activities, we are exposed to financial market risks, including those resulting from changes in interest rates and changes in equity market valuations. We manage the market risks through our investment policy, which establishes credit quality limits and limits of investments in individual issuers. Ineffective management of these risks could have an impact on our future earnings and financial position. Our investment portfolio includes fixed maturity securities with a fair value of \$17.0 billion at September 30, 2010. The weighted-average credit rating of these securities was A as of September 30, 2010. Included in this balance are investments in fixed maturity securities of states, municipalities and political subdivisions, mortgage-backed securities and corporate securities of \$2.5 billion, \$27.1 million and \$56.7 million, respectively, that are guaranteed by third parties. With the exception of eleven securities with a fair value of \$21.1 million, these securities are all investment-grade and carry a weighted-average credit rating of AA as of September 30, 2010 with the guarantee by the third party. The securities are guaranteed by a number of different guarantors and we do not have any significant exposure to any single guarantor (neither indirect through the guarantees, nor direct through investment in the guarantor). Further, due to the high underlying credit rating of the issuers, the weighted-average credit rating of these securities without the guarantee was AA as of September 30, 2010 for the securities for which such information is available.

At September 30, 2010, we owned \$3.2 billion of mortgage-backed securities and \$278.2 million of asset-backed securities out of a total available-for-sale investment portfolio of \$18.1 billion. These securities included

-63-

sub-prime and Alt-A securities with fair values of \$82.0 million and \$257.9 million, respectively. These sub-prime and Alt-A securities had accumulated net unrealized losses of \$7.0 million and \$7.3 million, respectively. The average credit rating of the sub-prime and Alt-A securities was BBB and BB, respectively.

Fair values of available-for-sale fixed maturity and equity securities are based on quoted market prices, where available. These fair values are obtained primarily from third party pricing services, which generally use Level I or Level II inputs for the determination of fair value in accordance with FASB guidance for fair value measurements and disclosures. We obtain only one quoted price for each security from third party pricing services, which are derived through recently reported trades for identical or similar securities making adjustments through the reporting date based upon available market observable information. For securities not actively traded, the third party pricing services may use quoted market prices of comparable instruments or discounted cash flow analyses, incorporating inputs that are currently observable in the markets for similar securities. Inputs that are often used in the valuation methodologies include, but are not limited to, broker quotes, benchmark yields, credit spreads, default rates and prepayment speeds. As we are responsible for the determination of fair value, we perform monthly analysis on the prices received from third parties to determine whether the prices are reasonable estimates of fair value. Our analysis includes a review of month-to-month price fluctuations. If unusual fluctuations are noted in this review, we may obtain additional information from other pricing services to validate the quoted price. There were no adjustments to quoted market prices obtained from third party pricing services during the three and nine months ended September 30, 2010 and 2009 that were material to the consolidated financial statements.

In certain circumstances, it may not be possible to derive pricing model inputs from observable market activity, and therefore, such inputs are estimated internally. Such securities are designated Level III in accordance with FASB guidance. Securities designated Level III at September 30, 2010 totaled \$317.5 million and represented 2% of our total consolidated assets measured at fair value on a recurring basis. Our Level III securities primarily consist of certain mortgage-backed, asset-backed and inverse floating rate securities that were thinly traded or not traded at all due to concerns in the securities markets and the resulting lack of liquidity. Consequently, observable inputs were not always available and the fair values of these securities were estimated using internal estimates for inputs including, but not limited to, prepayment speeds, credit spreads, default rates and benchmark yields.

For additional information, see Part II, Item 7A, Quantitative and Qualitative Disclosures about Market Risk and Notes 4 and 5 to our audited consolidated financial statements for the year ended December 31, 2009 included in our 2009 Annual Report on Form 10-K.

Retirement Benefits

Pension Benefits

We sponsor defined benefit pension plans for some of our employees. These plans are accounted for in accordance with FASB guidance for retirement benefits, which requires that amounts recognized in financial statements be determined on an actuarial basis. As permitted by the guidance, we calculate the value of plan assets as described below. Further, the difference between our expected rate of return and the actual performance of plan assets, as well as certain changes in pension liabilities, are amortized over future periods.

An important factor in determining our pension expense is the assumption for expected long-term return on plan assets. As of our December 31, 2009 measurement date, we selected a long-term rate of return on plan assets of 8.00% for all plans, which is consistent with our prior year assumption of 8.00%. We use a total portfolio return analysis in the development of our assumption. Factors such as past market performance, the long-term relationship between fixed maturity and equity securities, interest rates, inflation and asset allocations are considered in the assumption. The assumption includes an estimate of the additional return expected from active management of the investment portfolio. Peer data and an average of historical returns are also reviewed for

-64-

appropriateness of the selected assumption. We believe our assumption of future returns is reasonable. However, if we lower our expected long-term return on plan assets, future contributions to the pension plan and pension expense would likely increase.

This assumed long-term rate of return on assets is applied to a calculated value of plan assets, which recognizes changes in the fair value of plan assets in a systematic manner over three years, producing the expected return on plan assets that is included in the determination of pension expense. The difference between this expected return and the actual return on plan assets is deferred and amortized over the average remaining service of the workforce as a component of pension expense. The net deferral of past asset gains or losses affects the calculated value of plan assets and, ultimately, future pension expense.

The discount rate reflects the current rate at which the pension liabilities could be effectively settled at the end of the year based on our most recent measurement date (December 31, 2009). The selected discount rate for all plans is 5.36%, which was developed using a yield curve approach. Using yields available on high-quality fixed maturity securities with various maturity dates, the yield curve approach provides a customized rate, which is meant to match the expected cash flows of our specific benefit plans. The net effect of changes in the discount rate, as well as the net effect of other changes in actuarial assumptions and experience, have been deferred and amortized as a component of pension expense in accordance with the guidance.

In managing the plan assets, our objective is to be a responsible fiduciary while minimizing financial risk. Plan assets include a diversified mix of investment grade fixed maturity securities, equity securities and alternative investments across a range of sectors and levels of capitalization to maximize the long-term return for a prudent level of risk. In addition to producing a reasonable return, the investment strategy seeks to minimize the volatility in our expense and cash flow. The target allocation for pension benefit plan assets is 44% equity securities, 45% fixed maturity securities, and 11% to all other types of investments. No plan assets were invested in WellPoint common stock as of the measurement date.

For the year ending December 31, 2010, no material contributions are expected to be necessary to meet the Employee Retirement Income Security Act, or ERISA, required minimum funding levels; however, we may elect to make discretionary contributions up to the maximum amount deductible for income tax purposes. No contributions were made to our pension benefit plans during the nine months ended September 30, 2010.

At September 30, 2010 our consolidated net pension liabilities were \$20.2 million, including liabilities of \$65.1 million for certain supplemental plans. We recognized a consolidated pre-tax pension credit of \$2.2 million and \$6.7 million for the three months ended September 30, 2010 and 2009, respectively. We recognized a consolidated pre-tax pension credit of \$6.7 million and \$20.3 million for the nine months ended September 30, 2010 and 2009, respectively.

Other Postretirement Benefits

We provide most associates with certain life, medical, vision and dental benefits upon retirement. We use various actuarial assumptions including a discount rate and the expected trend in health care costs to estimate the costs and benefit obligations for our retiree benefits. We recognized a postretirement benefit liability of \$473.2 million at September 30, 2010.

We recognized consolidated pre-tax other postretirement expense of \$7.6 million and \$8.5 million for the three months ended September 30, 2010 and 2009, respectively. We recognized consolidated pre-tax other postretirement expense of \$22.6 million and \$25.3 million for the nine months ended September 30, 2010 and 2009, respectively.

At our December 31, 2009 measurement date, the selected discount rate for all plans was 5.79% (compared to a discount rate of 5.73% for 2009 expense recognition). We developed this rate using a yield curve approach as described above.

-65-

The assumed health care cost trend rates used to measure the expected cost of other benefits at our December 31, 2009 measurement date was 8.50% for 2010 with a gradual decline to 5.00% by the year 2017. These estimated trend rates are subject to change in the future. The health care cost trend rate assumption has a significant effect on the amounts reported.

We made tax deductible discretionary contributions totaling \$15.0 million to the other postretirement benefit plans during the nine months ended September 30, 2010.

For additional information regarding retirement benefits, see Note 10 to our audited consolidated financial statements as of and for the year ended December 31, 2009 included in our 2009 Annual Report on Form 10-K.

New Accounting Pronouncements

In January 2010, the FASB issued Accounting Standards Update, or ASU, No. 2010-06, *Improving Disclosures about Fair Value Measurements*, or ASU 2010-06. ASU 2010-06 amends ASC Topic 820, *Fair Value Measurements and Disclosures*, to require a number of additional disclosures regarding fair value measurements. Effective January 1, 2010, ASU 2010-06 requires disclosure of the amounts of significant transfers between Level I and Level II and the reasons for such transfers, the reasons for any transfers in or out of Level III, and disclosure of the policy for determining when transfers between levels are recognized. ASU 2010-06 also clarified that disclosures should be provided for each class of assets and liabilities and clarified the requirement to disclose information about the valuation techniques and inputs used in estimating Level II and Level III measurements. Beginning January 1, 2011, ASU 2010-06 also requires that information in the reconciliation of recurring Level III measurements about purchases, sales, issuances and settlements be provided on a gross basis. The adoption of ASU 2010-06 only required additional disclosures and did not have an impact on our consolidated financial position or results of operations.

There were no other new accounting pronouncements issued during the first nine months of 2010 that had a material impact on our financial position, operating results or disclosures.

-66-

IX. Liquidity and Capital Resources

Introduction

Our cash receipts result primarily from premiums, administrative fees, investment income, other revenue, proceeds from the sale or maturity of our investment securities, proceeds from borrowings, and proceeds from exercise of stock options and our employee stock purchase plan. Cash disbursements result mainly from claims payments, administrative expenses, taxes, purchases of investment securities, interest expense, payments on long-term borrowings, capital expenditures and repurchases of our common stock. Cash outflows fluctuate with the amount and timing of settlement of these transactions. Any future decline in our profitability would likely have an unfavorable impact on our liquidity.

We manage our cash, investments and capital structure so we are able to meet the short and long-term obligations of our business while maintaining financial flexibility and liquidity. We forecast, analyze and monitor our cash flows to enable investment and financing within the overall constraints of our financial strategy.

A substantial portion of the assets held by our regulated subsidiaries are in the form of cash and cash equivalents and investments. After considering expected cash flows from operating activities, we generally invest cash that exceeds our near term obligations in longer term marketable fixed maturity securities, to improve our overall investment income returns. Our investment strategy is to make investments consistent with insurance statutes and other regulatory requirements, while preserving our asset base. Our investments are generally available-for-sale to meet liquidity and other needs. Our subsidiaries pay out excess capital annually in the form of dividends to their respective parent companies for general corporate use, as permitted by applicable regulations.

The availability of financing in the form of debt or equity is influenced by many factors including our profitability, operating cash flows, debt levels, debt ratings, contractual restrictions, regulatory requirements and market conditions. Since 2008, credit markets have experienced a tightening of available liquidity, primarily as a result of uncertainty surrounding the economic crisis and the resulting volatility experienced in the debt and equity markets. Beginning in October 2008, the Federal government and various governmental agencies have taken a number of steps to restore liquidity in the financial markets and to help relieve the credit crisis and strengthen the regulation of the financial services market. In addition, governments around the world have developed their own plans to provide liquidity and security in the credit markets and to ensure adequate capital in certain financial institutions.

We have a \$2.5 billion commercial paper program. The commercial paper markets continue to experience increased volatility and disruption, resulting in higher costs to issue commercial paper. We continue to monitor the commercial paper markets and will act in a prudent manner. Should commercial paper issuance be unavailable, we intend to use a combination of cash on hand and/or our \$2.0 billion senior credit facility to redeem our commercial paper when it matures. While there is no assurance in the current economic environment, we believe the lenders participating in our credit facility will be willing and able to provide financing in accordance with their legal obligations. In addition to the \$2.0 billion senior credit facility, we expect to receive approximately \$2.3 billion of ordinary dividends from our subsidiaries during 2010, which also provides further operating and financial flexibility.

-67-

The table below outlines the decrease in cash and cash equivalents for the nine months ended September 30, 2010 and 2009:

	Nine Months Ende			ıded
		Septem	iber 3	0
(In millions)	2	010		2009
Cash flows provided by (used in):				
Operating activities	\$	829.7	\$	3,009.2
Investing activities	(1	1,168.9)		(1,160.5)
Financing activities	(2	2,229.5)		(2,192.6)
Effect of foreign exchange rates on cash and cash equivalents		(1.2)		2.2
Decrease in cash and cash equivalents	\$ (2	2,569.9)	\$	(341.7)

Liquidity Nine Months Ended September 30, 2010 Compared to Nine Months Ended September 30, 2009

During the nine months ended September 30, 2010, net cash flows provided by operating activities was \$829.7 million, compared to cash flow provided by operating activities of \$3.0 billion for the nine months ended September 30, 2009, a decrease of \$2.2 billion. This decrease resulted primarily from tax payments of \$1.2 billion to the IRS, related to the gain we realized on the 2009 sale of our PBM business, increased incentive compensation payments in 2010, claims run out from the membership transfers in Texas and Illinois and a reduction in Medicare Part D Low-Income Subsidy enrollment. We expect our full year 2010 operating cash flow, as compared to historical patterns, to be unfavorably impacted by the \$1.2 billion tax payment.

In addition, we have also received notification from the IRS that it has proposed certain adjustments to our prior year tax returns currently being audited. We believe our tax positions comply with applicable tax law and intend to defend our positions vigorously through the appeals process. However, if we are not able to prevail, we will be required to make additional tax payments. While this will not impact our future results of operations, it could reduce future operating cash flow.

Net cash flow used in investing activities was \$1.2 billion during the nine months ended September 30, 2010, compared to \$1.2 billion for the nine months ended September 30, 2009. The increase in cash flow used in investing activities of \$8.4 million between the two periods primarily resulted from increases in securities lending collateral, increases in net purchases of property and equipment and increases in other investing activities, partially offset by decreases in net purchases of investments and decreases in purchases of subsidiaries.

Net cash flow used in financing activities was \$2.2 billion during the nine months ended September 30, 2010, compared to \$2.2 billion for the nine months ended September 30, 2009. The increase in cash flow used in financing activities of \$36.9 million primarily resulted from increases in the repurchase of common stock and reductions in net proceeds from borrowings, partially offset by increases in securities lending payables, issuance of debt and increases in cash proceeds from employee stock plans. We expect to complete more than \$4.0 billion of share repurchases this year, representing a significant return of capital to our shareholders following the 2009 sale of our PBM business.

Financial Condition

We maintained a strong financial condition and liquidity position, with consolidated cash, cash equivalents and investments, including long-term investments, of \$21.2 billion at September 30, 2010. Since December 31, 2009, total cash, cash equivalents and investments, including long-term investments, decreased by \$1.4 billion primarily due to tax payments of \$1.2 billion to the IRS principally related to the gain we realized on the sale of our PBM business, which occurred in the fourth quarter of 2009.

Many of our subsidiaries are subject to various government regulations that restrict the timing and amount of dividends and other distributions that may be paid to their respective parent companies. In addition, we have agreed to certain undertakings to regulatory authorities, including the requirement to maintain certain capital levels in certain of our subsidiaries.

At September 30, 2010, we held at the parent company approximately \$2.9 billion of cash and cash equivalents and investments, which is available for general corporate use, including investment in our businesses, acquisitions, share and debt repurchases and interest payments.

We calculate a non-GAAP measure, our consolidated debt-to-total capital ratio, which we believe assists investors and rating agencies in measuring our overall leverage and additional borrowing capacity. In addition, our bank covenants indicate a maximum debt-to-total capital ratio that we can not exceed. Our targeted debt-to-total capital ratio is 25% to 35%. Our debt-to-total capital ratio is calculated as the sum of debt divided by the sum of debt plus shareholders equity. Our debt-to-total capital ratio may not be comparable to similarly titled measures reported by other companies. Our consolidated debt-to-total capital ratio was 27.0% as of September 30, 2010 and 25.3% as of December 31, 2009.

Our senior debt is rated A- by Standard & Poor s, A- by Fitch, Inc., Baa1 by Moody s Investor Service, Inc. and bbb+ by AM Best Company, We intend to maintain our senior debt investment grade ratings. A significant downgrade in our debt ratings could adversely affect our borrowing capacity and costs.

Future Sources and Uses of Liquidity

On December 12, 2008, we filed an updated shelf registration statement with the SEC to register an unlimited amount of any combination of debt or equity securities in one or more offerings. Specific information regarding terms and securities being offered will be provided at the time of an offering. Proceeds from future offerings are expected to be used for general corporate purposes, including the repayment of debt, capitalization of our subsidiaries, repurchases of our common stock or the financing of possible acquisitions or business expansion.

On September 30, 2010, we entered into a senior credit facility, or the facility, with certain lenders for general corporate purposes. The facility provides credit up to \$2.0 billion and matures on September 30, 2013. The interest rate on the facility is based on either, (i) the LIBOR rate plus a predetermined percentage rate based on our credit rating at the date of utilization, or (ii) a base rate as defined in the facility agreement plus a predetermined percentage rate based on our credit rating at the date of utilization. Our ability to borrow under the facility is subject to compliance with certain covenants. Commitment and legal fees paid for the facility were \$7.5 million and there are no conditions that are probable of occurring under which the facility may be withdrawn. There were no amounts outstanding under the facility as of September 30, 2010 or under a previous facility during the three or nine months then ended. At September 30, 2010, we had \$2.0 billion available under the facility. This facility replaced our previous senior credit facility, which provided credit up to \$2.4 billion.

On August 12, 2010, we issued \$700.0 of 4.350% notes due 2020 and \$300.0 of 5.800% notes due 2040 under our shelf registration statement. We used a portion of the proceeds from this debt issuance to repay the remaining outstanding balance of our variable rate senior term loan. We intend to use the remainder of the proceeds from this debt issuance for general corporate purposes, including, but not limited to, repayment of short-term and long-term debt. The notes have a call feature that allows us to repurchase the notes at any time at our option and a put feature that allows a note holder to require us to repurchase the notes upon the occurrence of both a change of control event and a downgrade of the notes.

We are a member of the Federal Home Loan Bank of Indianapolis and the Federal Home Loan Bank of Cincinnati, collectively, the FHLBs, and as a member we have the ability to obtain cash advances subject to certain requirements. In order to obtain cash advances, we are required to pledge securities as collateral to the FHLBs, initially equal to a certain percentage of the cash borrowings, depending on the type of securities pledged as

-69-

collateral. The market value of the collateral is monitored daily by the FHLBs, and if it falls below the required percentage of the cash borrowings, we are required to pledge additional securities as collateral or repay a portion of the outstanding cash advance balance. In addition, our borrowings may be limited based on the amount of our investment in the FHLBs common stock. Our investment in the FHLBs common stock at September 30, 2010 totaled \$11.4 million, which is reported in Investments available-for-sale Equity securities on the consolidated balance sheets. On May 11, 2010, we borrowed \$100.0 million from the FHLBs with a six-month term at a fixed interest rate of 0.360%, which is reported in Short-term borrowings on the consolidated balance sheets. In addition, on April 12, 2010, we borrowed \$100.0 million from the FHLBs with a two-year term at a fixed interest rate of 1.430%, which is reported with Long-term debt, less current portion on the consolidated balance sheets. Securities, primarily certain U.S. government sponsored mortgage-backed securities, with a fair value of \$236.9 million at September 30, 2010 have been pledged as collateral. The securities pledged are reported in Investments available-for-sale Fixed maturity securities on the consolidated balance sheets.

We have Board of Directors approval to borrow up to \$2.5 billion under our commercial paper program. Proceeds from any issuance of commercial paper may be used for general corporate purposes, including the repurchase of our debt and common stock. Commercial paper notes are short-term senior unsecured notes, with a maturity not to exceed 270 days from date of issuance. When issued, the notes bear interest at the then current market rates. We had \$391.1 million of borrowings outstanding under this commercial paper program as of September 30, 2010. As previously discussed in Introduction to Liquidity and Capital Resources , the commercial paper markets have experienced increased volatility and disruption. We will continue to monitor the commercial paper markets and will act in a prudent manner. We continue to classify our commercial paper as long-term debt given our intent to continually issue commercial paper or our ability to redeem our commercial paper using our \$2.0 billion senior credit facility.

As discussed in Financial Condition above, many of our subsidiaries are subject to various government regulations that restrict the timing and amount of dividends and other distributions that may be paid. Based upon these requirements, we are currently estimating approximately \$2.3 billion of ordinary dividends to be paid to the parent company during 2010. During the nine months ended September 30, 2010, \$1.2 billion in dividends were paid by our subsidiaries.

We regularly review the appropriate use of capital. Accordingly, under our Board of Directors authorization, we maintain a common stock repurchase program. Repurchases may be made from time to time at prevailing market prices, subject to certain restrictions on volume, pricing and timing. The repurchases are effected from time to time in the open market, in private transactions, including accelerated share repurchase agreements, and through plans designed to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

During the nine months ended September 30, 2010, we repurchased and retired approximately 58.9 million shares at an average per share price of \$56.83, for an aggregate cost of \$3.3 billion. During the nine months ended September 30, 2009, we repurchased and retired approximately 40.8 million shares at an average per share price of \$44.38, for an aggregate cost of \$1.8 billion. The excess of cost of the repurchased shares over par value is charged on a pro rata basis to additional paid-in capital and retained earnings.

On January 26, 2010, our Board of Directors increased the share repurchase authorization by \$3.5 billion. As of September 30, 2010, \$538.6 million remained authorized for future repurchases. Subsequent to September 30, 2010, we repurchased and retired approximately 1.4 million shares for an aggregate cost of approximately \$76.7 million, leaving approximately \$461.9 million for authorized future repurchases at October 20, 2010. On October 29, 2010, our Board of Directors increased the share repurchase authorization by \$500.0 million. Our stock repurchase program is discretionary as we are under no obligation to repurchase shares. We repurchase shares under the program when we believe it is a prudent use of capital. We expect to complete more than \$4.0 billion of share repurchases this year, representing a significant return of capital to our shareholders following the 2009 sale of our PBM business.

-70-

Our current pension funding strategy is to fund an amount at least equal to the minimum required funding as determined under ERISA with consideration of maximum tax deductible amounts. For the year ending December 31, 2010, no material required contributions are expected to be necessary to meet the ERISA required funding levels; however, we may elect to make discretionary contributions up to the maximum amount deductible for income tax purposes. We made tax deductible discretionary contributions totaling \$15.0 million to the other postretirement benefit plans during the nine months ended September 30, 2010.

Contractual Obligations and Commitments

We believe that funds from future operating cash flows, cash and investments and funds available under our credit agreement or from public or private financing sources will be sufficient for future operations and commitments, and for capital acquisitions and other strategic transactions.

We are aware that the Pennsylvania Insurance Commissioner, or Insurance Commissioner, has placed Penn Treaty in rehabilitation, an intermediate action before insolvency. The Insurance Commissioner has petitioned the state court for liquidation, however, we do not know when a decision will be made, although we believe it is likely the state court will rule within the next twelve months. In the event that Penn Treaty is declared insolvent and placed in liquidation, we and other insurers may be required to pay a portion of their policyholder claims through NOLHGA guaranty association assessments in future periods. Given the uncertainty around whether Penn Treaty will ultimately be declared insolvent and, if so, the amount of the insolvency, the amount and timing of any associated future guaranty fund assessments and the availability and amount of any potential premium tax and other offsets, we currently cannot estimate our net exposure, if any, to this potential insolvency. We will continue to monitor the situation and may record a liability and expense in future reporting periods, which could be material to our operating results.

For additional information regarding our estimated contractual obligations and commitments at December 31, 2009, see Contractual Obligations and Commitments included in the Liquidity and Capital Resources section in our 2009 Annual Report on Form 10-K.

Risk-Based Capital

Our regulated subsidiaries states of domicile have statutory risk-based capital, or RBC, requirements for health and other insurance companies largely based on the NAIC state of the RBC requirements are intended to measure capital adequacy, taking into account the risk characteristics of an insurer stince investments and products. The NAIC sets forth the formula for calculating the RBC requirements, which are designed to take into account asset risks, insurance risks, interest rate risks and other relevant risks with respect to an individual insurance company studies. In general, under this Act, an insurance company must submit a report of its RBC level to the state insurance department or insurance commissioner, as appropriate, at the end of each calendar year. Our risk-based capital as of December 31, 2009, which was the most recent date for which reporting was required, was in excess of all mandatory RBC thresholds. In addition to exceeding the RBC requirements, we are in compliance with the liquidity and capital requirements for a licensee of the BCBSA and with the tangible net worth requirements applicable to certain of our California subsidiaries.

-71-

X. Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This document contains certain forward-looking information about us that is intended to be covered by the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not generally historical facts. Words such as expect(s), feel(s), believe(s), will, may, anticipate(s), intend, estimate, project and similar expressions are intended to identify forward-looking statements, which generally are not historical in nature. These statements include, but are not limited to, financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond our control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include: those discussed and identified in our public filings with the U.S. Securities and Exchange Commission, or SEC; increased government participation in, or regulation or taxation of health benefits and managed care operations, including, but not limited to, the impact of the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010; trends in health care costs and utilization rates; our ability to secure sufficient premium rates including regulatory approval for and implementation of such rates; our ability to contract with providers consistent with past practice; competitor pricing below market trends of increasing costs; reduced enrollment, as well as a negative change in our health care product mix; risks and uncertainties regarding Medicare and Medicaid programs, including those related to non-compliance with the complex regulations imposed thereon and funding risks with respect to revenue received from participation therein; a downgrade in our financial strength ratings; litigation and investigations targeted at health benefits companies and our ability to resolve litigation and investigations within estimates; our ability to meet expectations regarding repurchases of shares of our common stock; decreased revenues, increased operating costs and potential customer and supplier losses and business disruptions that may be greater than expected following the close of the Express Scripts transaction; events that result in negative publicity for us or the health benefits industry; failure to effectively maintain and modernize our information systems and e-business organization and to maintain good relationships with third party vendors for information system resources; events that may negatively affect our license with the Blue Cross and Blue Shield Association; possible impairment of the value of our intangible assets if future results do not adequately support goodwill and other intangible assets; intense competition to attract and retain employees; unauthorized disclosure of member sensitive or confidential information; changes in the economic and market conditions, as well as regulations that may negatively affect our investment portfolios and liquidity; possible restrictions in the payment of dividends by our subsidiaries and increases in required minimum levels of capital and the potential negative effect from our substantial amount of outstanding indebtedness; general risks associated with mergers and acquisitions; various laws and our governing documents may prevent or discourage takeovers and business combinations; future potential public health epidemics and catastrophes; and general economic downturns. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. Except to the extent otherwise required by federal securities law, we do not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Readers are also urged to carefully review and consider the various disclosures in our SEC reports.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

As a result of our investing and borrowing activities, we are exposed to financial market risks, including those resulting from changes in interest rates and changes in equity market valuations. Our investment portfolio is exposed to three primary risks: credit quality risk, interest rate risk and market valuation risk. Our long-term debt has fixed interest rates and the fair value of these instruments is affected by changes in market interest rates. We use derivative financial instruments, specifically interest rate swap agreements, to hedge exposure in interest rate risk on our borrowings. No material changes to any of these risks have occurred since December 31, 2009.

For a more detailed discussion of our market risks relating to these activities, refer to Item 7A, Quantitative and Qualitative Disclosures about Market Risk , included in our 2009 Annual Report on Form 10-K.

ITEM 4. CONTROLS AND PROCEDURES

We carried out an evaluation as of September 30, 2010, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective in timely alerting them to material information relating to us (including our consolidated subsidiaries) required to be disclosed in our reports under the Securities Exchange Act of 1934. In addition based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective in ensuring that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934 is accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosures.

There have been no changes in our internal control over financial reporting that occurred during the three months ended September 30, 2010 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

-73-

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

The information set forth under Litigation and Other Contingencies in Note 10 to our unaudited consolidated financial statements in Part I, Item 1 of this Form 10-Q is incorporated herein by reference.

ITEM 1A. RISK FACTORS

Except as set forth below, there have been no material changes to the risk factors disclosed in our 2009 Annual Report on Form 10-K.

Recently enacted federal health care reform legislation, as well as potential additional changes in federal or state regulations, or the application thereof, could adversely affect our business, cash flows, financial condition and results of operation.

During the first quarter of 2010, the U.S. Congress passed and the President signed into law the Patient Protection and Affordable Care Act as well as the Health Care and Education Reconciliation Act of 2010, which will result in significant changes to the current U.S. health care system. The legislation is far-reaching and is intended to expand access to health insurance coverage over time by increasing the eligibility thresholds for most state Medicaid programs and providing certain other individuals and small businesses with tax credits to subsidize a portion of the cost of health insurance coverage. The legislation includes a requirement that most individuals obtain health insurance coverage beginning in 2014 and also a requirement that most large employers offer coverage to their employees or they will be required to pay a financial penalty.

In addition, the new laws encompass certain new taxes and fees, including an excise tax on high premium insurance policies, limitations on the amount of compensation that is tax deductible and new fees on companies in our industry which may not be deductible for income tax purposes. The Patient Protection and Affordable Care Act also imposes new regulations on the health insurance sector, including, but not limited to, guaranteed coverage requirements, prohibitions on some annual and all lifetime limits, increased restrictions on rescinding coverage, establishment of minimum medical loss ratio requirements, a requirement to cover preventive services on a first dollar basis, the establishment of state insurance exchanges and essential benefit packages and greater limitations on how we price certain of our health insurance products. Additionally, the legislation reduces the reimbursement levels for health plans participating in the Medicare Advantage program over time.

Some provisions of the health care reform legislation became effective this year including those that bar health insurance companies from placing lifetime limits on insurance coverage, those related to the increased restrictions on rescinding coverage and those that extend coverage of dependents to the age of 26. The establishment of minimum medical loss ratios, which could have a significant impact on our operations, will take effect for certain of our businesses beginning in January 2011. Lastly, other significant changes, including the annual fees on health insurance companies, the excise tax on high premium insurance policies, the guaranteed coverage requirements and the requirement that individuals obtain coverage, do not become effective until 2014 or later.

Many of the details of the new law, including, but not limited to, the medical loss ratio requirements, require additional guidance and specificity to be provided by the Department of Health and Human Services, the Department of Labor, the Department of the Treasury and the National Association of Insurance Commissioners. While proposed regulations on some provisions have been released for review and comment, all of which we are carefully evaluating, it is too early to fully understand the impacts of the legislation on our overall business. For example, while the National Association of Insurance Commissioners has released their proposed regulations governing medical loss ratios, they are subject to finalization by the Department of Health and Human Services and could change significantly as a result. In addition, California recently passed legislation establishing an insurance exchange within that state to comply with the related provisions that become effective in 2014. As California is the first state to provide a structure for such state-based insurance exchanges, pursuant to the

legislation, other states may adopt a similar format for their exchanges. These legislations could have a material adverse effect on our business, cash flows, financial condition and results of operations, including potential impairments of our goodwill and other intangible assets.

In addition, federal and state regulatory agencies may further restrict our ability to obtain new product approvals, implement changes in premium rates or impose additional restrictions, under new or existing laws, such as minimum medical loss ratio requirements or restricted definitions of costs to be included when calculating medical loss ratios under such definitions. Our ability to secure sufficient premium rates, including regulatory approval for and implementation of such rates on a timely basis, may be restricted by additional changes in federal and state regulations or by the application of existing federal and state regulations. A limitation on our ability to increase or maintain our premium rates and more restrictive medical loss ratio requirements could adversely affect our business, cash flows, financial condition and results of operations.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS Issuer Purchases of Equity Securities

The following table presents information related to our repurchases of common stock for the periods indicated.

Period (In millions, except share and per share data)	Total Number of Shares Purchased ¹	Average Price Paid per Share	Total Number of Shares Purchased as Part of Publicly Announced Programs ²	Approxima Dollar Value of Share that May Yet Be Purchas Under th	s y sed e
July 1, 2010 to July 31, 2010	4,596,540	\$ 50.26	4,591,384	\$ 7	71
August 1, 2010 to August 31, 2010	3,601,595	51.11	3,598,700	5	87
September 1, 2010 to September 30, 2010	936,554	52.73	932,300	5:	39
	9,134,689		9,122,384		

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. (REMOVED AND RESERVED)

Total number of shares purchased includes 12,305 shares delivered to or withheld by us in connection with employee payroll tax withholding upon exercise or vesting of stock awards. Stock grants to employees and directors and stock issued for stock option plans and stock purchase plans in the consolidated statements of shareholders equity are shown net of these shares purchased.

Represents the number of shares repurchased through our repurchase program authorized by our Board of Directors. During the three months ended September 30, 2010, we repurchased approximately 9.1 million shares at a cost of \$463.8 million under the program. On January 26, 2010, our Board of Directors increased the share repurchase authorization by \$3.5 billion. Remaining authorization under the program was \$538.6 million as of September 30, 2010.

Edgar Filing: WELLPOINT, INC - Form 10-Q

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

Exhibits: A list of exhibits required to be filed as part of this Form 10-Q is set forth in the Index to Exhibits, which immediately precedes such exhibits, and is incorporated herein by reference.

-75-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

WELLPOINT, INC.

Registrant

Date: November 3, 2010 By: /s/ Wayne S. DeVeydt

Wayne S. DeVeydt

Executive Vice President and Chief Financial Officer

(Duly Authorized Officer and Principal Financial Officer)

Date: November 3, 2010 By: /s/ Martin L. Miller

Martin L. Miller

Senior Vice President, Controller, Chief Accounting Officer and

Chief Risk Officer (Principal Accounting Officer)

-76-

INDEX TO EXHIBITS

Exhibit Number 2.1	Exhibit Stock and Interest Purchase Agreement, dated April 9, 2009, by and between the Company and Express Scripts, Inc., incorporated by reference to Exhibit 2.1 to the Company s Current Report on Form 8-K filed on April 13, 2009.
3.1	Articles of Incorporation of the Company, as amended effective May 17, 2007, incorporated by reference to Exhibit 3.1 to the Company s Current Report on Form 8-K filed on May 18, 2007.
3.2	By-Laws of the Company, amended effective April 30, 2010 with certain amendments effective July 29, 2009, incorporated by reference to Exhibit 3.2 to the Company s Current Report on Form 8-K filed on April 30, 2010.
4.1	Indenture, dated as of January 20, 2006, between The Company and The Bank of New York Mellon Trust Company, N.A. (formerly known as The Bank of New York Trust Company, N.A.) filed as Exhibit 4.1 to the Company s Current Report on Form 8-K dated January 10, 2006 and incorporated herein by reference.
	(a) Form of the 4.350% Notes due 2020, incorporated by reference to Exhibit 4.2 to the Company s Current Report on Form 8-K, filed on August 12, 2010.
	(b) Form of the 5.800% Notes due 2040, incorporated by reference to Exhibit 4.3 to the Company s Current Report on Form 8-K, filed on August 12, 2010.
4.2	Upon the request of the Securities and Exchange Commission, the Company will furnish copies of any other instruments defining the rights of holders of long-term debt of the Company or its subsidiaries.
31.1	Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Exchange Act Rules, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Exchange Act Rules, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2	Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101	The following material from WellPoint, Inc. s Quarterly Report on Form 10-Q, for the quarter ended September 30, 2010, formatted in XBRL (Extensible Business Reporting Language): (i) the Consolidated Balance Sheets; (ii) the Consolidated Statements of Income; (iii) the Consolidated Statements of Cash Flows; (iv) the Consolidated Statements of Shareholders Equity; and (v) Notes to Consolidated Financial Statements.

-77-